documents incorporated reference document part proxy statement annual meeting part iii shareholders held may filed securities exchange commission within days close fiscal year covered reporttable contents table contents part item business item risk factors cautionary factors may affect future results item b unresolved staff comments item properties item legal proceedings item mine safety disclosures executive officers registrant part ii item market registrants common equity related stockholder matters issuer purchases equity securities item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data financial statements notes consolidated financial statements report independent registered public accounting firm b supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures managements report item b information part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accountant fees services part iv item exhibits financial statement schedules signatures consent independent registered public accounting firm table contents part item business merck co inc merck company global health care company delivers innovative health solutions prescription medicines vaccines biologic therapies animal health consumer care products markets directly joint ventures companys operations principally managed products basis comprised four operating segments pharmaceutical animal health consumer care alliances segments one reportable segment pharmaceutical segment pharmaceutical segment includes human health pharmaceutical vaccine products marketed either directly company joint ventures human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities company also animal health operations discover develop manufacture market animal health products including vaccines company sells veterinarians distributors animal producers additionally company consumer care operations develop manufacture market overthecounter foot care sun care products sold wholesale retail drug food chain mass merchandiser outlets financial information information pharmaceutical segment see item managements discussion analysis financial condition results operations item financial statements supplementary data product service marks appearing type form different surrounding text trademarks service marks owned licensed promoted distributed merck subsidiaries affiliates except noted trademarks services marks respective owners overview company focused accelerating revenue growth reducing costs drive efficiencies allocating resources drive future growth making strategic investments product launches well emerging markets advancing augmenting research development pipeline worldwide sales totaled billion increase compared billion foreign exchange favorably affected global sales performance revenue increase driven largely growth januvia sitagliptin janumet sitagliptinmetformin hydrochloride hci treatments type diabetes singulair montelukast sodium medicine chronic treatment asthma relief symptoms allergic rhinitis isentress raltegravir antiretroviral therapy use combination therapy treatment hiv infection gardasil human papillomavirus quadrivalent types vaccine recombinant vaccine help prevent certain diseases caused four types human papillomavirus hpv simponi golimumab treatment inflammatory diseases rotateq rotavirus vaccine live oral pentavalent vaccine help protect rotavirus gastroenteritis infants children zetia ezetimibe cholesterol absorption inhibitor pneumovax pneumococcal vaccine polyvalent vaccine help prevent pneumococcal disease bridion sugammadex reversal certain muscle relaxants used surgery addition revenue benefited higher sales companys animal health products launch victrelis boceprevir treatment chronic hepatitis c increases partially offset lower sales cozaar losartan potassium hyzaar losartan potassium hydrochlorothiazide treatments hypertension lost patent protection united states april number major european markets march well lower sales caelyx subutex suboxone company longer marketing rights products revenue also negatively affected lower sales vytorin ezetimibesimvastatin cholesterol modifying medicine temodar temozolomide treatment certain types brain tumors proquad measles mumps rubella varicella virus vaccine live pediatric combination vaccine help protect measles mumps rubella varicella varivax varicella virus vaccine live vaccine help table contents prevent chickenpox varicella addition discussed ongoing implementation certain provisions us health care reform legislation resulted increases medicaid rebates impacts reduced revenues additionally many countries european union eu undertaken austerity measures aimed reducing costs health care implemented pricing actions negatively impacted sales april merck johnson johnson jj reached agreement amend agreement governing distribution rights remicade infliximab simponi agreement concluded arbitration proceeding jj initiated may terms amended distribution agreement merck relinquished marketing rights remicade simponi jj territories including canada central south america middle east africa asia pacific effective july merck retained exclusive marketing rights throughout europe russia turkey retained territories retained territories represented approximately mercks revenue billion remicade simponi addition beginning july profits derived mercks exclusive distribution two products retained territories equally divided merck jj jj also received onetime payment merck million april company continued advancement drug candidates pipeline victrelis companys innovative oral medicine treatment chronic hepatitis c approved us food drug administration fda european commission ec fda also approved juvisync sitagliptin simvastatin new treatment type diabetes combines active ingredient glucoselowering medication januvia cholesterollowering medication zocor simvastatin addition ec approved zoely nomace monophasic combined oral contraceptive tablet use women prevent pregnancy cubicin antibacterial agent activity methicillinresistant staphylococcus aureus mrsa company licensed development distribution rights japan approved use country february fda approved janumet xr sitagliptin metformin hci extendedrelease new treatment type diabetes combines sitagliptin active component januvia extendedrelease metformin oncedaily formulation cosopt pf dorzolamide hydrochloridetimolol maleate ophthalmic solution mercks preservativefree formulation cosopt indicated reduction elevated intraocular pressure appropriate patients openangle glaucoma ocular hypertension zioptan tafluprost ophthalmic solution preservativefree prostaglandin analogue ophthalmic solution company also received additional indications several existing products fda approved expanded age indication zostavax zoster vaccine live vaccine help prevent shingles herpes zoster include adults ages addition fda approved sylatron peginterferon alfab injection adjuvant treatment melanoma patients microscopic gross nodal involvement also simponi received indication eu use combination methotrexate adults severe active progressive rheumatoid arthritis previously treated methotrexate shown reduce rate progression joint damage measured xray improve physical function january fda approved use isentress combination antiretroviral medicines treatment hiv infection pediatric patients two years age older weighing least kg company currently two candidates review fda mk ridaforolimus treatment metastatic softtissue bone sarcomas patients favorable response chemotherapy mkc zetia combined atorvastatin treatment primary mixed hyperlipidemia mk also review eu company currently candidates phase iii development anticipates filing new drug application nda fda respect certain candidates including mk suvorexant investigational treatment insomnia mk bridion medication reversal certain muscle relaxants used surgery v ninevalent hpv vaccine company also anticipates filings among others mk odanacatib investigational treatment osteoporosis mka tredaptive extendedrelease niacinlaropiprantsimvastatin development treatment atherosclerosis merck continues pursue opportunities potential drive near longterm growth company completed variety transactions including acquisition inspire table contents pharmaceuticals inc specialty pharmaceutical company focused developing commercializing ophthalmic products additionally company entered transactions designed strengthen presence emerging markets longer term merck continues realize cost savings across areas company savings result various actions including merger restructuring program discussed previously announced ongoing cost reduction activities well nonrestructuringrelated activities end company realized approximately billion annual net cost savings activities since merger legacy merck co inc scheringplough corporation scheringplough november merger july company announced latest phase global restructuring program merger restructuring program initiated conjunction integration legacy merck legacy scheringplough businesses merger restructuring program intended optimize cost structure combined company part latest phase company expects reduce workforce measured time merger additional across company worldwide majority workforce reductions phase merger restructuring program relate manufacturing including animal health administrative headquarters organizations previously announced workforce reductions approximately earlier phases program primarily reflect elimination positions sales administrative headquarters organizations well sale closure certain manufacturing research development sites consolidation office facilities company continue hire employees strategic growth areas business necessary company continue pursue productivity efficiencies evaluate manufacturing supply chain capabilities ongoing basis may result future restructuring actions company recorded total pretax restructuring costs billion billion billion related program restructuring actions merger restructuring program expected substantially completed end exception certain actions principally manufacturingrelated expected substantially completed total cumulative pretax costs estimated approximately billion billion company estimates approximately twothirds cumulative pretax costs relate cash outlays primarily related employee separation expense approximately onethird cumulative pretax costs noncash relating primarily accelerated depreciation facilities closed divested company expects merger restructuring program yield annual savings end approximately billion billion annual savings upon completion program approximately billion billion company continued affected us health care reform legislation enacted additional provisions went effect beginning law requires pharmaceutical manufacturers pay discount medicare part beneficiaries medicare part coverage gap ie socalled donut hole approximately million recorded reduction revenue related estimated impact provision health care reform also company recorded million expenses annual health care reform fee company required pay beginning law also increased mandated medicaid rebates reduced revenues approximately million million respectively effective december richard clark chairman retired company merck board directors kenneth c frazier mercks president chief executive officer elected board serve chairman following mr clarks retirement november mercks board directors raised companys quarterly dividend per share per share earnings per common share assuming dilution attributable common shareholders eps reflect net unfavorable impact resulting acquisitionrelated costs restructuring costs well charge related settlement arbitration proceeding jj discussed partially offset favorable impact certain tax items gains disposition companys interest johnson johnsonmerck consumer pharmaceuticals company joint venture sale certain manufacturing facilities related assets nongaap eps excluding items see nongaap income nongaap eps table contents product sales sales companys products follows years ended december pharmaceutical cardiovascular zetia vytorin integrilin diabetes obesity januvia janumet diversified brands cozaarhyzaar zocor propecia claritin rx remeron vasotecvaseretic proscar infectious disease isentress pegintron cancidas primaxin invanz avelox noxafil crixivanstocrin rebetol victrelis neurosciences ophthalmology maxalt cosopttrusopt oncology temodar emend intron respiratory immunology singulair remicade nasonex clarinex arcoxia simponi asmanex proventil dulera vaccines gardasil proquadmmr iivarivax rotateq pneumovax zostavax womens health endocrine fosamax nuvaring follistim aq implanon cerazette pharmaceutical total pharmaceutical segment sales segment sales total segment sales sales legacy scheringplough products included postmerger period addition prior merger substantially sales zetia vytorin recognized msp partnership results mercks interest msp partnership recorded equity income affiliates result merger msp partnership became wholly owned company accordingly sales msp partnership products merger reflected table sales zetia vytorin reflect mercks sales products latin america part msp partnership well sales products postmerger period amounts reflect sales vaccines sold major european markets companys joint venture sanofi pasteur msd results reflected equity income affiliates amounts however reflect supply sales sanofi pasteur msd pharmaceutical primarily reflects sales human health pharmaceutical products including products within franchises listed separately reflects nonreportable segments including animal health consumer care revenue companys relationship azlp primarily relating sales nexium well prilosec revenue azlp billion billion billion respectively revenues primarily comprised miscellaneous corporate revenues thirdparty manufacturing sales sales related divested products businesses supply sales included segment results table contents pharmaceutical companys pharmaceutical products include therapeutic preventive agents generally sold prescription treatment human disorders certain products within companys franchises follows cardiovascular zetia marketed ezetrol outside united states vytorin marketed inegy outside united states integrilin eptifibatide injection treatment patients acute coronary syndrome diabetes obesity januvia janumet treatment type diabetes diversified brands cozaar hyzaar zocor propecia finasteride product treatment male pattern hair loss claritin rx loratadine treatment seasonal outdoor allergies yearround indoor allergies remeron mirtazapine antidepressant vasotec enalapril maleate vaseretic enalapril maleatehydrochlorothiazide hypertension andor heart failure products proscar finasteride urology product treatment symptomatic benign prostate enlargement infectious disease isentress pegintron peginterferon alphab treatment chronic hepatitis c cancidas caspofungin acetate antifungal product primaxin imipenem cilastatin sodium antibacterial product invanz ertapenem sodium treatment certain infections avelox moxifloxacin company markets united states broadspectrum fluoroquinolone antibiotic certain respiratory skin infections noxafil posaconazole prevention invasive fungal infections crixivan indinavir sulfate stocrin efavirenz antiretroviral therapies treatment hiv infection rebetol ribavirin usp capsules oral solution use combination pegintron intron interferon alphab recombinant treating chronic hepatitis c victrelis neurosciences ophthalmology maxalt rizatriptan benzoate product acute treatment migraine cosopt trusopt dorzolamide hydrochloride ophthalmic solution ophthalmic products oncology temodar marketed temodal outside united states emend aprepitant prevention chemotherapyinduced post operative nausea vomiting intron injection marketed chronic hepatitis b c numerous anticancer indications worldwide including adjuvant therapy malignant melanoma respiratory immunology singulair remicade nasonex mometasone furoate monohydrate inhaled nasal corticosteroid treatment nasal allergy symptoms clarinex desloratadine nonsedating antihistamine arcoxia etoricoxib treatment arthritis pain simponi asmanex twisthaler mometasone furoate inhalation powder oral drypowder corticosteroid inhaler firstline maintenance treatment asthma patients older proventil hfa albuterol sulfate inhalation aerosol relief bronchospasm patients years older dulera inhalation aerosol mometasone furoateformoterol fumarate dihydrate fixeddose combination asthma treatment patients years age older vaccines gardasil proquad mmr ii measles mumps rubella virus vaccine live vaccine help prevent measles mumps rubella varivax rotateq pneumovax zostavax vaccine help prevent shingles herpes zoster patients aged older womens health endocrine fosamax alendronate sodium treatment prevention osteoporosis nuvaring etonogestrelethinyl estradiol vaginal ring vaginal contraceptive ring follistim aq follitropin beta injection biological fertility treatment implanon etonogestrel implant single rod subdermal contraceptive implant cerazette desogestrel progestin oral contraceptive animal health animal health segment discovers develops manufactures markets animal health products including vaccines principal marketed products segment include livestock products nuflor antibiotic range use cattle swine bovilisvista vaccine lines infectious diseases cattle banamine bovine swine antiinflammatory estrumate treatment fertility disorders cattle regumatematrix fertility management swine horses resflor combination broadspectrum antibiotic nonsteroidal antiinflammatory drug bovine respiratory disease zilmax revalor table contents improve production efficiencies beef cattle mpac swine pneumonia vaccine porcilis vaccine line infectious diseases swine poultry products nobilisinnovax vaccine lines poultry paracox coccivac coccidiosis vaccines companion animal products nobivaccontinuum vaccine lines flexible dog cat vaccination otomaxmometamaxposatex ear ointments acute chronic otitis caninsulinvetsulin diabetes mellitus treatment dogs cats panacursafeguard broadspectrum anthelmintic dewormer use many animals scaliborexspot protecting bites fleas ticks mosquitoes sandflies aquaculture products slice parasiticide sea lice salmon aquavacnorvax vaccines bacterial viral disease fish compact pd vaccine salmon aquaflor antibiotic farmraised fish consumer care consumer care segment develops manufactures markets overthecounter foot care sun care products principal products segment include overthecounter products claritin nondrowsy antihistamines miralax treatment occasional constipation coricidin hbp decongestantfree coldflu medicine people high blood pressure afrin nasal decongestant spray zegerid otc treatment frequent heartburn foot care dr scholls foot care products lotrimin topical antifungal products tinactin topical antifungal products foot sneaker odorwetness products sun care coppertone sun care lotions sprays dry oils discussion sales companys products see item managements discussion analysis financial condition results operations product approvals february fda approved zioptan tafluprost preservativefree prostaglandin analog ophthalmic solution reducing elevated intraocular pressure patients openangle glaucoma ocular hypertension merck exclusive commercial rights tafluprost western europe excluding germany north america south america africa middle east india australia zioptan marketed saflutan certain markets outside united states also february fda approved janumet xr new treatment type diabetes combines sitagliptin active component januvia extendedrelease metformin janumet xr provides convenient oncedaily treatment option health care providers patients need help control blood sugar addition february fda approved cosopt pf mercks preservativefree formulation cosopt ophthalmic solution indicated reduction elevated intraocular pressure appropriate patients openangle glaucoma ocular hypertension october fda approved juvisync new treatment type diabetes combines glucoselowering medication sitagliptin cholesterollowering medication zocor juvisync first treatment option health care providers help patients need blood sugarlowering benefits dpp inhibitor cholesterollowering benefits simvastatin convenience single tablet daily august zoely oral contraceptive granted marketing authorization ec use women prevent pregnancy zoely combined oral contraceptive tablet containing unique monophasic combination two hormones nomegestrol acetate highly selective progesteronederived progestin beta estradiol estrogen similar one naturally present womans body marketing authorization zoely applies eu member states plus iceland liechtenstein norway teva pharmaceutical industries ltd holds exclusive marketing rights zoely france italy belgium spain table contents may fda approved victrelis companys innovative oral medicine treatment chronic hepatitis c victrelis approved treatment chronic hepatitis c genotype infection combination peginterferon alfa ribavirin adult patients years age older compensated liver disease including cirrhosis previously untreated failed previous interferon ribavirin therapy victrelis antiviral agent designed interfere ability hepatitis c virus replicate inhibiting key viral enzyme july ec approved victrelis ecs decision grants single marketing authorization valid countries members eu well unified labeling applicable iceland liechtenstein norway addition united states victrelis launched markets including france germany canada brazil joint ventures astrazeneca lp merck entered agreement astra ab astra develop market astra products united states merck astra formed equally owned joint venture developed marketed astras new prescription medicines united states including prilosec omeprazole first class medications known proton pump inhibitors slows production acid cells stomach lining merck astra restructured joint venture whereby merck acquired astras interest joint venture renamed kbi inc kbi contributed kbis operating assets new us limited partnership named astra pharmaceuticals lp partnership exchange limited partner interest astra contributed net assets wholly owned subsidiary astra usa inc partnership exchange general partner interest partnership renamed astrazeneca lp azlp upon astras merger zeneca group plc became exclusive distributor products kbi retained rights company earns certain partnership returns well ongoing revenue based sales current future kbi products partnership returns include priority return provided partnership agreement preferential return representing companys share undistributed partnership azlp generally accepted accounting principles gaap earnings variable return related companys limited partner interest conjunction restructuring discussed astra purchased option asset option payment million recorded deferred income buy mercks interest kbi products excluding gastrointestinal medicines nexium prilosec nonppi products april astrazeneca exercised asset option merck received million astrazeneca representing net present value march projected future pretax revenue received merck nonppi products recorded reduction companys investment azlp company recognized million deferred income component income expense net addition merck granted astra option shares option buy mercks common stock interest kbi mercks interest nexium prilosec exercisable exercise price shares option primarily based net present value projected future pretax revenue received merck nexium prilosec determined time exercise subject certain trueup mechanisms company believes likely astrazeneca exercise shares option sanofi pasteur msd merck pasteur mrieux connaught sanofi pasteur sa formed joint venture market human vaccines europe collaborate development combination vaccines distribution thenexisting eu european free trade association merck sanofi pasteur contributed among things european vaccine businesses equal shares joint venture known pasteur mrieux msd snc sanofi pasteur msd snc joint venture maintains presence directly affiliates branches belgium italy germany spain france austria ireland sweden portugal netherlands switzerland united kingdom distributors rest territory table contents licenses subsidiary scheringplough entered licensing agreement centocor ortho biotech inc centocor jj company market remicade prescribed treatment inflammatory diseases scheringploughs subsidiary exercised option contract centocor license rights develop commercialize simponi fully human monoclonal antibody company exclusive marketing rights products outside united states japan certain asian markets december scheringplough centocor revised distribution agreement regarding development commercialization distribution remicade simponi extending companys rights exclusively market remicade match duration companys exclusive marketing rights simponi addition scheringplough centocor agreed share certain development costs relating simponis autoinjector delivery system october ec approved simponi treatment rheumatoid arthritis immune system disorders two presentations novel autoinjector prefilled syringe result companys marketing rights products extend years first commercial sale simponi eu following receipt pricing reimbursement approval within eu april merck jj reached agreement amend agreement governing distribution rights remicade simponi agreement concluded arbitration proceeding jj initiated may terms amended distribution agreement merck relinquished marketing rights remicade simponi jj territories including canada central south america middle east africa asia pacific effective july merck retained exclusive marketing rights throughout europe russia turkey retained territories addition beginning july profits derived mercks exclusive distribution two products retained territories equally divided merck jj prior terms distribution agreement contribution income profit split merck percent jj would declined merck increased jj year would equally divided jj also received onetime payment merck million april competition health care environment competition markets company conducts business pharmaceutical industry highly competitive highly regulated companys competitors include worldwide researchbased pharmaceutical companies smaller research companies limited therapeutic focus generic drug consumer health care manufacturers companys operations may affected technological advances competitors industry consolidation patents granted competitors competitive combination products new products competitors generic availability competitors branded products new information clinical trials marketed products postmarketing surveillance generic competition companys products mature addition patent positions increasingly challenged competitors outcome highly uncertain adverse result patent dispute preclude commercialization products negatively affect sales existing products could result recognition impairment charge respect certain products competitive pressures intensified pressures industry grown effect operations competitive factors patent disputes predicted pharmaceutical competition involves rigorous search technological innovations ability market innovations effectively longstanding emphasis research development company well positioned compete search technological innovations additional resources required meet market challenges include quality control flexibility meet customer specifications efficient distribution system strong technical information service company active acquiring marketing products external alliances joint ventures licenses refining sales marketing efforts address changing industry conditions however introduction new products processes competitors may result price reductions product displacements even products protected patents example number compounds available treat particular disease typically increases time result slowed sales growth companys products therapeutic category table contents highly competitive animal health business affected several factors including regulatory legislative issues scientific technological advances product innovation quality price companys products effective promotional efforts frequent introduction generic products competitors companys consumer care operations face competition consumer health care businesses well retailers carry private label brands companys competitive position affected several factors including regulatory legislative issues scientific technological advances quality price companys products promotional efforts growth lower cost private label brands health care environment global efforts toward health care cost containment continue exert pressure product pricing market access united states federal state governments many years also pursued methods reduce cost drugs vaccines pay example federal laws require company pay specified rebates medicines reimbursed medicaid provide discounts outpatient medicines purchased certain public health service entities disproportionate share hospitals hospitals meeting certain criteria federal vaccines children entitlement program us centers disease control prevention funds purchases recommended pediatric vaccines public sector price immunization medicaid eligible uninsured native american certain underinsured children merck contracted provide pediatric vaccines program backdrop united states enacted major health care reform legislation began implemented various insurance market reforms advanced continue full implementation new law expected expand access health care million americans end decade previously regular access health care respect effect law pharmaceutical industry law increased mandated medicaid rebate expanded rebate medicaid managed care utilization increased types entities eligible federal b drug discount program law also requires pharmaceutical manufacturers pay discount medicare part beneficiaries medicare part coverage gap ie socalled donut hole also pharmaceutical manufacturers required pay annual health care reform fee total annual industry fee billion billion fee assessed company proportion share sales certain government programs medicare medicaid company also faces increasing pricing pressure globally managed care organizations government agencies programs could negatively affect companys sales profit margins united states include practices managed care groups institutional governmental purchasers ii us federal laws regulations related medicare medicaid including medicare prescription drug improvement modernization act patient protection affordable care act changes health care system enacted part health care reform united states well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries could result pricing pressures addition effort contain us federal deficit pharmaceutical industry could considered potential source savings via legislative proposals debated enacted prior years types revenue generating cost saving proposals include direct price controls medicare prescription drug program part addition congress may consider proposals allow certain conditions importation medicines countries remains uncertain proposals may included part future federal budget deficit reduction proposals would directly indirectly affect company global efforts toward health care cost containment intense several european countries many countries announced austerity measures include implementation pricing actions reduce prices generic patented drugs company taking steps mitigate impact eu austerity measures negatively affected companys revenue performance company anticipates austerity measures continue negatively affect revenue performance additionally global economic downturn sovereign debt issues certain european countries among factors adversely impacted foreign receivables certain european countries table contents company continues receive payment receivables conditions resulted increase average length time takes collect accounts receivable outstanding thereby adversely affecting cash flows full impact us health care reform well continuing budget pressures governments around world predicted time addressing cost containment pressures company continues attempt demonstrate medicines provide value patients pay health care markets historically low rates government health care spending company encourages governments increase investments order improve citizens access appropriate health care including medicines operating conditions become challenging global pressures competition industry regulation cost containment efforts although one predict effect factors companys business company continually takes measures evaluate adapt improve organization business practices better meet customer needs believes well positioned respond evolving health care environment market forces government regulation pharmaceutical industry subject regulation regional country state local agencies around world governmental regulation legislation tend focus standards processes determining drug safety effectiveness well conditions sale reimbursement especially related pricing products particular importance fda united states administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals many cases fda requirements practices increased amount time resources necessary develop new products bring market united states eu adopted directives legislation concerning classification labeling advertising wholesale distribution integrity supply chain enhanced pharmacovigilance monitoring approval marketing medicinal products human use provide mandatory standards throughout eu may supplemented implemented additional regulations eu member states companys policies procedures already consistent substance directives consequently believed material effect companys business company believes continue able conduct operations including launching new drugs market regulatory environment access medicines global health care company mercks primary role discover develop innovative medicines vaccines company also recognizes important role play helping improve access products around world companys efforts regard wideranging example company recognized pricing many products differential pricing framework taking consideration factors countrys level economic development public health need addition merck patient assistance program provides medicines adult vaccines free people prescription drug health insurance coverage without companys assistance afford merck medicine vaccines building companys efforts merck undertaken collaborations many stakeholders improve access medicines enhance quality life people around world example merck announced would launch merck mothers longterm effort global health partners create world woman die preventable complications pregnancy childbirth launch includes year million initiative applies mercks scientific business expertise making proven solutions widely available developing new technologies improving public awareness policy efforts private sector engagement maternal mortality merck also past provided funds merck company foundation independent organization partnered variety organizations dedicated improving global health one table contents partnerships african comprehensive hivaids partnership botswana collaboration government botswana bill melinda gates foundation renewed supports botswanas response hivaids comprehensive sustainable approach hiv prevention care treatment support privacy data protection company subject number privacy data protection laws regulations globally legislative regulatory landscape privacy data protection continues evolve increased attention privacy data protection issues developed emerging markets potential affect directly companys business including recently enacted laws regulations united states europe asia latin america increased enforcement activity united states developed markets distribution company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions human health vaccines sold primarily physicians wholesalers physician distributors government entities companys professional representatives communicate effectiveness safety value companys pharmaceutical vaccine products health care professionals private practice group practices hospitals managed care organizations company sells animal health products veterinarians distributors animal producers companys overthecounter foot care sun care products sold wholesale retail drug food chain mass merchandiser outlets raw materials raw materials supplies generally available multiple sources purchased worldwide normally available quantities adequate meet needs companys business patents trademarks licenses patent protection considered aggregate material importance companys marketing products united states major foreign markets patents may cover products per se pharmaceutical formulations processes intermediates useful manufacture products uses products protection individual products extends varying periods accordance legal life patents various countries protection afforded may also vary country country depends upon type patent scope coverage food drug administration modernization act fda modernization act includes pediatric exclusivity provision may provide additional six months market exclusivity united states indications new currently marketed drugs certain agreed upon pediatric studies completed applicant exclusivity provisions reauthorized prescription drug user fee act passed september current us patent law provides additional patent term patent term restoration periods patented product regulatory review fda table contents patent portfolios developed products introduced company normally provide market exclusivity company following key us patent protection including patent term restoration pediatric exclusivity major marketed products product year expiration us maxalt singulair cancidas compound composition propecia formulationuse asmanex use formulation avelox dulera use combination integrilin compound useformulation nasonex useformulationformulation temodar emend follistim aq pegintron conjugates mature ifnalpha invanz compound composition zostavax use zetiavytorin zioptan nuvaring delivery system noxafil rotateq clarinex formulation comvax method makingvectors intron recombivax method makingvectors saphrissycrest useformulation pending patent term restoration januviajanumetjuvisyncjanumet xr compound salt isentress victrelis pending patent term restoration gardasil method makinguseproduct process compound patent unless otherwise noted company determined enforce additional patent set expire agreement one generic manufacturer given right enter market january another given right enter july agreement generic manufacturer may launch generic us early february six months pediatric exclusivity may extend date august agreement generic manufacturer may launch generic us august agreement generic manufacturer may launch generic version zetia us december application patent term restoration zioptan compound patent filed within prescribed time limits company expects five years patent term restoration virtue litigation settlements certain generic manufacturers given right enter us market expiration product patent normally results loss market exclusivity covered pharmaceutical product commercial benefits may continue derived latergranted patents processes intermediates related economical method manufacture active ingredient product ii patents relating use product iii patents relating novel compositions formulations iv united states certain countries market exclusivity may available relevant law effect product patent expiration pharmaceutical products also depends upon many factors nature market position product growth market complexities economics process manufacture active ingredient product requirements new drug provisions federal food drug cosmetic act similar laws regulations countries table contents patent provides us market exclusivity singulair companys largest selling product expires august company expects within two years following patent expiration lose substantially us sales singulair declines coming first full year following patent expiration also patent provides market exclusivity singulair expire number major european markets february company expects sales singulair markets decline significantly thereafter patent provides market exclusivity singulair japan expire addition patent provides us market exclusivity maxalt expire december also patent provides market exclusivity maxalt expire number major european markets february company anticipates sales united states european markets decline significantly patent expiries additions market exclusivity sought united states countries relevant laws including laws increasing patent life benefits increases patent life partially offset general increase number incentives use generic products additionally improvements intellectual property laws sought united states countries reform patent relevant laws implementation international treaties company following key us patent protection drug candidates review currently anticipated review year expiration us mkc ezetimibeatorvastatin mk ridaforolimus company also following key us patent protection drug candidates phase iii development currently anticipated phase iii drug candidate year expiration us mk grass pollen na mk ragweed na mka extendedrelease niacinlaropiprant mkb extendedrelease niacinlaropiprantsimvastatin mk anacetrapib mk vernakalant iv mka clostridium difficile infection mka nomace use mke sitagliptinatorvastatin compound salt mk corifollitropin alfa injection formulation mk vaniprevir v inactivated varicella zoster virus vzv vaccine method use v hpv vaccine valent compound method makinguse mk suvorexant mk bridion mk odanacatib mk preladenant v pediatric hexavalent combination vaccine method makingvectors mk vorapaxar compound patent unless otherwise noted subject future patent term restoration five years six month pediatric market exclusivity either may available depending circumstances surrounding final regulatory approval compound may listed patents patent applications pending could relevance product finally approved relevance application would depend upon claims ultimately may granted nature final regulatory approval product regulatory exclusivity tied protection clinical data complementary patent protection many cases may provide efficacious longer lasting marketing exclusivity compounds patent estate united states data protection generally runs years first marketing approval new chemical entity extended years orphan drug indication years first marketing approval biological product twelve years data exclusivity first marketing approval expected table contents information respect companys patents see item risk factors item financial statements supplementary data note contingencies environmental liabilities worldwide companys important products sold trademarks considered aggregate material importance trademark protection continues countries long used countries long registered registration fixed terms renewed indefinitely royalty income patent knowhow licenses rights amounted million merck also incurred royalty expenses amounting billion patent knowhow licenses holds research development companys business characterized introduction new products new uses existing products strong research development program approximately people employed companys research activities research development expenses billion billion billion included restructuring costs years well million billion inprocess research development impairment charges respectively company maintains ongoing commitment research broad range therapeutic areas clinical development support new products company maintains number longterm exploratory fundamental research programs biology chemistry well research programs directed toward product development companys research development model designed increase productivity improve probability success prioritizing companys research development resources disease areas unmet medical needs scientific opportunity commercial opportunity merck managing research development portfolio across diverse approaches discovery development balancing investments appropriately novel innovative targets potential major impact human health developing bestinclass approaches delivering maximum value approved medicines vaccines new indications new formulations another important component companys sciencebased diversification based expanding companys portfolio modalities include small molecules vaccines also biologics peptides small proteins antibodies rnai merck moved diversify portfolio merck bioventures division potential harness market opportunity presented biological medicine patent expiries delivering high quality followon biologic products enhance access patients worldwide company supplements internal research licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds well new technologies companys clinical pipeline includes candidates multiple disease areas including atherosclerosis cancer cardiovascular diseases diabetes infectious diseases inflammatoryautoimmune diseases insomnia neurodegenerative diseases ophthalmics osteoporosis respiratory diseases womens health development human health products industry practice government regulations united states foreign countries provide determination effectiveness safety new chemical compounds preclinical tests controlled clinical evaluation new drug vaccine may marketed united states recorded data preclinical clinical experience included nda drug biologics license application bla vaccine biologic submitted fda required approval companys scientists discover new small molecule compound biologics molecule believe promise treat medical condition company commences preclinical testing compound preclinical testing includes laboratory testing animal safety studies gather data chemistry pharmacology immunogenicity toxicology pending acceptable preclinical data company initiate clinical testing accordance established regulatory requirements clinical testing begins phase studies designed assess safety tolerability pharmacokinetics preliminary pharmacodynamic activity compound humans favorable additional larger phase ii studies initiated determine efficacy compound affected population define appropriate dosing compound well identify adverse table contents effects could limit compounds usefulness data phase ii trials satisfactory company commences largescale phase iii trials confirm compounds efficacy safety upon completion trials satisfactory company submits regulatory filings appropriate regulatory agencies around world product candidate approved marketing assurance compound result particular program obtain regulatory approvals necessary marketed vaccine development follows general pathway drugs preclinical testing focuses vaccines safety ability elicit protective immune response immunogenicity premarketing vaccine clinical trials typically done three phases initial phase clinical studies conducted normal subjects evaluate safety tolerability immunogenicity vaccine candidate phase ii studies doseranging studies finally phase iii trials provide necessary data effectiveness safety successful company submits regulatory filings appropriate regulatory agencies also stage proposed manufacturing facility undergoes preapproval inspection production vaccine progress examined detail united states fda review process begins complete nda submitted received fda pursuant prescription drug user fee act fda review period targets ndas supplemental ndas either six months priority review ten months standard review within days receipt nda fda determines application sufficiently complete permit substantive review fda also assesses time whether application granted priority review standard review review timelines defined fda generally act upon application within timelines unless major amendment submitted either companys initiative fdas request pending application occurs fda may extend review period allow review new information three months extensions review period communicated company fda act application either issuing approval letter issuing complete response letter stating application approved present form describing deficiencies fda identified company wish pursue application receiving complete response letter resubmit application information addresses questions issues identified fda order support approval resubmissions subject review period targets vary depending underlying submission type content resubmission research development update company currently two candidates regulatory review united states internationally mk ridaforolimus investigational oral mtor mammalian target rapamycin inhibitor development treatment metastatic softtissue bone sarcomas patients favorable response chemotherapy accepted standard review fda september august european medicines agency ema accepted marketing authorization application ridaforolimus part exclusive license agreement ariad pharmaceuticals inc ariad merck responsible development worldwide commercialization ridaforolimus ariad option copromote ridaforolimus sarcoma united states subject execution copromotion agreement mkc zetia combined atorvastatin accepted standard review fda treatment primary mixed hyperlipidemia response notice companys filing pfizer inc pfizer filed patent infringement lawsuit us district court company asserting certain pfizer patent rights respect atorvastatin lawsuit potential bar fda approval companys nda months january subject shortened lengthened court decision shortened agreement parties addition candidates regulatory review company drug candidates phase iii development targeting broad range diseases company plans file five major products approval including suvorexant insomnia bridion reversal neuromuscular blockade v cervical cancer vaccine odanacatib osteoporosis tredaptive atherosclerosis mk suvorexant investigational dual orexin receptor antagonist potential new approach treatment insomnia orexins neuropeptides chemical messengers released specialized table contents neurons hypothalamus region brain believed important regulator brains sleepwake process february merck announced based positive results two pivotal phase iii efficacy trials suvorexant company anticipates filing nda mk fda mk bridion medication reversal certain muscle relaxants used surgery bridion currently approved launched many countries outside united states prior merger scheringplough received notapprovable letter fda bridion company conducted additional clinical trials address fdas comments plans file nda bridion fda v ninevalent hpv vaccine development help protect certain hpvrelated diseases v incorporates antigens five additional cancercausing hpv types compared gardasil phase iii clinical program includes eventdriven clinical trial ongoing merck continues anticipate filing bla v fda mk odanacatib oral onceweekly investigational treatment osteoporosis postmenopausal women osteoporosis disease reduces bone density strength results increased risk bone fractures odanacatib cathepsin k inhibitor selectively inhibits cathepsin k enzyme cathepsin k known play central role function osteoclasts cells break existing bone tissue particularly protein components bone inhibition cathepsin k novel approach treatment osteoporosis odanacatib continues studied determine safety potential effects hip vertebral nonvertebral fractures eventdriven phase iii clinical trial company anticipates filing nda mk fda mka drug candidate combines extendedrelease niacin novel flushing inhibitor laropiprant mka demonstrated ability lower ldlcholesterol ldlc bad cholesterol raise hdlcholesterol hdlc good cholesterol lower triglycerides significantly less flushing traditional extendedrelease niacin alone high ldlc low hdlc elevated triglycerides risk factors associated heart attacks strokes april merck received notapprovable letter fda response nda mka meeting discuss letter fda stated additional efficacy safety data required suggested merck wait results hpsthrive treatment hdl reduce incidence vascular events eventdriven cardiovascular outcomes study expected completed company anticipates filing nda fda mka mka approved countries outside united states treatment dyslipidemia particularly patients combined mixed dyslipidemia characterized elevated levels ldlc triglycerides low hdlc patients primary hypercholesterolemia heterozygous familial nonfamilial marketed tredaptive cordaptive certain countries tredaptive used patients combination statins cholesterol lowering effects statin monotherapy inadequate tredaptive used monotherapy patients statins considered inappropriate tolerated mk elonva corifollitropin alpha injection approved eu controlled ovarian stimulation combination gnrh antagonist development multiple follicles women participating assisted reproductive technology program currently phase iii development united states based feedback fda additional data ongoing phase iii trial required time filing merck anticipates filing nda elonva fda mk vernakalant iv investigational candidate treatment atrial fibrillation marketed brinavess eu merck acquired exclusive rights develop commercialize vernakalant iv well exclusive worldwide rights oral formulations vernakalant prior mercks acquisition rights vernakalant iv canada mexico united states program placed clinical hold fda phase iii act v trial suspended act v terminated united states program remains hold company plans discussions fda mka nomace marketed zoely eu oral contraceptive use women prevent pregnancy nomace combined oral contraceptive tablet containing unique monophasic combination two hormones nomegestrol acetate highly selective progesteronederived progestin beta table contents estradiol estrogen similar one naturally present womens body november merck received complete response letter fda nomace company planning conduct additional clinical study requested fda update application future mk vorapaxar thrombin receptor antagonist developed prevention thrombosis clot formation reduction cardiovascular events vorapaxar evaluated two major clinical outcomes studies different patient groups tracer thrombin receptor antagonist clinical event reduction acute coronary syndrome clinical outcomes trial patients acute coronary syndrome trap thrombin receptor antagonist secondary prevention atherothrombotic ischemic events secondary prevention study patients previous heart attack ischemic stroke documented peripheral vascular disease february merck announced topline results trap study trap showed addition vorapaxar standard care significantly reduced risk protocolspecified primary endpoint composite cardiovascular death heart attack myocardial infarction stroke urgent coronary revascularization compared standard care significant increase bleeding including intracranial hemorrhage among patients taking vorapaxar addition standard care although lower risk intracranial hemorrhage patients without history stroke full results trap presented american college cardiology scientific sessions march november researchers presented results tracer outcomes study american heart association scientific sessions results published tracer achieve primary endpoint january merck external study investigators announced combined data safety monitoring board dsmb two clinical trials reviewed available safety efficacy data recommended patients tracer trial discontinue study drug investigators close study merck review data trap tracer investigators outside experts help better understand profile investigational medicine specific patient populations determine next steps including potential regulatory filings mkb drug candidate combines novel approach raising hdlc lowering triglycerides extendedrelease niacin combined laropiprant proven benefits simvastatin one combination product merck anticipates filing nda mkb fda mk investigational allergy immunotherapy sublingual tablet ait phase iii development grass pollen allergy company north american rights ait dissolvable oral tablet designed prevent allergy symptoms inducing protective immune response allergies thereby treating underlying cause disease merck investigating ait treatment grass pollen allergic rhinoconjunctivitis children adults company anticipates filing nda mk fda mk ait ragweed allergy also phase iii development north american market company anticipates filing nda mk fda mk preladenant selective adenosine receptor antagonist phase iii development treatment parkinsons disease company anticipates filing nda preladenant fda mka investigational candidate treatment clostridium difficile infection combination two monoclonal antibodies used treat patients single infusion company anticipates filing nda mka fda v inactivated varicellazoster virus vaccine development prevention herpes zoster company enrolling two phase iii trials one autologous hematopoietic cell transplant patients patients solid tumor malignancies undergoing chemotherapy hematological malignancies company anticipates filing bla first autologous hematopoietic cell transplant data filing second indication cancer patients later date v investigational hexavalent pediatric combination vaccine contains components current vaccines designed help protect six potentially serious diseases diphtheria tetanus whooping cough bordetella pertussis polio poliovirus types invasive disease caused haemophilus influenzae type b hepatitis b developed collaboration sanofipasteur company anticipates filing bla v fda table contents mke combines januvia atorvastatin single tablet developed treatment diabetes atherosclerosis company anticipates filing nda mke fda mk vaniprevir investigational oral twice daily protease inhibitor treatment chronic hepatitis c virus drug phase iii trials japan company anticipates filing new drug application mk japan mk anacetrapib investigational inhibitor cholesteryl ester transfer protein cetp investigated lipid management raise hdlc reduce ldlc based results phase iii define determining efficacy tolerability cetp inhibition anacetrapib safety study patients coronary heart disease coronary heart disease risk equivalents company initiated large eventdriven cardiovascular clinical outcomes trial reveal randomized evaluation effects anacetrapib lipidmodification involving patients preexisting vascular disease company continues anticipate filing nda anacetrapib fda beyond merck discontinued clinical development program telcagepant companys investigational calcitonin generelated peptide receptor antagonist treatment acute migraine decision based assessment data across clinical program company also discontinued clinical development program mkc combination sitagliptin pioglitazone treatment diabetes based review regulatory commercial prospects combination drug candidate merck discontinued clinical development program eu mka zenhale fixed dose combination two previously approved drugs treatment asthma mometasone furoate formoterol fumarate dehydrate marketed united states dulera inhalation aerosol table contents chart reflects companys research pipeline february candidates shown phase iii include specific products date candidate entered phase iii development candidates shown phase ii include advanced compound specific mechanism listed compounds mechanism currently intended commercialization given therapeutic area small molecules biologics given mknumber designations vaccine candidates given vnumber designations candidates phase additional indications therapeutic area additional claims line extensions formulations inline products shown phase ii phase iii phase iii entry date review allergy allergy atherosclerosis mk immunotherapy mk grass pollen march mkc ezetimibeatorvastatin us cancer mk ragweed september sarcoma mk dalotuzumab atherosclerosis mk ridaforolimus us eu mk mka extendedrelease niacinlaropiprant us mk december mk dinaciclib mkb extendedrelease niacinlaropiprant contraception medicated ius simvastatin july mk mk anacetrapib may diabetes mellitus atrial fibrillation mk mk vernakalant iv us august hepatitis c clostridium difficile infection mk mka november insomnia contraception mk mka nomace us june mk diabetes atherosclerosis overactive bladder mke sitagliptinatorvastatin october mk fertility pneumoconjugate vaccine mk corifollitropin alfa injection us july footnotes v hepatitis c north american rights psoriasis mk vaniprevir june prior mercks acquisition rights mk herpes zoster vernakalant iv canada mexico v inactivated vzv vaccine december united states program placed hpvrelated cancers clinical hold fda v hpv vaccine valent september suspended phase iii trial act v insomnia terminated program remains mk suvorexant december hold united states company neuromuscular blockade reversal plans discussions fda mk bridion us november osteoporosis f ino r n oe vv ee mlo bp em r en mjap era cn k rn ecly ei ved mk odanacatib september complete response letter fda parkinsons disease nomace mka company mk preladenant july planning conduct additional clinical pediatric hexavalent combination vaccine study requested fda update v april application future thrombosis mk vorapaxar september employees december company approximately employees worldwide approximately employed united states including puerto rico approximately worldwide employees company represented various collective bargaining groups february company commenced actions merger restructuring program conjunction integration legacy merck legacy scheringplough businesses merger restructuring program intended optimize cost structure combined company additional actions program continued july company announced latest phase merger restructuring program company expects reduce workforce measured time table contents merger additional across company worldwide majority workforce reductions phase merger restructuring program relate manufacturing including animal health administrative headquarters organizations previously announced workforce reductions approximately earlier phases program primarily reflect elimination positions sales administrative headquarters organizations well sale closure certain manufacturing research development sites consolidation office facilities since inception merger restructuring program december merck eliminated approximately positions comprised employee separations well elimination contractors positions vacant time merger october merck announced global restructuring program restructuring program reduce cost structure increase efficiency enhance competitiveness part restructuring program company expects eliminate approximately positions active employees vacancies across company worldwide since inception restructuring program december merck eliminated approximately positions comprised employee separations elimination contractors vacant positions prior merger scheringplough commenced productivity transformation program designed reduce avoid costs increase productivity position eliminations associated program largely complete environmental matters company believes compliance issues associated applicable environmental laws regulations would material adverse effect company company also remediating environmental contamination resulting past industrial activity certain sites expenditures remediation environmental liabilities million million million estimated million aggregate years amounts consider potential recoveries parties company taken active role identifying providing costs managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million december although possible predict certainty outcome environmental matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures material adverse effect companys financial position results operations liquidity capital resources year merck believes climate change could present risks business potential impacts climate change business include increased operating costs due additional regulatory requirements physical risks companys facilities water limitations disruptions supply chain potential risks integrated companys business planning including investment reducing energy water use greenhouse gas emissions company believe risks material business time geographic area information companys operations outside united states conducted primarily subsidiaries sales worldwide subsidiaries outside united states sales sales sales increase proportion sales outside united states primarily due inclusion results scheringplough following close merger companys worldwide business subject risks currency fluctuations governmental actions governmental proceedings abroad company regard risks deterrent expansion operations abroad however company closely reviews methods operations adopts strategies responsive changing economic political conditions merck expanded operations countries located latin america middle east africa eastern europe asia pacific business developing areas sometimes less stable offers important opportunities growth time table contents financial information geographic areas companys business discussed item financial statements supplementary data available information companys internet website address wwwmerckcom company make available free charge investors portion website annual report quarterly reports form q current reports form k amendments reports filed furnished pursuant section securities exchange act amended soon reasonably practicable reports electronically filed furnished securities exchange commission sec companys corporate governance guidelines charters board directors six standing committees available companys website wwwmerckcomaboutleadership information available print stockholder requests company item risk factors investors carefully consider information set forth including following risk factors deciding invest companys securities risks ones company faces additional risks currently known company company presently deems immaterial may also impair business operations companys business financial condition results operations prospects could materially adversely affected risks also contains forwardlooking statements involve risks uncertainties companys results could materially differ anticipated forwardlooking statements result certain factors including risks faces described elsewhere see cautionary factors may affect future results certain companys major products going lose patent protection near future including singulair occurs company expects significant decline sales products company depends upon patents provide exclusive marketing rights products period time product patents several companys products recently expired united states countries company faces strong competition lower priced generic drugs loss patent protection one companys products typically leads rapid loss sales product lower priced generic versions drug become available case products contribute significantly companys sales loss patent protection material adverse effect companys business cash flow results operations financial position prospects patent provides us market exclusivity singulair companys largest selling product us sales approximately billion expires august company expects within two years following patent expiration lose substantially us sales singulair declines coming first full year following patent expiration also patent provides market exclusivity singulair expire number major european markets february company expects sales singulair markets decline significantly thereafter addition patent provides us market exclusivity maxalt expire december also patent provides market exclusivity maxalt expire number major european markets february company anticipates sales united states approximately million european markets decline significantly patent expiries addition previously disclosed astrazeneca right exercise option acquire companys interest subsidiary companys interest nexium prilosec company believes likely astrazeneca exercise option chart listing us patent protection companys major marketed products set forth item business patents trademarks licenses company dependent patent rights patent rights invalidated circumvented business would adversely affected patent protection considered aggregate material importance companys marketing human health products united states major foreign markets patents covering table contents products introduced normally provide market exclusivity important successful marketing sale products company seeks patents covering products markets intends sell products meaningful patent protection available even company succeeds obtaining patents covering products third parties government authorities may challenge seek invalidate circumvent patents patent applications important companys business defend successfully patent rights provide market exclusivity products company often involved patent disputes relating challenges patents infringement similar claims company company aggressively defends important patents within outside united states including filing claims infringement parties see item financial statements supplementary data note contingencies environmental liabilities particular manufacturers generic pharmaceutical products time time file abbreviated new drug applications fda seeking market generic forms companys products prior expiration relevant patents owned company company normally responds vigorously defending patent including filing lawsuits alleging patent infringement trial relating companys us patent nasonex expected take place patent litigation challenges companys patents costly unpredictable may deprive company market exclusivity patented product cases third party patents may prevent company marketing selling product particular geographic area additionally certain foreign governments indicated compulsory licenses patents may granted case national emergencies could diminish eliminate sales profits regions negatively affect companys results operations recent court decisions relating companies us patents potential us legislation relating patent reform well regulatory initiatives may result erosion intellectual property protection one important products lose patent protection profitable markets sales products likely decline significantly result generic versions products becoming available case certain products loss could result material noncash impairment charge companys results operations may adversely affected lost sales unless company successfully launched commercially successful replacement products key company products generate significant amount companys profits cash flows events adversely affect markets leading products could material negative impact results operations cash flows companys ability generate profits operating cash flow depends largely upon continued profitability companys key products singulair januvia remicade zetia vytorin janumet isentress nasonex gardasil temodar result companys dependence key products event adversely affects products markets products could significant impact results operations cash flows events could include loss patent protection increased costs associated manufacturing generic overthecounter availability companys product competitive product discovery previously unknown side effects increased competition introduction new effective treatments discontinuation removal market product reason events material adverse effect sales certain products event could result material noncash impairment charge companys research development efforts may succeed developing commercially successful products company may able acquire commercially successful products ways consequence company may able replace sales successful products lost patent protection like major pharmaceutical companies order remain competitive company must continue launch new products year expected declines sales products singulair maxalt loss market exclusivity mean companys future success dependent pipeline new products including new products may develop joint ventures products able obtain table contents license acquisition accomplish company commits substantial effort funds resources research development dedicated resources various collaborations third parties high rate failure inherent research develop new drugs treat diseases result high risk funds invested company research programs generate financial returns risk profile compounded fact research long investment cycle bring pharmaceutical compound discovery phase market may take decade failure occur point process including later process significant funds invested description research development process see item business research development phase testing highly regulated phase substantial risk company encounter serious obstacles achieve goals therefore company may abandon product invested substantial amounts time resources risks encountered research development process include following preclinical testing new compound may yield disappointing results clinical trials new drug may successful new drug may effective may harmful side effects new drug may approved fda intended use may possible obtain patent new drug sales new product may disappointing company state certainty whether products development approved launched whether able develop license otherwise acquire compounds product candidates products whether products launched commercially successful company must maintain continuous flow successful new products successful new indications brand extensions existing products sufficient cover substantial research development costs replace sales lost profitable products singular maxalt lose patent protection displaced competing products therapies failure short term long term would material adverse effect companys business results operations cash flow financial position prospects companys success dependent successful development marketing new products subject substantial risks products appear promising development may fail reach market numerous reasons including following findings ineffectiveness superior safety efficacy competing products harmful side effects clinical preclinical testing failure receive necessary regulatory approvals including delays approval new products new indications increasing uncertainties time required obtain regulatory approvals benefitrisk standards applied regulatory agencies determining whether grant approvals lack economic feasibility due manufacturing costs factors preclusion commercialization proprietary rights others future certain pipeline programs cancelled company believes commercial prospects reduced company may recognize material noncash impairment charges programs measured fair value capitalized connection merger non cash impairment charges company anticipates would excluded companys nongaap earnings could material companys future gaap earnings example company recognized noncash impairment charge billion respect vorapaxar legacy schering plough pipeline program companys products including products development marketed unless company obtains maintains regulatory approval companys activities including research preclinical testing clinical trials manufacturing marketing products subject extensive regulation numerous federal state local governmental authorities united states including fda foreign regulatory authorities including eu united states fda particular importance company administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals table contents many cases fda requirements increased amount time money necessary develop new products bring market united states regulation outside united states also primarily focused drug safety effectiveness many cases cost reduction fda foreign regulatory authorities substantial discretion require additional testing delay withhold registration marketing approval otherwise preclude distribution sale product even company successful developing new products able market products unless obtained required regulatory approvals jurisdiction proposes market new products obtained company must maintain approval long plans market new products jurisdiction approval required companys failure obtain approval significant delays approval process failure maintain approval jurisdiction prevent selling new products jurisdiction approval obtained ever company would able realize revenues new products jurisdiction approval developments following regulatory approval may adversely affect sales companys products even product reaches market certain developments following regulatory approval including results postmarketing phase iv trials studies may decrease demand companys products including following rereview products already marketed new scientific information evolution scientific theories recall loss marketing approval products already marketed changing government standards public expectations regarding safety efficacy labeling changes greater scrutiny advertising promotion past several years clinical trials postmarketing surveillance certain marketed drugs company competitors within industry raised concerns led recalls withdrawals adverse labeling marketed products clinical trials postmarketing surveillance certain marketed drugs also raised concerns among prescribers patients relating safety efficacy pharmaceutical products general negatively affected sales products addition increased scrutiny outcomes clinical trials led increased volatility market reaction matters often attract litigation even basis litigation groundless considerable resources may needed respond addition following wake product withdrawals significant safety issues health authorities fda ema japans pharmaceutical medical device agency increased focus safety assessing benefitrisk balance drugs health authorities appear become cautious making decisions approvability new products indications rereviewing select products already marketed adding uncertainties regulatory processes also greater regulatory scrutiny especially united states advertising promotion particular directtoconsumer advertising previously unknown side effects discovered increase negative publicity regarding known side effects companys products could significantly reduce demand product require company take actions could negatively affect sales including removing product market restricting distribution applying labeling changes current environment pharmaceutical companies operate company risk product liability consumer protection claims civil criminal governmental actions related products research andor marketing activities company faces intense competition lowercost generic products general company faces increasing competition lowercost generic products patent rights protect products varying strengths durations addition countries patent table contents protection significantly weaker united states eu united states political pressure reduce spending prescription drugs led legislation encourages use generic products although companys policy actively protect patent rights generic challenges companys products arise time may able prevent emergence generic competition products loss patent protection product typically followed promptly generic substitutes reducing companys sales product availability generic substitutes companys drugs may adversely affect results operations cash flow addition proposals emerge time time united states countries legislation encourage early rapid approval generic drugs proposal enacted law could worsen substantial negative effect companys sales potentially business cash flow results operations financial position prospects company faces intense competition competitors products addition factors could certain circumstances lead non cash impairment charges companys products face intense competition competitors products competition may increase new products enter market event competitors products may safer effective effectively marketed sold companys products alternatively case generic competition including generic availability competitors branded products may equally safe effective products sold substantially lower price companys products result company fails maintain competitive position could material adverse effect business cash flow results operations financial position prospects addition legacy scheringplough products measured fair value capitalized connection merger saphris former merckschering plough partnership products vytorin zetia experience difficulties market negatively impact product cash flows company may recognize material noncash impairment charges respect value products noncash impairment charges company anticipates would excluded companys nongaap earnings could material companys future gaap earnings company faces pricing pressure respect products company faces increasing pricing pressure globally managed care organizations government agencies programs could negatively affect companys sales profit margins united states include practices managed care groups institutional governmental purchasers ii us federal laws regulations related medicare medicaid including medicare prescription drug improvement modernization act patient protection affordable care act changes health care system enacted part health care reform united states well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries could result pricing pressures addition company faces risk litigation government pricing calculations outside united states numerous major markets pervasive government involvement funding health care regard fix pricing reimbursement pharmaceutical vaccine products consequently markets company subject government decision making budgetary actions respect products company expects pricing pressures increase future health care industry continue subject increasing regulation political action company believes health care industry continue subject increasing regulation well political legal action future proposals reform health care system considered congress state legislatures major health care reform adopted law united states important market reforms begun continue full implementation new law expected expand access health care million americans end decade merck incurred additional costs result new law including increased medicaid rebates impacts reduced revenues minimum rebate states participating medicaid program table contents increased companys branded prescription drugs medicaid rebate extended medicaid managed care organizations eligibility federal b drug discount program extended rural referral centers sole community hospitals critical access hospitals certain free standing cancer hospitals certain additional childrens hospitals addition law requires drug manufacturers pay discount medicare part beneficiaries medicare part coverage gap ie socalled donut hole also beginning company required pay annual health care reform fee assessed branded prescription drug manufacturers importers fee calculated based industrys total sales branded prescription drugs specified government programs percentage manufacturers sales included determined tiered scale based manufacturers individual revenues manufacturers portion total annual fee based manufacturers proportion total includable sales prior year annual industry fee billion annual industry fee billion company predict likelihood future changes health care industry general pharmaceutical industry particular impact may companys results operations financial condition business current uncertainty global economic conditions together austerity measures taken certain governments could negatively affect companys operating results current uncertainty global economic conditions may result slowdown global economy could affect companys business reducing prices drug wholesalers retailers hospitals government agencies managed health care providers may able willing pay companys products reducing demand companys products could turn negatively impact companys sales result material adverse effect companys business cash flow results operations financial position prospects many companys brands experienced positive growth trends eu environment eu across europe continues challenging many countries announced austerity measures aimed reducing costs areas health care implementation pricing actions varies country many announced measures reduce prices generic patented drugs company taking steps mitigate immediate impact eu austerity measures negatively affected companys revenue performance company anticipates midsingle digit pricing pressures across europe furthermore european austerity measures could negatively affect companys revenue performance company anticipates lastly company subject biennial price reductions japan furthermore company believes credit economic conditions within greece spain italy portugal among members eu deteriorated may continue deteriorate conditions well inherent variability timing cash receipts resulted may continue result increase average length time takes collect accounts receivable outstanding countries may also impact likelihood collecting outstanding accounts receivable december companys accounts receivable greece italy spain portugal totaled approximately billion amount hospital public sector receivables approximately billion aggregate approximately related greece italy spain portugal respectively december companys total accounts receivable outstanding one year approximately million approximately related accounts receivable greece italy spain portugal mostly comprised hospital public sector receivables conditions europe worsen one countries euro zone exits euro zone reintroduces legacy currency resulting economic currency impacts affected markets globally could material adverse effect companys results table contents company significant global operations expose additional risks adverse event could material negative impact companys results operations extent companys operations outside united states significant risks inherent conducting global business include changes medical reimbursement policies programs pricing restrictions key markets multiple regulatory requirements could restrict companys ability manufacture sell products key markets trade protection measures import export licensing requirements foreign exchange fluctuations diminished protection intellectual property countries possible nationalization expropriation addition may changes companys business political position instability disruption destruction significant geographic region regardless cause including war terrorism riot civil insurrection social unrest natural manmade disasters including famine flood fire earthquake storm disease company experienced difficulties delays manufacturing certain products previously disclosed merck past experienced difficulties manufacturing certain vaccines products similarly company past experienced difficulties manufacturing certain animal health products currently experiencing difficulty manufacturing certain womens health products company working manufacturing issues assurance issues finally resolved addition difficulties company experiencing currently company may experience difficulties delays inherent manufacturing products failure company vendors suppliers comply current good manufacturing practices applicable regulations quality assurance guidelines could lead manufacturing shutdowns product shortages delays product manufacturing ii construction delays related construction new facilities expansion existing facilities including intended support future demand companys products iii manufacturing distribution problems including changes manufacturing production sites limits manufacturing capacity due regulatory requirements changes types products produced physical limitations could impact continuous supply manufacturing difficulties result product shortages leading lost sales company faces significant litigation related vioxx september merck voluntarily withdrew vioxx arthritis acute pain medication market worldwide although merck settled major portion us product liability litigation company still faces material litigation arising voluntary withdrawal vioxx addition vioxx product liability lawsuits various purported class actions individual lawsuits brought merck several current former officers directors merck alleging merck made false misleading statements regarding vioxx violation federal securities laws state laws suits referred vioxx securities lawsuits vioxx securities lawsuits transferred judicial panel multidistrict litigation jpml us district court district new jersey district judge stanley r chesler inclusion nationwide mdl shareholder mdl consolidated purposes vioxx securities lawsuits discussed fully item financial statements supplementary data note contingencies environmental liabilities merck also named defendant actions various countries outside united states suits referred vioxx foreign lawsuits merck also sued number states one county private citizen qui tam lawsuit respect marketing vioxx table contents previously disclosed us department justice doj issued subpoenas requesting information relating mercks research marketing selling activities respect vioxx federal health care investigation criminal statutes company established million reserve vioxx liability reserve connection anticipated resolution dojs investigation november company announced reached resolution federal state authorities regarding matter pending court approval civil settlement agreements signed united states individually states district columbia merck pay approximately twothirds reserved charge resolve civil allegations related vioxx result united states participating states released merck civil liability related governments allegations regarding sale promotion vioxx company also agreed plead guilty one count misdemeanor misbranding vioxx federal food drug cosmetic act promoting drug treatment rheumatoid arthritis prior fdas approval indication april company pay fine approximately onethird reserved amount federal government part plea agreement regard nonparticipating states merck continues face lawsuits filed states december united states district court district massachusetts conducted hearing regard resolution hearing parties advised court nature resolution core documents comprising resolution court scheduled subsequent hearing march court may issue ruling concerning whether accepts mercks plea resolution vioxx litigation discussed fully item financial statements supplementary data note contingencies environmental liabilities trial missouri state court action scheduled begin may company predict timing trials related vioxx litigation company believes meritorious defenses vioxx product liability lawsuits vioxx securities lawsuits vioxx foreign lawsuits collectively vioxx lawsuits vigorously defend companys insurance coverage respect vioxx lawsuits adequate cover defense costs losses company currently able estimate additional amounts may required pay connection vioxx lawsuits proceedings still expected continue years company predict course proceedings take view inherent difficulty predicting outcome litigation particularly many claimants claimants seek unspecified damages company unable predict outcome matters time reasonably estimate possible loss range loss respect remaining vioxx lawsuits company established reserves potential liability relating remaining vioxx lawsuits vioxx liability reserve reserve related settlement canadian vioxx litigation discussed item financial statements supplementary data note contingencies environmental liabilities series unfavorable outcomes vioxx lawsuits resulting payment substantial damages could material adverse effect companys business cash flow results operations financial position prospects issues concerning vytorin enhance clinical trial adverse effect sales vytorin zetia united states results ongoing trials could adverse effect sales company sells vytorin zetia previously disclosed january legacy companies announced results enhance clinical trial imaging trial patients heterozygous familial hypercholesterolemia rare genetic condition causes high levels ldl bad cholesterol greatly increases risk premature coronary artery disease previously reported despite fact ezetimibesimvastatin mg vytorin significantly lowered ldl bad cholesterol simvastatin mg alone significant difference treatment ezetimibesimvastatin simvastatin alone prespecified primary endpoint change thickness carotid artery walls two years measured ultrasound improve trial underway designed provide cardiovascular outcomes data ezetimibesimvastatin patients acute coronary syndrome incremental benefit ezetimibesimvastatin table contents cardiovascular morbidity mortality demonstrated simvastatin established january fda announced completed review final clinical study report enhance fda stated results enhance change position elevated ldl cholesterol risk factor cardiovascular disease lowering ldl cholesterol reduces risk cardiovascular disease discussion concerning shareholder litigation arising enhance study see item financial statements supplementary data note contingencies environmental liabilities improveit trial scheduled completion improveit trial blinded interim efficacy analysis conducted dsmb trial approximately endpoints accrued dsmb recommended continuing trial changes study protocol another blinded interim efficacy analysis planned dsmb first quarter approximately primary events accrued based results interim analysis trial halted concerns related vytorin could material adverse effect sales vytorin zetia issues concerning enhance clinical trial adverse effect sales vytorin zetia could continue adverse effect sales results improveit trial fail demonstrate incremental benefit ezetimibesimvastatin cardiovascular morbidity mortality demonstrated simvastatin sales zetia vytorin could materially adversely affected sales products materially adversely affected companys business cash flow results operations financial position prospects could also materially adversely affected company could required record material noncash impairment charge addition unfavorable outcomes resulting shareholder litigation concerning enhance clinical trial results could material adverse effect companys business cash flow results operations financial position prospects company may fail realize anticipated cost savings revenue enhancements benefits expected merger could adversely affect value companys common stock success merger depend part companys ability successfully combine businesses merck scheringplough realize anticipated benefits cost savings combination two companies combined company able achieve objectives within anticipated time frame value companys common stock may adversely affected possible integration process could result loss key employees result disruption companys ongoing business identify inconsistencies standards controls procedures policies adversely affect ability maintain relationships customers suppliers distributors creditors lessors clinical trial investigators managers achieve anticipated benefits merger specifically issues must addressed integrating operations two legacy companies order realize anticipated benefits merger include among things integrating research development manufacturing distribution marketing promotion activities information technology systems merck scheringplough conforming standards controls procedures accounting policies business cultures compensation structures companies identifying eliminating redundant underperforming operations assets managing tax costs inefficiencies associated integrating operations combined company integration efforts two companies continue divert management attention resources companys integration efforts involve plans close sell certain facilities worldwide implementation plans subject satisfaction local legal requirements including limited compliance relevant information consultation obligations applicable processes may result delays failure company realize anticipated synergies inability realize full extent anticipated benefits merger well delays encountered integration process could adverse effect companys business results operations may affect value shares company common stock table contents addition actual integration may result additional unforeseen expenses new information technology systems anticipated benefits integration plan may realized actual cost sales synergies may lower company expects may take longer achieve anticipated company able adequately address challenges may unable successfully integrate operations two legacy companies realize anticipated benefits integration two legacy companies delays encountered integration process could material adverse effect revenues expenses operating results financial condition company although company expects significant benefits increased cost savings result merger assurance company realize anticipated benefits company may able realize expected benefits investments emerging markets company taking steps increase presence emerging markets however guarantee companys efforts expand sales emerging markets succeed countries within emerging markets may especially vulnerable periods global financial instability may limited resources spend health care order company successfully implement emerging markets strategy must attract retain qualified personnel company may also required increase reliance thirdparty agents within less developed markets addition many countries currencies fluctuate substantially currencies devalue offset devaluations companys financial performance within countries could adversely affected reasons sales within emerging markets carry significant risks however failure continue expand companys business emerging markets could material adverse effect business financial condition results companys operations company exposed market risk fluctuations currency exchange rates interest rates company operates multiple jurisdictions virtually sales denominated currencies local jurisdiction additionally company entered enter acquisition licensing borrowings financial transactions may give rise currency interest rate exposure since company certainty foresee mitigate adverse fluctuations fluctuations currency exchange rates interest rates could negatively affect companys results operations financial position cash flows order mitigate adverse impact market fluctuations company time time enter hedging agreements hedging agreements currency options interest rate swaps may limit exposure exchange rate interest rate fluctuations attempts mitigate risks may costly always successful company subject evolving complex tax laws may result additional liabilities may affect results operations company subject evolving complex tax laws jurisdictions operates significant judgment required determining companys tax liabilities companys tax returns periodically examined various tax authorities company believes accrual tax contingencies adequate open years based past experience interpretations tax law judgments potential actions tax authorities however due complexity tax contingencies ultimate resolution tax matters may result payments greater less amounts accrued february president obamas administration reproposed significant changes us international tax laws including changes would tax companies excess returns attributable certain offshore intangible assets limit us tax deductions expenses related unrepatriated foreignsource income table contents modify us foreign tax credit rules potentially significant changes us international laws including move toward territorial tax system set various congressional committees company determine whether proposals enacted law changes may made proposals prior enacted law changes us international tax laws enacted could significant impact financial results company addition company may impacted changes tax laws including tax rate changes changes laws related remittance foreign earnings deferral limitations impacting us tax treatment foreign earnings new tax laws revised tax law interpretations domestic foreign jurisdictions pharmaceutical products develop unexpected safety efficacy concerns unexpected safety efficacy concerns arise respect marketed products whether scientifically justified leading product recalls withdrawals declining sales well product liability consumer fraud andor claims including potential civil criminal governmental actions changes laws regulations could adversely affect companys business aspects companys business including research development manufacturing marketing pricing sales litigation intellectual property rights subject extensive legislation regulation changes applicable federal state laws agency regulations could material adverse effect companys business reliance third party relationships outsourcing arrangements could adversely affect companys business company depends third parties including suppliers alliances pharmaceutical biotechnology companies third party service providers key aspects business including development manufacture commercialization products support information technology systems failure third parties meet contractual regulatory obligations company development factors materially disrupt relationships company third parties could material adverse effect companys business company increasingly dependent sophisticated information technology infrastructure company increasingly dependent sophisticated information technology infrastructure significant breakdown intrusion interruption corruption systems data breaches could material adverse effect business addition company currently proceeding multiyear implementation enterprise wide resource planning system certain operations united states began implemented us operations includes modification design operation documentation internal controls financial reporting company implemented resource planning system major european markets canada intends implement additional markets material problems implementation could material adverse effect companys business negative events animal health industry could negative impact future results operations future sales key animal health products could adversely impacted number risk factors including certain risks specific animal health business example outbreak disease carried animals bovine spongiform encephalopathy mad cow disease could lead widespread death precautionary destruction well reduced consumption demand animals could adversely impact companys results operations also outbreak highly contagious diseases near companys main production sites could require company immediately halt production vaccines sites force company incur substantial expenses procuring raw materials vaccines elsewhere risks specific animal health include epidemics pandemics government procurement pricing practices table contents weather global agribusiness economic events animal health segment companys business becomes significant impact events future results operations would also become significant biologics carry unique risks uncertainties could negative impact future results operations successful development testing manufacturing commercialization biologics particularly human animal health vaccines long expensive uncertain process unique risks uncertainties biologics including may limited access supply normal diseased tissue samples cell lines pathogens bacteria viral strains biological materials addition government regulations multiple jurisdictions united states european countries within eu could result restricted access transport use materials company loses access sufficient sources materials tighter restrictions imposed use materials company may able conduct research activities planned may incur additional development costs development manufacturing marketing biologics subject regulation fda ema regulatory bodies regulations often complex extensive regulations applicable pharmaceutical products example united states bla including preclinical clinical trial data extensive data regarding manufacturing procedures required human vaccine candidates fda approval required release manufactured commercial lot manufacturing biologics especially large quantities often complex may require use innovative technologies handle living micro organisms lot approved biologic must undergo thorough testing identity strength quality purity potency manufacturing biologics requires facilities specifically designed validated purpose sophisticated quality assurance quality control procedures necessary slight deviations anywhere manufacturing process including filling labeling packaging storage shipping quality control testing may result lot failures product recalls spoilage changes made manufacturing process company may required provide preclinical clinical data showing comparable identity strength quality purity potency products changes biologics frequently costly manufacture production ingredients derived living animal plant material biologics made synthetically particular keeping demand vaccines may difficult due complexity producing vaccines use biologically derived ingredients lead allegations harm including infections allergic reactions closure product facilities due possible contamination events could result substantial costs product liability insurance products may limited cost prohibitive unavailable result number factors product liability insurance become less available cost increased significantly respect product liability company selfinsures substantially risk availability commercial insurance become restrictive company evaluated risks determined cost obtaining product liability insurance outweighs likely benefits coverage available insurance certain product liabilities effective august including liability legacy merck products first sold date company continually assess efficient means address risk however guarantee insurance coverage obtained obtained sufficient fully cover product liabilities may arise table contents cautionary factors may affect future results cautionary statements private securities litigation reform act report written reports oral statements made time time company may contain socalled forwardlooking statements based managements current expectations subject risks uncertainties may cause results differ materially set forth statements one identify forwardlooking statements use words anticipates expects plans estimates forecasts projects words similar meaning one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product development product approvals product potential development programs one must carefully consider statement understand many factors could cause actual results differ materially companys forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially company assume obligation update forwardlooking statement company cautions place undue reliance forwardlooking statements although possible predict identify factors may include following competition generic products companys products lose patent protection increased brand competition therapeutic areas important companys longterm business performance difficulties uncertainties inherent new product development outcome lengthy complex process new product development inherently uncertain drug candidate fail stage process one latestage product candidates could fail receive regulatory approval new product candidates may appear promising development fail reach market efficacy safety concerns inability obtain necessary regulatory approvals difficulty excessive cost manufacture andor infringement patents intellectual property rights others furthermore sales new products may prove disappointing fail reach anticipated levels pricing pressures united states abroad including rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement pricing general changes government laws regulations including laws governing intellectual property enforcement thereof affecting companys business efficacy safety concerns respect marketed products whether scientifically justified leading product recalls withdrawals declining sales significant litigation related vioxx vytorin zetia legal factors including product liability claims antitrust litigation governmental investigations including tax disputes environmental concerns patent disputes branded generic competitors could preclude commercialization products negatively affect profitability existing products lost market opportunity resulting delays uncertainties approval process fda foreign regulatory authorities increased focus privacy issues countries around world including united states eu legislative regulatory landscape privacy data protection continues evolve increasing amount focus privacy data protection issues potential affect directly companys business including recently enacted laws majority states united states requiring security breach notification changes tax laws including changes related taxation foreign earnings table contents changes accounting pronouncements promulgated standardsetting regulatory bodies including financial accounting standards board sec adverse company economic factors company control including changes inflation interest rates foreign currency exchange rates list considered exhaustive statement potential risks uncertainties see risk factors item b unresolved staff comments none item properties companys corporate headquarters located whitehouse station new jersey companys us commercial operations headquartered upper gwynedd pennsylvania companys us pharmaceutical business conducted divisional headquarters located upper gwynedd whitehouse station companys vaccines business conducted divisional headquarters located west point pennsylvania part companys worldwide strategic plan mercks animal health global headquarters functions currently located boxmeer netherlands centralized new jersey principal us research facilities located rahway kenilworth summit new jersey west point pennsylvania palo alto california elkhorn nebraska animal health principal research facilities outside us located netherlands company also production facilities human health products locations united states puerto rico outside united states subsidiaries company owns interest manufacturing plants properties australia canada japan singapore south africa countries western europe central south america asia capital expenditures billion united states amounted billion million abroad expenditures amounted million million company subsidiaries principal facilities manufacturing plants titles consider satisfactory company considers properties good operating condition machinery equipment well maintained plants manufacture products suitable intended purposes capacities projected capacities adequate current projected needs existing company products capacity plants converted needed modification requirements newly introduced future products item legal proceedings information called item incorporated herein reference note contingencies environmental liabilities included part ii item financial statements supplementary data item mine safety disclosures applicable executive officers registrant ages february time merger november certain executive officers assumed position newly merged company noted kenneth c frazier age december chairman president chief executive officer merck co inc january president chief executive officer merck co inc may president merck co inc responsible companys three largest worldwide divisions global human health merck manufacturing division merck research laboratories table contents november executive vice president president global human health merck co inc responsible companys marketing sales organizations worldwide including global pharmaceutical vaccine franchises august executive vice president president global human health merck co inc responsible companys marketing sales organizations worldwide including global pharmaceutical vaccine franchises november executive vice president general counsel merck co inc responsible legal public affairs functions merck company foundation notforprofit charitable organization affiliated company adele ambrose age november senior vice president chief communications officer merck co inc responsible global communications organization december vice president chief communications officer merck co inc responsible global communications organization richard bowles iii age november executive vice president chief ethics compliance officer merck co inc responsible companys compliance function including global safety environment systems assurance ethics privacy prior november dr bowles senior vice president global quality operations scheringplough corporation since march john canan age november senior vice president financeglobal controller merck co inc responsible companys global controllers organization including accounting controls external reporting financial standards policies january senior vice president controller merck co inc responsible corporate controllers group september vice president controller merck co inc responsible corporate controllers group willie deese age november executive vice president president merck manufacturing division merck co inc responsible companys global manufacturing procurement distribution logistics functions january executive vice president president merck manufacturing division merck co inc responsible companys global manufacturing procurement distribution logistics functions may president merck manufacturing division merck co inc responsible companys global manufacturing procurement operational excellence functions richard r deluca jr age september executive vice president president merck animal health merck co inc responsible merck animal health organization prior september mr deluca chief financial officer becton dickinson biosciences medical technology company since president wyeths fort dodge animal health division also served chief operating officer fort dodge executive vice president chief financial officer table contents cuong viet age october executive vice president chief strategy officer merck co inc responsible leading formulation execution companys long term strategic plan prior october mr senior vice president corporate strategy business development te connectivity global company designs manufactures markets products customers variety industries senior vice president chief strategy officer lenovo personal technology company mirian graddickweir age november executive vice president human resources merck co inc responsible global human resources organization january executive vice president human resources merck co inc responsible global human resources organization september senior vice president human resources merck co inc bridgette p heller age march executive vice president president merck consumer care merck co inc responsible merck consumer care organization prior march ms heller president johnson johnsons baby global business unit president global baby kids wound care peter n kellogg age november executive vice president chief financial officer merck co inc responsible companys worldwide financial organization investor relations corporate development licensing companys joint venture relationships august executive vice president chief financial officer merck co inc responsible companys worldwide financial organization investor relations corporate development licensing companys joint venture relationships prior august mr kellogg executive vice president finance chief financial officer biogen idec biotechnology company merger biogen inc idec pharmaceuticals corporation november peter kim age november executive vice president president merck research laboratories merck co inc responsible companys research development efforts worldwide january executive vice president president merck research laboratories merck co inc responsible companys research development efforts worldwide january president merck research laboratories merck co inc responsible companys research development efforts worldwide bruce n kuhlik age november executive vice president general counsel merck co inc responsible legal communications public policy functions merck company foundation notforprofit charitable organization affiliated company january executive vice president general counsel merck co inc responsible legal communications public policy functions merck company foundation notforprofit charitable organization affiliated company table contents august senior vice president general counsel merck co inc responsible legal communications public policy functions merck company foundation notforprofit charitable organization affiliated company may vice president associate general counsel merck co inc primary responsibility companys vioxx litigation defense michael rosenblatt md age december executive vice president chief medical officer merck co inc companys primary voice global medical community critical issues patient safety oversight companys global center scientific affairs prior december dr rosenblatt dean tufts university school medicine since j chris scalet age november executive vice president global services chief information officer merck co inc responsible global shared services across human resources finance site services information services function enterprise business process redesign initiative january executive vice president global services chief information officer merck co inc responsible global shared services across human resources finance site services information services function enterprise business process redesign initiative january senior vice president global services chief information officer merck co inc responsible global shared services across human resources finance site services information services function enterprise business process redesign initiative adam h schechter age may executive vice president president global human health merck co inc responsible companys pharmaceutical vaccine worldwide business november president global human health us marketintegration leader merck co inc commercial responsibility united states companys portfolio prescription medicines leader integration efforts merckscheringplough merger across divisions functions august president global pharmaceuticals global human health merck co inc global responsibilities companys atherosclerosiscardiovascular diabetesobesity oncology specialtyneuroscience respiratory bone arthritis analgesia franchises well commercial responsibility united states companys portfolio prescription medicines july president us human health merck co inc commercial responsibility united states companys portfolio prescription medicines officers listed serve pleasure board directors none officers elected pursuant arrangement understanding officer board table contents part ii item market registrants common equity related stockholder matters issuer purchases equity securities principal market trading companys common stock new york stock exchange nyse symbol mrk common stock market price information set forth table based historical nyse market prices following table also sets forth calendar periods indicated dividend per share information cash dividends paid per common share year th q rd q nd q st q common stock market prices th q rd q nd q st q high low high low january approximately shareholders record table contents equity compensation plan information following table summarizes information options warrants rights equity compensation companys equity compensation plans close business december table include information tax qualified plans msd employee savings security plan scheringplough employees savings plan number weighted securities remaining number average available future securities exercise issuance equity issued upon price compensation plans exercise outstanding excluding outstanding options securities options warrants warrants reflected column rights rights plan category b c equity compensation plans approved security holders equity compensation plans approved security holders total includes options purchase shares company common stock rights following shareholderapproved plans merck sharp dohme incentive stock plans merck co inc nonemployee directors stock option plans merck co inc scheringplough stock incentive plans excludes approximately shares restricted stock units performance share units assuming maximum payouts merck sharp dohme incentive stock plans shares restricted stock units performance share units excluding accrued dividends merck co inc scheringplough stock incentive plan also excludes shares phantom stock deferred msd deferral program table include information equity compensation plans options warrants rights assumed company connection mergers acquisitions pursuant remain outstanding options warrants rights collectively assumed plans include rosetta inpharmatics inc employee stock option plans total shares merck common stock may purchased assumed plans weighted average exercise price grants may made assumed plans table contents performance graph following graph assumes investment december reinvestment dividends companys common shares sp index composite peer group major usbased pharmaceutical companies abbott laboratories bristolmyers squibb company johnson johnson eli lilly company pfizer inc comparison fiveyear cumulative total return merck co inc composite peer group sp index end period value cagr merck peer grp sp merck peer grp sp performance graph reflects scheringploughs stock performance december close merger mercks stock performance november december assumes cash component merger consideration reinvested merck stock closing price november compound annual growth rate october wyeth pfizer inc completed previously announced merger pfizerwyeth merger wyeth became whollyowned subsidiary pfizer inc discussed november merck scheringplough completed merger together pfizerwyeth merger transactions merck subsequently renamed merck sharp dohme corp msd became whollyowned subsidiary scheringplough subsequently renamed merck co inc result transactions wyeth msd longer exist publicly traded entities ceased trading common stock close business respective merger dates wyeth msd permanently removed peer group index table contents item selected financial data following selected financial data read conjunction item managements discussion analysis financial condition results operations consolidated financial statements notes thereto contained item financial statements supplementary data report merck co inc subsidiaries millions except per share amounts results year sales materials production marketing administrative research development restructuring costs equity income affiliates income expense net income taxes taxes income net income less net income attributable noncontrolling interests net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders cash dividends declared cash dividends paid per common share capital expenditures depreciation average common shares outstanding millions average common shares outstanding assuming dilution millions yearend position working capital property plant equipment net total assets longterm debt total equity yearend statistics number stockholders record number employees amounts include amortization purchase accounting adjustments inprocess research development impairment charges reflected research development expenses impact restructuring actions arbitration settlement charge favorable impact certain tax items including net favorable impact approximately million relating settlement federal income tax audit amounts include amortization purchase accounting adjustments inprocess research development impairment charges billion reflected research development expenses impact restructuring actions reserve related vioxx gain recognized astrazeneca lps exercise option acquire certain assets company favorable impact certain tax items amounts include reclassification million expenses marketing administrative research development amounts include impact merger scheringplough corporation november including recognition gain representing fair value stepup mercks previously held interest merckscheringplough partnership result obtaining controlling interest amortization purchase accounting adjustments recorded postmerger period also included gain sale mercks interest merial limited favorable impact certain tax items impact restructuring actions amounts include gain distribution astrazeneca lp gain related sale remaining worldwide rights aggrastat favorable impact certain tax items impact restructuring actions expense contribution merck company foundation amounts include impact us vioxx settlement agreement charge restructuring actions civil governmental investigations charge insurance arbitration settlement gain inprocess research development expense resulting acquisition gains sales assets product divestitures well net gain settlements certain patent disputes amount reflects dividends paid common shareholders merck addition approximately million dividends paid subsequent merger scheringplough million paid prior merger relating common stock preferred stock dividends declared scheringplough table contents item managements discussion analysis financial condition results operations description mercks business merck co inc merck company global health care company delivers innovative health solutions prescription medicines vaccines biologic therapies animal health consumer care products markets directly joint ventures companys operations principally managed products basis comprised four operating segments pharmaceutical animal health consumer care alliances segments one reportable segment pharmaceutical segment pharmaceutical segment includes human health pharmaceutical vaccine products marketed either directly company joint ventures human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities company also animal health operations discover develop manufacture market animal health products including vaccines company sells veterinarians distributors animal producers additionally company consumer care operations develop manufacture market overthecounter foot care sun care products sold wholesale retail drug food chain mass merchandiser outlets november legacy merck co inc scheringplough corporation scheringplough merged merger results scheringploughs business included mercks financial statements periods subsequent completion merger therefore mercks financial results reflect full year scheringplough operations overview company focused accelerating revenue growth reducing costs drive efficiencies allocating resources drive future growth making strategic investments product launches well emerging markets advancing augmenting research development pipeline worldwide sales totaled billion increase compared billion foreign exchange favorably affected global sales performance revenue increase driven largely growth januvia janumet treatments type diabetes singulair medicine chronic treatment asthma relief symptoms allergic rhinitis isentress antiretroviral therapy use combination therapy treatment hiv infection gardasil vaccine help prevent certain diseases caused four types human papillomavirus hpv simponi treatment inflammatory diseases rotateq vaccine help protect rotavirus gastroenteritis infants children zetia cholesterol absorption inhibitor pneumovax vaccine help prevent pneumococcal disease bridion reversal certain muscle relaxants used surgery addition revenue benefited higher sales companys animal health products launch victrelis treatment chronic hepatitis c increases partially offset lower sales cozaar hyzaar treatments hypertension lost patent protection united states april number major european markets march well lower sales caelyx subutex suboxone company longer marketing rights products revenue also negatively affected lower sales vytorin cholesterol modifying medicine temodar treatment certain types brain tumors proquad pediatric combination vaccine help protect measles mumps rubella varicella varivax vaccine help prevent chickenpox varicella addition discussed ongoing implementation certain provisions us health care reform legislation resulted increases medicaid rebates impacts reduced revenues additionally many countries european union eu undertaken austerity measures aimed reducing costs health care implemented pricing actions negatively impacted sales april merck johnson johnson jj reached agreement amend agreement governing distribution rights remicade simponi agreement concluded arbitration proceeding table contents jj initiated may terms amended distribution agreement merck relinquished marketing rights remicade simponi jj territories including canada central south america middle east africa asia pacific effective july merck retained exclusive marketing rights throughout europe russia turkey retained territories retained territories represented approximately mercks revenue billion remicade simponi addition beginning july profits derived mercks exclusive distribution two products retained territories equally divided merck jj jj also received onetime payment merck million april company continued advancement drug candidates pipeline victrelis companys innovative oral medicine treatment chronic hepatitis c approved us food drug administration fda european commission ec fda also approved juvisync new treatment type diabetes combines active ingredient glucoselowering medication januvia cholesterollowering medication zocor addition ec approved zoely monophasic combined oral contraceptive tablet use women prevent pregnancy cubicin antibacterial agent activity methicillinresistant staphylococcus aureus mrsa company licensed development distribution rights japan approved use country february fda approved janumet xr new treatment type diabetes combines sitagliptin active component januvia extendedrelease metformin oncedaily formulation cosopt pf mercks preservativefree formulation cosopt ophthalmic solution indicated reduction elevated intraocular pressure appropriate patients openangle glaucoma ocular hypertension zioptan preservativefree prostaglandin analogue ophthalmic solution company also received additional indications several existing products fda approved expanded age indication zostavax vaccine help prevent shingles herpes zoster include adults ages addition fda approved sylatron adjuvant treatment melanoma patients microscopic gross nodal involvement also simponi received indication eu use combination methotrexate adults severe active progressive rheumatoid arthritis previously treated methotrexate shown reduce rate progression joint damage measured xray improve physical function january fda approved use isentress combination antiretroviral medicines treatment hiv infection pediatric patients two years age older weighing least kg company currently two candidates review fda mk ridaforolimus treatment metastatic softtissue bone sarcomas patients favorable response chemotherapy mkc zetia ezetimibe combined atorvastatin treatment primary mixed hyperlipidemia mk also review eu company currently candidates phase iii development anticipates filing new drug application nda fda respect certain candidates including mk suvorexant investigational treatment insomnia mk bridion medication reversal certain muscle relaxants used surgery v ninevalent hpv vaccine company also anticipates filings among others mk odanacatib investigational treatment osteoporosis mka tredaptive development treatment atherosclerosis merck continues pursue opportunities potential drive near longterm growth company completed variety transactions including acquisition inspire pharmaceuticals inc specialty pharmaceutical company focused developing commercializing ophthalmic products additionally company entered transactions designed strengthen presence emerging markets longer term merck continues realize cost savings across areas company savings result various actions including merger restructuring program discussed previously announced ongoing cost reduction activities well nonrestructuringrelated activities end company realized approximately billion annual net cost savings activities since merger july company announced latest phase global restructuring program merger restructuring program initiated conjunction integration legacy merck legacy table contents scheringplough businesses merger restructuring program intended optimize cost structure combined company part latest phase company expects reduce workforce measured time merger additional across company worldwide majority workforce reductions phase merger restructuring program relate manufacturing including animal health administrative headquarters organizations previously announced workforce reductions approximately earlier phases program primarily reflect elimination positions sales administrative headquarters organizations well sale closure certain manufacturing research development sites consolidation office facilities company continue hire employees strategic growth areas business necessary company continue pursue productivity efficiencies evaluate manufacturing supply chain capabilities ongoing basis may result future restructuring actions company recorded total pretax restructuring costs billion billion billion related program restructuring actions merger restructuring program expected substantially completed end exception certain actions principally manufacturingrelated expected substantially completed total cumulative pretax costs estimated approximately billion billion company estimates approximately twothirds cumulative pretax costs relate cash outlays primarily related employee separation expense approximately onethird cumulative pretax costs noncash relating primarily accelerated depreciation facilities closed divested company expects merger restructuring program yield annual savings end approximately billion billion annual savings upon completion program approximately billion billion company continued affected us health care reform legislation enacted additional provisions went effect beginning law requires pharmaceutical manufacturers pay discount medicare part beneficiaries medicare part coverage gap ie socalled donut hole approximately million recorded reduction revenue related estimated impact provision health care reform also company recorded million expenses annual health care reform fee company required pay beginning law also increased mandated medicaid rebates reduced revenues approximately million million respectively effective december richard clark chairman retired company merck board directors kenneth c frazier mercks president chief executive officer elected board serve chairman following mr clarks retirement november mercks board directors raised companys quarterly dividend per share per share earnings per common share assuming dilution attributable common shareholders eps reflect net unfavorable impact resulting acquisitionrelated costs restructuring costs well charge related settlement arbitration proceeding jj discussed partially offset favorable impact certain tax items gains disposition companys interest johnson johnsonmerck consumer pharmaceuticals company jjmcp joint venture sale certain manufacturing facilities related assets nongaap eps excluding items see nongaap income nongaap eps competition health care environment competition markets company conducts business pharmaceutical industry highly competitive highly regulated companys competitors include worldwide researchbased pharmaceutical companies smaller research companies limited therapeutic focus generic drug consumer health care manufacturers companys operations may affected technological advances competitors industry consolidation patents granted competitors competitive combination products new products competitors generic availability competitors branded products new information clinical trials marketed products postmarketing surveillance generic competition companys products table contents mature addition patent positions increasingly challenged competitors outcome highly uncertain adverse result patent dispute preclude commercialization products negatively affect sales existing products could result recognition impairment charge respect certain products competitive pressures intensified pressures industry grown effect operations competitive factors patent disputes predicted pharmaceutical competition involves rigorous search technological innovations ability market innovations effectively longstanding emphasis research development company well positioned compete search technological innovations additional resources required meet market challenges include quality control flexibility meet customer specifications efficient distribution system strong technical information service company active acquiring marketing products external alliances joint ventures licenses refining sales marketing efforts address changing industry conditions however introduction new products processes competitors may result price reductions product displacements even products protected patents example number compounds available treat particular disease typically increases time result slowed sales growth companys products therapeutic category highly competitive animal health business affected several factors including regulatory legislative issues scientific technological advances product innovation quality price companys products effective promotional efforts frequent introduction generic products competitors companys consumer care operations face competition consumer health care businesses well retailers carry private label brands companys competitive position affected several factors including regulatory legislative issues scientific technological advances quality price companys products promotional efforts growth lower cost private label brands health care environment global efforts toward health care cost containment continue exert pressure product pricing market access united states federal state governments many years also pursued methods reduce cost drugs vaccines pay example federal laws require company pay specified rebates medicines reimbursed medicaid provide discounts outpatient medicines purchased certain public health service entities disproportionate share hospitals hospitals meeting certain criteria federal vaccines children entitlement program us centers disease control prevention cdc funds purchases recommended pediatric vaccines public sector price immunization medicaideligible uninsured native american certain underinsured children merck contracted provide pediatric vaccines program backdrop united states enacted major health care reform legislation began implemented various insurance market reforms advanced continue full implementation new law expected expand access health care million americans end decade previously regular access health care respect effect law pharmaceutical industry law increased mandated medicaid rebate expanded rebate medicaid managed care utilization increased types entities eligible federal b drug discount program law also requires pharmaceutical manufacturers pay discount medicare part beneficiaries medicare part coverage gap ie socalled donut hole also pharmaceutical manufacturers required pay annual health care reform fee total annual industry fee billion billion fee assessed company proportion share sales certain government programs medicare medicaid company also faces increasing pricing pressure globally managed care organizations government agencies programs could negatively affect companys sales profit margins united states include practices managed care groups institutional governmental purchasers ii us federal laws regulations related medicare medicaid including medicare prescription drug table contents improvement modernization act patient protection affordable care act changes health care system enacted part health care reform united states well increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries could result pricing pressures addition effort contain us federal deficit pharmaceutical industry could considered potential source savings via legislative proposals debated enacted prior years types revenue generating cost saving proposals include direct price controls medicare prescription drug program part addition congress may consider proposals allow certain conditions importation medicines countries remains uncertain proposals may included part future federal budget deficit reduction proposals would directly indirectly affect company global efforts toward health care cost containment intense several european countries many countries announced austerity measures include implementation pricing actions reduce prices generic patented drugs company taking steps mitigate impact eu austerity measures negatively affected companys revenue performance company anticipates austerity measures continue negatively affect revenue performance additionally global economic downturn sovereign debt issues certain european countries among factors adversely impacted foreign receivables certain european countries company continues receive payment receivables conditions resulted increase average length time takes collect accounts receivable outstanding thereby adversely affecting cash flows full impact us health care reform well continuing budget pressures governments around world predicted time addressing cost containment pressures company continues attempt demonstrate medicines provide value patients pay health care markets historically low rates government health care spending company encourages governments increase investments order improve citizens access appropriate health care including medicines operating conditions become challenging global pressures competition industry regulation cost containment efforts although one predict effect factors companys business company continually takes measures evaluate adapt improve organization business practices better meet customer needs believes well positioned respond evolving health care environment market forces government regulation pharmaceutical industry subject regulation regional country state local agencies around world governmental regulation legislation tend focus standards processes determining drug safety effectiveness well conditions sale reimbursement especially related pricing products particular importance fda united states administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals many cases fda requirements practices increased amount time resources necessary develop new products bring market united states eu adopted directives legislation concerning classification labeling advertising wholesale distribution integrity supply chain enhanced pharmacovigilance monitoring approval marketing medicinal products human use provide mandatory standards throughout eu may supplemented implemented additional regulations eu member states companys policies procedures already consistent substance directives consequently believed material effect companys business company believes continue able conduct operations including launching new drugs market regulatory environment table contents access medicines global health care company mercks primary role discover develop innovative medicines vaccines company also recognizes important role play helping improve access products around world companys efforts regard wideranging example company recognized pricing many products differential pricing framework taking consideration factors countrys level economic development public health need addition merck patient assistance program provides medicines adult vaccines free people prescription drug health insurance coverage without companys assistance afford merck medicine vaccines building companys efforts merck undertaken collaborations many stakeholders improve access medicines enhance quality life people around world example merck announced would launch merck mothers longterm effort global health partners create world woman die preventable complications pregnancy childbirth launch includes year million initiative applies mercks scientific business expertise making proven solutions widely available developing new technologies improving public awareness policy efforts private sector engagement maternal mortality merck also past provided funds merck company foundation independent organization partnered variety organizations dedicated improving global health one partnerships african comprehensive hivaids partnership botswana collaboration government botswana bill melinda gates foundation renewed supports botswanas response hivaids comprehensive sustainable approach hiv prevention care treatment support privacy data protection company subject number privacy data protection laws regulations globally legislative regulatory landscape privacy data protection continues evolve increased attention privacy data protection issues developed emerging markets potential affect directly companys business including recently enacted laws regulations united states europe asia latin america increased enforcement activity united states developed markets operating results segment composition reflects certain managerial changes implemented consumer care product sales outside united states canada previously included pharmaceutical segment included consumer care segment segment disclosures prior years recast comparable basis sales worldwide sales totaled billion increase compared billion foreign exchange favorably affected global sales performance revenue increase driven largely growth januvia janumet singulair isentress gardasil simponi rotateq zetia pneumovax bridion addition revenue benefited higher sales companys animal health products launch victrelis increases partially offset lower sales cozaar hyzaar lost patent protection united states april number major european markets march well lower sales caelyx subutex suboxone company longer marketing rights products revenue also negatively affected lower sales vytorin temodar proquad varivax addition discussed ongoing implementation certain provisions us health care reform legislation resulted increases medicaid rebates impacts reduced revenues domestic sales billion increase compared billion domestic sales increase driven higher sales singulair januvia gardasil janumet isentress well launch victrelis increases partially offset lower sales cozaar hyzaar vytorin varivax proquad table contents foreign sales billion increase compared billion driven growth japan emerging markets foreign exchange favorably affected foreign sales performance foreign sales growth reflects strong performance januvia janumet singulair simponi isentress zetia nasonex well higher sales animal health products partially offset lower sales cozaar hyzaar temodar foreign sales represented total sales total sales many companys brands experienced positive growth trends eu environment eu continues challenging many countries announced austerity measures include implementation pricing actions reduce prices generic patented drugs company taking steps mitigate impact eu austerity measures negatively affected companys revenue performance company anticipates midsingle digit pricing pressures across europe well biennial price reductions japan worldwide sales totaled billion compared billion foreign exchange favorably affected global sales performance revenue increase driven largely incremental sales resulting inclusion full year results legacy scheringplough products remicade nasonex temodar pegintron clarinex well inclusion full year results merckscheringplough partnership msp partnership products zetia vytorin prior merger substantially sales zetia vytorin recognized msp partnership results mercks interest msp partnership recorded equity income affiliates result merger msp partnership became wholly owned company therefore revenues products reflected sales additionally company recognized full year sales legacy scheringplough animal health consumer care products sales include revenue legacy scheringplough msp partnership products postmerger period december also contributing sales increase growth januvia janumet isentress singulair increases partially offset lower sales cozaar hyzaar fosamax fosamax plus lower revenue companys relationship azlp products experienced declines include gardasil zocor addition implementation certain provisions us health care reform legislation resulted increased medicaid rebates impacts reduced revenues table contents sales companys products follows years ended december pharmaceutical cardiovascular zetia vytorin integrilin diabetes obesity januvia janumet diversified brands cozaarhyzaar zocor propecia claritin rx remeron vasotecvaseretic proscar infectious disease isentress pegintron cancidas primaxin invanz avelox noxafil crixivanstocrin rebetol victrelis neurosciences ophthalmology maxalt cosopttrusopt oncology temodar emend intron respiratory immunology singulair remicade nasonex clarinex arcoxia simponi asmanex proventil dulera vaccines gardasil proquadmmr iivarivax rotateq pneumovax zostavax womens health endocrine fosamax nuvaring follistim aq implanon cerazette pharmaceutical total pharmaceutical segment sales segment sales total segment sales sales legacy scheringplough products included postmerger period addition prior merger substantially sales zetia vytorin recognized msp partnership results mercks interest msp partnership recorded equity income affiliates result merger msp partnership became wholly owned company accordingly sales msp partnership products merger reflected table sales zetia vytorin reflect mercks sales products latin america part msp partnership well sales products postmerger period amounts reflect sales vaccines sold major european markets companys joint venture sanofi pasteur msd results reflected equity income affiliates amounts however reflect supply sales sanofi pasteur msd pharmaceutical primarily reflects sales human health pharmaceutical products including products within franchises listed separately reflects nonreportable segments including animal health consumer care revenue companys relationship azlp primarily relating sales nexium well prilosec revenue azlp billion billion billion respectively revenues primarily comprised miscellaneous corporate revenues thirdparty manufacturing sales sales related divested products businesses supply sales included segment results table contents pharmaceutical segment sales cardiovascular worldwide sales zetia also marketed ezetrol outside united states cholesterol absorption inhibitor increased billion reflecting higher sales international markets particularly japan due part positive impact foreign exchange partially offset volume declines united states global sales vytorin marketed outside united states inegy combination product containing active ingredients zetia zocor declined billion reflecting volume declines united states partially offset increases international markets sales zetia vytorin million million respectively postmerger period prior merger substantially sales products recognized msp partnership results mercks interest msp partnership recorded equity income affiliates result merger msp partnership became wholly owned company therefore revenues products reflected sales total sales zetia vytorin including sales recognized msp partnership billion billion respectively january fda approved updated label vytorin includes results sharp study heart renal protection clinical trial sharp vytorin mg lowered ldl lowdensity lipoprotein cholesterol patients moderate severe chronic kidney disease major vascular events reduced treatment group compared placebo trial therefore demonstrated treatment vytorin mg versus placebo reduced risk major vascular events chronic kidney disease population sharp studied combination simvastatin ezetimibe compared placebo designed assess independent contributions drug observed effect reason fda approve new indication vytorin zetia studys efficacy results incorporated label zetia previously disclosed data safety monitoring board dsmb improveit large cardiovascular outcomes study evaluating zetiavytorin patients acute coronary syndrome plans conduct second interim analysis efficacy approximately prespecified primary clinical endpoints occurred september merck advised improveit executive committee decided schedule studys second interim analysis first quarter rather previously anticipated late products contained cardiovascular franchise include among others integrilin injection treatment patients acute coronary syndrome sold company united states canada diabetes obesity global sales januvia mercks dipeptidyl peptidase dpp inhibitor treatment type diabetes rose billion reflecting volume growth united states well international markets particularly japan across europe sales januvia grew billion reflecting continued growth united states internationally dpp inhibitors represent class prescription medications improve blood sugar control patients type diabetes enhancing natural body system called incretin system helps regulate glucose affecting beta cells alpha cells pancreas worldwide sales janumet mercks oral antihyperglycemic agent combines sitagliptin januvia metformin single tablet target three key defects type diabetes billion million million reflecting growth internationally due part ongoing launches certain markets well growth united states october fda approved juvisync new treatment type diabetes combines glucoselowering medication sitagliptin active component januvia cholesterollowering medication zocor juvisync first treatment option health care providers help patients need blood sugarlowering benefits dpp inhibitor cholesterollowering benefits simvastatin convenience single tablet daily table contents february fda approved janumet xr new treatment type diabetes combines sitagliptin extendedrelease metformin janumet xr provides convenient oncedaily treatment option health care providers patients need help control blood sugar february fda sent warning letter company relating januvia janumet stating company fulfill post marketing requirement month pancreatic safety study diabetic rodent model treated sitagliptin merck communication fda regarding study mercks efforts complete timely satisfactory manner terms warning letter within days date letter company must submit fda final study protocol new month rodent study satisfy fdas requirements proposed revised timetable completion study within months date letter fda expects company obtained agreement fda adequate study protocol initiated study letter states failure correct violation may result regulatory actions fda including limited civil money penalties merck remains fully committed fulfilling fdas requirements diversified brands mercks diversified brands human health pharmaceutical products approaching expiration marketing exclusivity longer protected patents developed markets continue core part companys offering markets around world global sales cozaar companion agent hyzaar combination cozaar hydrochlorothiazide treatment hypertension declined billion fell billion patents provided us market exclusivity cozaar hyzaar expired april addition cozaar hyzaar lost patent protection number major european markets march accordingly company experienced significant declines cozaar hyzaar sales company expects declines continue products contained diversified brands franchise include among others zocor statin modifying cholesterol propecia product treatment male pattern hair loss prescription claritin treatment seasonal outdoor allergies yearround indoor allergies remeron antidepressant vasotec vaseretic hypertension andor heart failure proscar urology product treatment symptomatic benign prostate enlargement remeron lost market exclusivity united states january also lost market exclusivity major european markets formulationuse patent provides us market exclusivity propecia expires october however previously disclosed agreement one generic manufacturer given right enter market january another given right enter july infectious disease worldwide sales isentress hiv integrase inhibitor use combination antiretroviral agents treatment hiv infection treatmentnave treatmentexperienced adults grew billion reflecting volume growth united states internationally partially offset unfavorable pricing european markets sales isentress increased billion primarily due positive performance united states well internationally resulting continued uptake since launch isentress works inhibiting insertion hiv dna human dna integrase enzyme inhibiting integrase performing essential function helps limit ability virus replicate infect new cells january fda approved use isentress combination antiretroviral medicines treatment hiv infection pediatric patients two years age older weighing least kg worldwide sales pegintron treatment chronic hepatitis c million decline compared million sales reflecting competitive pressures addition company believes sales decline attributable part patient treatment delayed health care providers anticipation new therapeutic options becoming available september company initiated voluntary recall pegintron single dose redipen injection united states consultation fda well recalls globally resulting reduction revenue approximately million representing estimated sales returns addition company recognized charge approximately million materials table contents production primarily inventory discard costs recall conducted precautionary measure due thirdparty manufacturing issue could affected small number redipens recall specific pegintron redipen affect pegintron vial products sales pegintron million postmerger period may fda approved victrelis companys innovative oral medicine treatment chronic hepatitis c victrelis approved treatment chronic hepatitis c genotype infection combination peginterferon alfa ribavirin adult patients years age older compensated liver disease including cirrhosis previously untreated failed previous interferon ribavirin therapy victrelis antiviral agent designed interfere ability hepatitis c virus replicate inhibiting key viral enzyme july ec approved victrelis ecs decision grants single marketing authorization valid countries members eu well unified labeling applicable iceland liechtenstein norway addition united states victrelis launched markets including france germany canada brazil sales victrelis million sales primaxin antibacterial product declined million decreased million results primarily reflect lower volumes unfavorable pricing due competitive pressures patents primaxin expired worldwide multiple generics launched europe accordingly company experiencing decline sales primaxin company expects decline continue products contained infectious disease franchise include among others cancidas antifungal product invanz treatment certain infections avelox fluoroquinolone antibiotic treatment certain respiratory skin infections noxafil prevention certain invasive fungal infections crixivan stocrin antiretroviral therapies treatment hiv infection rebetol use combination pegintron treating chronic hepatitis c compound patent provides us market exclusivity cancidas expires september neurosciences ophthalmology global sales maxalt mercks tablet acute treatment migraine increased million reflecting higher inventory level favorable pricing united states sales maxalt declined million reflecting generic availability competing product patent provides us market exclusivity maxalt expire december us sales maxalt million addition patent provides market exclusivity maxalt expire number major european markets february company anticipates sales united states european markets decline significantly patent expiries worldwide sales ophthalmic products cosopt trusopt declined million reflecting unfavorable pricing volume declines europe mitigated part positive impact foreign exchange partially offset higher cosopt sales japan sales cosopt trusopt decreased million patent provided us market exclusivity cosopt trusopt expired trusopt also lost market exclusivity number major european markets patent cosopt expire number major european markets march company expects sales markets decline significantly thereafter february fda approved cosopt pf mercks preservativefree formulation cosopt ophthalmic solution indicated reduction elevated intraocular pressure appropriate patients openangle glaucoma ocular hypertension company plans launch cosopt pf end bridion reversal certain muscle relaxants used surgery currently approved launched many countries outside united states sales bridion million million bridion phase iii development united states fda approved saphris asenapine antipsychotic treatment schizophrenia adults acute treatment monotherapy adjunctive therapy lithium valproate manic mixed episodes associated bipolar disorder adults asenapine sold brand name sycrest received marketing approval eu treatment moderate severe manic episodes associated bipolar disorder adults merck h lundbeck lundbeck announced worldwide table contents commercialization agreement sycrest sublingual tablets mg mg terms agreement lundbeck paid fee makes product supply payments exchange exclusive commercial rights sycrest markets outside united states china japan mercks sales saphris million merck continues focus building brand awareness saphris united states company continues monitor assess saphrissycrest related intangible asset increasing brand awareness lundbecks launch product eu successful company may take noncash impairment charge respect saphrissycrest charge could material neurosciences ophthalmology franchise also included products subutexsuboxone treatment opiate addiction march merck sold rights subutexsuboxone nearly markets back reckitt benckiser group plc reckitt rights products major markets reverted reckitt july remainder reverted reckitt exception small markets sales subutexsuboxone million february fda approved zioptan tafluprost preservativefree prostaglandin analog ophthalmic solution reducing elevated intraocular pressure patients openangle glaucoma ocular hypertension merck exclusive commercial rights tafluprost western europe excluding germany north america south america africa middle east india australia zioptan marketed saflutan certain markets outside united states oncology sales temodar marketed temodal outside united states treatment certain types brain tumors declined million billion primarily reflecting generic competition europe sales temodar million postmerger period temodar lost patent exclusivity eu previously disclosed agreement one generic manufacturer given right enter us market august us patent exclusivity periods otherwise expire february global sales emend treatment chemotherapyinduced nausea vomiting increased million primarily reflecting growth international markets sales emend increased million driven increases united states due launch japan products oncology franchise include among others intron adjuvant treatment melanoma marketing rights caelyx treatment ovarian cancer metastatic breast cancer kaposis sarcoma transitioned jj december sales caelyx million march fda approved sylatron onceweekly subcutaneous injection indicated adjuvant treatment melanoma microscopic gross nodal involvement within days definitive surgical resection including complete lymphadenectomy respiratory immunology worldwide sales singulair onceaday oral medicine chronic treatment asthma relief symptoms allergic rhinitis grew reaching billion driven favorable pricing united states volume growth japan emerging markets well beneficial impact foreign exchange global sales singulair rose billion reflecting price increases positive performance japan patent provides us market exclusivity singulair expires august company expects within two years following patent expiration lose substantially us sales singulair declines coming first full year following patent expiration us sales singulair billion addition patent provides market exclusivity singulair expire number major european markets february company expects sales singulair markets decline significantly thereafter patent provides market exclusivity singulair japan expire sales remicade treatment inflammatory diseases billion decline compared foreign exchange favorably affected sales performance prior july remicade marketed company outside united states except japan certain asian markets result agreement reached april amend agreement governing distribution rights remicade simponi discussed effective july merck relinquished marketing rights products certain territories including canada central south america middle east africa table contents asia pacific sales performance reflects changes retained territories remicade sales grew reflect favorable impact foreign exchange sales remicade million postmerger period simponi oncemonthly subcutaneous treatment certain inflammatory diseases approved ec october january simponi approved eu use combination methotrexate adults severe active progressive rheumatoid arthritis previously treated methotrexate shown reduce rate progression joint damage measured xray improve physical function sales simponi million million revenue increase driven growth retained territories due part ongoing launches global sales nasonex inhaled nasal corticosteroid treatment nasal allergy symptoms billion increase compared sales billion driven largely volume growth japan latin america positive effect foreign exchange partially offset volume declines united states sales nasonex million postmerger period global sales clarinex marketed aerius many countries outside united states nonsedating antihistamine million compared sales million sales clarinex million postmerger period products included respiratory immunology franchise include among others arcoxia treatment arthritis pain asmanex inhaled corticosteroid asthma proventil inhalation aerosol relief bronchospasm dulera inhalation aerosol combination medicine treatment asthma january merck received complete response letter fda supplemental new drug application snda dulera treatment chronic obstructive pulmonary disease company plans discussions fda regard complete response letter vaccines following discussion vaccines include sales vaccines sold major european markets sanofi pasteur msd spmsd companys joint venture sanofi pasteur results reflected equity income affiliates see selected joint venture affiliate information supply sales spmsd however included worldwide sales gardasil recorded merck grew billion driven increased vaccination males years age united states higher sales conjunction launch japan growth emerging markets partially offset lower government orders canada sales gardasil declined million driven largely declines united states australia sales include million result government purchases cdcs strategic national stockpile gardasil worlds topselling hpv vaccine indicated girls women years age prevention cervical vulvar vaginal anal cancer caused hpv types certain precancerous dysplastic lesions caused hpv types genital warts caused hpv types gardasil also approved united states use boys men years age prevention anal cancer caused hpv types anal dysplasias precancerous lesions caused hpv types genital warts caused hpv types company party certain thirdparty license agreements respect gardasil including crosslicense settlement agreement glaxosmithkline result agreements company pays royalties worldwide gardasil sales vary country included materials production costs recent years company experienced difficulties producing varicella zoster virus vzvcontaining vaccines difficulties resulted supply constraints proquad varivax zostavax company manufacturing bulk varicella producing doses varivax zostavax limited quantity proquad pediatric combination vaccine help protect measles mumps rubella varicella one vzv containing vaccines became available united states ordering second quarter supply exhausted proquad longer available ordering mercks sales proquad million million proquad available ordering due supply constraints mercks sales varivax vaccine help prevent chickenpox varicella million million billion sales reflect million million table contents respectively revenue result government purchases cdcs strategic national stockpile mercks sales mmr ii vaccine help protect measles mumps rubella million million million sales varivax mmr ii affected unavailability proquad noted mercks sales rotateq vaccine help protect rotavirus gastroenteritis infants children grew million reflecting favorable public sector inventory fluctuations growth emerging markets sales rotateq declined million sales benefited modestly temporary competitor supply issue sales pneumovax vaccine help prevent pneumococcal disease million million million increase compared primarily due positive performance united states due part favorable pricing japan mercks sales zostavax vaccine help prevent shingles herpes zoster million million million sales years affected supply issues company filled backorders resumed normal supply schedule united states zostavax company increasing promotional efforts zostavax united states broad international launches immunization programs currently planned march fda approved expanded age indication zostavax prevention shingles include adults ages zostavax indicated prevention herpes zoster individuals years age older mercks adult formulation vaqta vaccine hepatitis currently unavailable womens health endocrine worldwide sales fosamax fosamax plus marketed fosavance throughout eu fosamac japan treatment case fosamax prevention osteoporosis declined million decreased million medicines lost market exclusivity united states also lost market exclusivity major european markets accordingly company experiencing sales declines within fosamax product franchise company expects declines continue worldwide sales nuvaring contraceptive product grew million million driven positive performance united states internationally including beneficial impact foreign exchange sales nuvaring million postmerger period global sales follistim aq marketed countries outside united states puregon biological fertility treatment million compared million reflecting growth emerging markets offset declines europe due primarily supply constraints sales follistim aq million postmerger period puregon lost market exclusivity eu august products contained womens health endocrine franchise include among others implanon singlerod subdermal contraceptive implant cerazette progestin oral contraceptive company currently experiencing difficulty manufacturing certain womens health products company working resolve issues august zoely oral contraceptive granted marketing authorization ec use women prevent pregnancy zoely combined oral contraceptive tablet containing unique monophasic combination two hormones nomegestrol acetate highly selective progesteronederived progestin beta estradiol estrogen similar one naturally present womans body marketing authorization zoely applies eu member states plus iceland liechtenstein norway teva pharmaceutical industries ltd holds exclusive marketing rights zoely france italy belgium spain november merck received complete response letter fda nomace mka marketed zoely eu company planning conduct additional clinical study requested fda update application future table contents animal health animal health includes pharmaceutical vaccine products prevention treatment control disease major farm companion animal species animal health sales affected intense competition frequent introduction generic products global sales animal health products grew billion billion foreign exchange favorably affected global sales performance increase sales driven positive performance among cattle swine poultry companion animal products global sales animal health products million post merger period consumer care consumer care products include overthecounter foot care sun care products claritin nondrowsy antihistamines dr scholls foot care products coppertone sun care products miralax treatment occasional constipation global sales consumer care products increased billion reflecting strong performance coppertone offset declines dr scholls claritin consumer care product sales million postmerger period consumer care product sales affected competition consumer spending patterns alliances astrazeneca option buy mercks interest subsidiary mercks interest nexium prilosec exercisable company believes likely astrazeneca exercise option see selected joint venture affiliate information astrazeneca exercises option company longer record equity income azlp supply sales azlp decline substantially costs expenses millions change change materials production marketing administrative research development restructuring costs equity income affiliates income expense net greater amounts include reclassification million expenses marketing administrative research development includes million billion iprd impairment charges respectively materials production materials production costs billion billion billion materials production costs include expenses related sale legacy scheringplough msp partnership products postmerger period costs unfavorably affected billion billion billion respectively expenses amortization intangible assets recorded connection mergers acquisitions additionally expenses include billion billion respectively amortization purchase accounting adjustments scheringploughs inventories recognized result merger costs include intangible asset impairment charge million company may recognize additional noncash impairment charges future related product intangibles measured fair value capitalized connection mergers acquisitions charges could material also included materials production costs associated restructuring activities amounted million million million respectively including accelerated depreciation asset writeoffs related planned sale closure manufacturing facilities separation costs associated manufacturingrelated headcount reductions incurred reflected restructuring costs discussed table contents gross margin compared amortization intangible assets purchase accounting adjustments inventories well restructuring impairment charges noted unfavorable impact gross margin percentage points percentage points percentage points gross margin improvement compared reflects changes product mix manufacturing efficiencies well benefit foreign exchange marketing administrative marketing administrative expenses billion billion billion increase compared due part unfavorable effect foreign exchange strategic investments made emerging markets additionally marketing administrative expenses include million expenses annual health care reform fee required part us health care reform legislation expenses include restructuring costs million million respectively primarily related accelerated depreciation facilities closed divested separation costs associated sales force reductions incurred reflected restructuring costs discussed expenses also include million million acquisitionrelated costs respectively consisting largely integration costs related merger also consist severance costs associated acquisition inspire pharmaceuticals inc part companys formal restructuring programs marketing administrative expenses include expenses related scheringplough activities postmerger period include acquisition related costs million largely comprised transaction costs directly related merger including advisory legal fees integration costs research development research development expenses billion billion billion expenses include expenses related scheringplough activities postmerger period research development expenses comprised costs directly incurred merck research labs mrl companys research development division focuses human healthrelated activities approximately billion billion respectively also included research development expenses costs incurred divisions support research development activities including depreciation production general administrative well certain costs operating segments including pharmaceutical animal health consumer care billion billion aggregate respectively research development expenses favorably affected cost savings resulting restructuring activities research development expenses also include inprocess research development iprd impairment charges research development related restructuring charges company recorded iprd impairment charges million primarily pipeline programs abandoned determined alternative use well expected delays launch timing changes cash flow assumptions certain compounds addition impairment charges related pipeline programs previously deprioritized either deemed alternative use period outlicensed third party consideration less related assets carrying value company recorded billion iprd impairment charges amount billion related writedown intangible asset vorapaxar resulting developments clinical program compound see research development remaining million iprd impairment charges attributable compounds abandoned determined either alternative use returned respective licensor well expected delays launch timing changes cash flow assumptions certain compounds company may recognize additional noncash impairment charges future cancellation delay pipeline programs measured fair value capitalized connection mergers acquisitions charges could material research development expenses reflect million million million respectively accelerated depreciation asset abandonment costs associated restructuring activities sharebased compensation total pretax sharebased compensation expense million million million december million total pretax unrecognized compensation table contents expense related nonvested stock option restricted stock unit performance share unit awards recognized weighted average period years segment reporting sharebased compensation costs unallocated expenses restructuring costs restructuring costs billion million billion respectively nearly costs recorded relate merger restructuring program restructuring costs recorded million related merger restructuring program million related global restructuring program initiated restructuring program remaining activity related legacy scheringplough program included gain sale manufacturing facility restructuring costs recorded billion related merger restructuring program million related restructuring program million related legacy scheringplough program separation costs billion million billion respectively incurred associated actual headcount reductions well estimated expenses existing severance programs headcount reductions probable could reasonably estimated merck eliminated positions related merger restructuring program related restructuring program related legacy scheringplough program positions related merger restructuring program related restructuring program remainder legacy scheringplough program positions related restructuring program position eliminations comprised actual headcount reductions elimination contractors vacant positions also included restructuring costs curtailment settlement termination charges associated pension postretirement benefit plans sharebased compensation plan costs well contract termination shutdown costs segment reporting restructuring costs unallocated expenses additional costs associated companys restructuring activities included materials production marketing administrative research development discussed equity income affiliates equity income affiliates reflects performance companys joint ventures equity method affiliates increased million primarily due higher partnership returns azlp company divested interest jjmcp joint venture equity income affiliates declined million billion equity income affiliates longer included equity income msp partnership became wholly owned company result merger merial limited merial due sale mercks interest addition lower partnership returns azlp well lower equity income spmsd result restructuring charges recorded joint venture also contributed decline see selected joint venture affiliate information income expense net income expense net million expense reflecting million charge related resolution arbitration proceeding involving companys rights market remicade simponi see note consolidated financial statements million gain disposition companys interest jjmcp joint venture see note consolidated financial statements million gain sale certain manufacturing facilities related assets see note consolidated financial statements income expense net billion expense reflecting million charge vioxx liability reserve see note consolidated financial statements charges related settlement certain pending awp litigation million exchange losses due two venezuelan currency devaluations discussed partially offset million income recognized upon astrazenecas asset option exercise see note consolidated financial statements million income recognized settlement certain disputed royalties income expense net billion income primarily reflecting billion gain resulting recognizing mercks previously held equity interest msp partnership fair value result obtaining control msp partnership merger billion gain sale mercks interest merial see note consolidated financial statements table contents noted exchange losses reflect losses relating venezuelan currency devaluations effective january venezuelan government devalued currency bsf per us dollar twotiered official exchange rate essentials rate bsf per us dollar nonessentials rate bsf per us dollar january company required remeasure local currency operations venezuela us dollars venezuelan economy determined hyperinflationary throughout company settled transactions essentials rate therefore remeasured monetary assets liabilities utilizing essentials rate december venezuelan government announced would eliminate essentials rate effective january transactions would settled official rate bsf per us dollar result announcement company remeasured december monetary assets liabilities new official rate segment profits millions pharmaceutical segment profits nonreportable segment profits income income taxes segment profits comprised segment revenues less certain elements materials production costs operating expenses including components equity income loss affiliates depreciation amortization expenses internal management reporting presented chief operating decision maker merck allocate production costs standard costs research development expenses general administrative expenses cost financing activities separate divisions maintain responsibility monitoring managing costs including depreciation related fixed assets utilized divisions therefore included segment profits also excluded determination segment profits arbitration settlement charge gain divestiture jjmcp joint venture gain sale certain manufacturing facilities related assets recorded charge vioxx liability reserve income recognized astrazenecas asset option exercise recognized gains related msp partnership disposition merial addition amortization purchase accounting adjustments acquisitionrelated costs intangible asset impairment charges restructuring costs taxes paid joint venture level portion equity income also excluded determination segment profits additionally segment profits reflect expenses corporate manufacturing cost centers miscellaneous income expense unallocated items reflected table also included miscellaneous corporate profits operating profits related thirdparty manufacturing sales divested products businesses well supply sales pharmaceutical segment profits rose driven largely increase sales gross margin improvement discussed pharmaceutical segment profits increased driven largely inclusion legacy scheringplough results taxes income effective income tax rates reflect impacts purchase accounting adjustments restructuring costs partially offset beneficial impact foreign earnings addition effective tax rate also reflects net favorable impact approximately million relating settlement mercks federal income tax audit favorable impact certain foreign state tax rate changes resulted net million reduction deferred tax liabilities intangibles established purchase accounting impact million charge related resolution arbitration proceeding jj effective tax rate reflects impact vioxx liability reserve tax impact recorded million charge associated change tax law requires taxation prescription drug subsidy companys retiree health benefit plans enacted first quarter part us health care reform legislation impact astrazenecas asset option exercise unfavorable impacts partially offset million tax benefit changes foreign table contents entitys tax rate resulted reduction deferred tax liabilities product intangibles recorded conjunction merger favorable impact enactment tax extenders legislation including rd tax credit favorable impact foreign earnings dividends companys foreign subsidiaries effective tax rate reflects favorable impacts increased income lower tax jurisdictions includes favorable impact msp partnership gain tax settlements including previously announced settlement canada revenue agency cra favorable impacts partially offset unfavorable effect gain sale mercks interest merial taxable united states combined federal state tax rate approximately net income earnings per common share net income attributable merck co inc billion million billion eps increases net income eps compared primarily due lower iprd impairment charges amortization inventory stepup lower legal reserves favorable impact tax settlements partially offset arbitration settlement charge recorded income recognized astrazenecas asset option exercise declines net income eps compared primarily due gains recognized associated msp partnership result merger disposition merial well incremental costs result merger including recognition full year amortization intangible assets inventory stepup addition iprd impairment charges charge establish vioxx liability reserve lower equity income affiliates impact us health care reform legislation also contributed declines net income eps compared income recognized astrazenecas asset option exercise benefited net income eps eps also affected dilutive impact shares issued merger nongaap income nongaap eps nongaap income nongaap eps alternative views companys performance used management merck providing management believes information enhances investors understanding companys results nongaap income nongaap eps exclude certain items nature items impact analysis underlying business performance trends excluded items consist acquisitionrelated costs restructuring costs certain items excluded items significant components understanding assessing financial performance therefore information nongaap income nongaap eps considered addition lieu net income eps prepared accordance generally accepted accounting principles united states gaap additionally since nongaap income nongaap eps measures determined accordance gaap standardized meaning prescribed gaap therefore may comparable calculation similar measures companies nongaap income nongaap eps important internal measures company senior management receives monthly analysis operating results includes nongaap income nongaap eps performance company measured basis along performance metrics senior managements annual compensation derived part using nongaap income nongaap eps table contents reconciliation gaap financial measures nongaap financial measures follows millions except per share amounts pretax income reported gaap increase decrease excluded items acquisitionrelated costs restructuring costs items arbitration settlement charge gain disposition interest jjmcp joint venture gain sale manufacturing facilities related assets vioxx liability reserve income recognized astrazenecas asset option exercise gain related msp partnership gain disposition interest merial taxes income reported gaap estimated tax benefit expense excluded items tax benefit settlement federal income tax audit tax benefit foreign state tax rate changes tax charge related us health care reform legislation nongaap net income less net income attributable noncontrolling interests nongaap net income attributable merck co inc eps assuming dilution reported gaap eps difference nongaap eps assuming dilution represents difference calculated gaap eps calculated nongaap eps may different amount calculated dividing impact excluded items weightedaverage shares applicable year acquisitionrelated costs nongaap income nongaap eps exclude ongoing impact certain amounts recorded connection mergers acquisitions amounts include amortization intangible assets inventory stepup well intangible asset impairment charges also excluded integration transaction costs associated merger well costs associated mergers acquisitions severance costs part companys formal restructuring programs costs excluded management believes costs representative ongoing normal business activities restructuring costs nongaap income nongaap eps exclude costs related restructuring actions including restructuring activities related merger see note consolidated financial statements amounts include employee separation costs accelerated depreciation associated facilities closed divested accelerated depreciation costs represent difference depreciation expense recognized revised useful life site based upon anticipated date site closed divested depreciation table contents expense determined utilizing useful life prior restructuring actions company undertaken restructurings different types covered periods therefore charges considered nonrecurring however management excludes amounts nongaap income non gaap eps believes helpful understanding performance continuing business certain items nongaap income nongaap eps exclude certain items items represent substantive unusual items evaluated individual basis evaluation considers quantitative qualitative aspect unusual nature generally represent items either result nature magnitude management would anticipate would occur part companys normal business regular basis certain items comprised arbitration settlement charge gain disposition companys interest jjmcp joint venture gain associated sale certain manufacturing facilities related assets charge establish vioxx liability reserve income recognized upon astrazenecas asset option exercise gain resulting recognizing mercks previously held equity interest msp partnership fair value result obtaining controlling interest merger gain divestiture mercks interest merial also excluded nongaap income nongaap eps tax benefits settlement federal income tax audit favorable impact certain foreign state tax rate changes resulted net reduction deferred tax liabilities intangibles established purchase accounting tax charge related us health care reform legislation research development chart reflecting companys current research pipeline february set forth item business research development research development update company currently two candidates regulatory review united states internationally mk ridaforolimus investigational oral mtor mammalian target rapamycin inhibitor development treatment metastatic softtissue bone sarcomas patients favorable response chemotherapy accepted standard review fda september august european medicines agency accepted marketing authorization application ridaforolimus part exclusive license agreement ariad pharmaceuticals inc ariad merck responsible development worldwide commercialization ridaforolimus ariad option co promote ridaforolimus sarcoma united states subject execution copromotion agreement mkc zetia ezetimibe combined atorvastatin accepted standard review fda treatment primary mixed hyperlipidemia response notice companys filing pfizer inc pfizer filed patent infringement lawsuit us district court company asserting certain pfizer patent rights respect atorvastatin lawsuit potential bar fda approval companys nda months january subject shortened lengthened court decision shortened agreement parties addition candidates regulatory review company drug candidates phase iii development targeting broad range diseases company plans file five major products approval including suvorexant insomnia bridion reversal neuromuscular blockade v cervical cancer vaccine odanacatib osteoporosis tredaptive atherosclerosis mk suvorexant investigational dual orexin receptor antagonist potential new approach treatment insomnia orexins neuropeptides chemical messengers released specialized neurons hypothalamus region brain believed important regulator brains sleepwake process february merck announced based positive results two pivotal phase iii efficacy trials suvorexant company anticipates filing nda mk fda table contents mk bridion medication reversal certain muscle relaxants used surgery bridion currently approved launched many countries outside united states prior merger scheringplough received notapprovable letter fda bridion company conducted additional clinical trials address fdas comments plans file nda bridion fda v ninevalent hpv vaccine development help protect certain hpvrelated diseases v incorporates antigens five additional cancercausing hpv types compared gardasil phase iii clinical program includes eventdriven clinical trial ongoing merck continues anticipate filing biologics license application bla v fda mk odanacatib oral onceweekly investigational treatment osteoporosis postmenopausal women osteoporosis disease reduces bone density strength results increased risk bone fractures odanacatib cathepsin k inhibitor selectively inhibits cathepsin k enzyme cathepsin k known play central role function osteoclasts cells break existing bone tissue particularly protein components bone inhibition cathepsin k novel approach treatment osteoporosis odanacatib continues studied determine safety potential effects hip vertebral nonvertebral fractures eventdriven phase iii clinical trial company anticipates filing nda mk fda mka drug candidate combines extendedrelease niacin novel flushing inhibitor laropiprant mka demonstrated ability lower ldlcholesterol ldlc bad cholesterol raise hdlcholesterol hdlc good cholesterol lower triglycerides significantly less flushing traditional extended release niacin alone high ldlc low hdlc elevated triglycerides risk factors associated heart attacks strokes april merck received notapprovable letter fda response nda mka meeting discuss letter fda stated additional efficacy safety data required suggested merck wait results hpsthrive treatment hdl reduce incidence vascular events eventdriven cardiovascular outcomes study expected completed company anticipates filing nda fda mka mka approved countries outside united states treatment dyslipidemia particularly patients combined mixed dyslipidemia characterized elevated levels ldlc triglycerides low hdlc patients primary hypercholesterolemia heterozygous familial nonfamilial marketed tredaptive cordaptive certain countries tredaptive used patients combination statins cholesterol lowering effects statin monotherapy inadequate tredaptive used monotherapy patients statins considered inappropriate tolerated mk elonva corifollitropin alpha injection approved eu controlled ovarian stimulation combination gnrh antagonist development multiple follicles women participating assisted reproductive technology program currently phase iii development united states based feedback fda additional data ongoing phase iii trial required time filing merck anticipates filing nda elonva fda mk vernakalant iv investigational candidate treatment atrial fibrillation marketed brinavess eu merck acquired exclusive rights develop commercialize vernakalant iv well exclusive worldwide rights oral formulations vernakalant prior mercks acquisition rights vernakalant iv canada mexico united states program placed clinical hold fda phase iii act v trial suspended act v terminated united states program remains hold company plans discussions fda mka nomace marketed zoely eu oral contraceptive use women prevent pregnancy nomace combined oral contraceptive tablet containing unique monophasic combination two hormones nomegestrol acetate highly selective progesteronederived progestin beta estradiol estrogen similar one naturally present womens body november merck received complete response letter fda nomace company planning conduct additional clinical study requested fda update application future table contents mk vorapaxar thrombin receptor antagonist developed prevention thrombosis clot formation reduction cardiovascular events vorapaxar evaluated two major clinical outcomes studies different patient groups tracer thrombin receptor antagonist clinical event reduction acute coronary syndrome clinical outcomes trial patients acute coronary syndrome trap thrombin receptor antagonist secondary prevention atherothrombotic ischemic events secondary prevention study patients previous heart attack ischemic stroke documented peripheral vascular disease february merck announced topline results trap study trap showed addition vorapaxar standard care significantly reduced risk protocolspecified primary endpoint composite cardiovascular death heart attack myocardial infarction stroke urgent coronary revascularization compared standard care significant increase bleeding including intracranial hemorrhage among patients taking vorapaxar addition standard care although lower risk intracranial hemorrhage patients without history stroke full results trap presented american college cardiology scientific sessions march november researchers presented results tracer outcomes study american heart association scientific sessions results published tracer achieve primary endpoint january merck external study investigators announced combined dsmb two clinical trials reviewed available safety efficacy data recommended patients tracer trial discontinue study drug investigators close study merck review data trap tracer investigators outside experts help better understand profile investigational medicine specific patient populations determine next steps including potential regulatory filings mkb drug candidate combines novel approach raising hdlc lowering triglycerides extendedrelease niacin combined laropiprant proven benefits simvastatin one combination product merck anticipates filing nda mkb fda mk investigational allergy immunotherapy sublingual tablet ait phase iii development grass pollen allergy company north american rights ait dissolvable oral tablet designed prevent allergy symptoms inducing protective immune response allergies thereby treating underlying cause disease merck investigating ait treatment grass pollen allergic rhinoconjunctivitis children adults company anticipates filing nda mk fda mk ait ragweed allergy also phase iii development north american market company anticipates filing nda mk fda mk preladenant selective adenosine receptor antagonist phase iii development treatment parkinsons disease company anticipates filing nda preladenant fda mka investigational candidate treatment clostridium difficile infection combination two monoclonal antibodies used treat patients single infusion company anticipates filing nda mka fda v inactivated varicellazoster virus vaccine development prevention herpes zoster company enrolling two phase iii trials one autologous hematopoietic cell transplant patients patients solid tumor malignancies undergoing chemotherapy hematological malignancies company anticipates filing bla first autologous hematopoietic cell transplant data filing second indication cancer patients later date v investigational hexavalent pediatric combination vaccine contains components current vaccines designed help protect six potentially serious diseases diphtheria tetanus whooping cough bordetella pertussis polio poliovirus types invasive disease caused haemophilus influenzae type b hepatitis b developed collaboration sanofipasteur company anticipates filing bla v fda mke combines januvia atorvastatin single tablet developed treatment diabetes atherosclerosis company anticipates filing nda mke fda table contents mk vaniprevir investigational oral twice daily protease inhibitor treatment chronic hepatitis c virus drug phase iii trials japan company anticipates filing new drug application mk japan mk anacetrapib investigational inhibitor cholesteryl ester transfer protein cetp investigated lipid management raise hdlc reduce ldlc based results phase iii define determining efficacy tolerability cetp inhibition anacetrapib safety study patients coronary heart disease coronary heart disease risk equivalents company initiated large eventdriven cardiovascular clinical outcomes trial reveal randomized evaluation effects anacetrapib lipidmodification involving patients preexisting vascular disease company continues anticipate filing nda anacetrapib fda beyond merck discontinued clinical development program telcagepant companys investigational calcitonin generelated peptide receptor antagonist treatment acute migraine decision based assessment data across clinical program company also discontinued clinical development program mkc combination sitagliptin pioglitazone treatment diabetes based review regulatory commercial prospects combination drug candidate merck discontinued clinical development program eu mka zenhale fixed dose combination two previously approved drugs treatment asthma mometasone furoate formoterol fumarate dehydrate marketed united states dulera inhalation aerosol company maintains number longterm exploratory fundamental research programs biology chemistry well research programs directed toward product development companys research development model designed increase productivity improve probability success prioritizing companys research development resources disease areas unmet medical needs scientific opportunity commercial opportunity merck managing research development portfolio across diverse approaches discovery development balancing investments appropriately novel innovative targets potential major impact human health developing bestinclass approaches delivering maximum value approved medicines vaccines new indications new formulations another important component companys sciencebased diversification based expanding companys portfolio modalities include small molecules vaccines also biologics peptides small proteins antibodies rnai merck moved diversify portfolio merck bioventures division potential harness market opportunity presented biological medicine patent expiries delivering high quality followon biologic products enhance access patients worldwide company supplements internal research licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds well new technologies companys clinical pipeline includes candidates multiple disease areas including atherosclerosis cancer cardiovascular diseases diabetes infectious diseases inflammatoryautoimmune diseases insomnia neurodegenerative diseases ophthalmics osteoporosis respiratory diseases womens health inprocess research development connection merger company recorded fair value human animal health research projects underway schering plough msp partnership fair value projects allocated pharmaceutical animal health operating segments billion billion respectively significant projects include victrelis bridion vorapaxar well ezetimibeatorvastatin combination product victrelis medicine treatment hepatitis c approved fda eu noted company filed nda fda ezetimibeatorvastatin combination product company anticipates filing nda fda bridion approximately million million respectively iprd projects received marketing approval major market company began amortizing assets based estimated useful lives company also recognized intangible assets fair value research projects underway connection smartcells inc acquisition see note consolidated financial statements insmed inc acquisition table contents iprd projects remain development subject inherent risks uncertainties drug development possible company able successfully develop complete iprd programs profitably commercialize underlying product candidates time periods receive approvals fda regulatory agencies subject uncertainty significant delays approval process companys failure obtain approval would delay prevent company realizing revenues products additionally certain iprd programs fail abandoned development company realize future cash flows estimated recorded iprd merger acquisition date company may also recover research development expenditures made since merger develop program circumstances occur companys future operating results could adversely affected company may recognize impairment charges charges could material company recorded million iprd impairment charges within research development expenses primarily pipeline programs abandoned determined alternative use well expected delays launch timing changes cash flow assumptions certain compounds addition impairment charges related pipeline programs previously deprioritized either deemed alternative use period outlicensed third party consideration less related assets carrying value company recorded billion iprd impairment charges company determined developments clinical research program vorapaxar discussed constituted triggering event required company evaluate vorapaxar intangible asset impairment utilizing market participant assumptions considering several different scenarios company concluded best estimate current fair value intangible asset related vorapaxar million resulted recognition impairment charge billion february merck announced topline results trap study result merck evaluated vorapaxar intangible asset impairment concluded impairment necessary december noted merck continue review data trap tracer investigators outside experts help better understand profile investigational medicine specific patient populations determine next steps including potential regulatory filings process company may required take impairment charges related vorapaxar remaining million iprd impairment charges recorded attributable compounds abandoned determined either alternative use returned respective licensor well expected delays launch timing changes cash flow assumptions certain compounds additional research development required remaining programs reach technological feasibility costs complete research projects depend whether projects brought final stages development ultimately submitted fda regulatory agencies approval december estimated costs complete projects acquired connection merger phase iii development human health analogous stage development animal health approximately billion acquisitions research collaborations license agreements merck continues remain focused pursuing opportunities potential drive near longterm growth company completed transactions across broad range therapeutic categories including earlystage technology transactions merck actively monitoring landscape growth opportunities meet companys strategic criteria may merck completed acquisition inspire pharmaceuticals inc inspire specialty pharmaceutical company focused developing commercializing ophthalmic products terms merger agreement merck acquired outstanding shares common stock inspire price per share cash total approximately million transaction accounted acquisition business accordingly assets acquired liabilities assumed recorded respective fair values acquisition date determination fair value requires management make significant estimates assumptions connection acquisition substantially purchase price allocated inspires table contents product product right intangible assets related deferred tax liabilities deferred tax asset relating inspires net operating loss carryforwards goodwill transaction closed may accordingly results operations acquired business included companys results operations since acquisition date pro forma financial information included inspires historical financial results significant compared companys financial results selected joint venture affiliate information expand research base realize synergies combining capabilities opportunities assets previous years merck formed number joint ventures astrazeneca lp merck entered agreement astra ab astra develop market astra products royaltybearing license mercks total sales astra products reached level triggered first step establishment joint venture business carried astra merck inc ami merck astra owned share joint venture formed developed marketed astras new prescription medicines united states including prilosec first class medications known proton pump inhibitors slows production acid cells stomach lining merck astra completed restructuring ownership operations joint venture whereby merck acquired astras interest ami renamed kbi inc kbi contributed kbis operating assets new us limited partnership astra pharmaceuticals lp partnership exchange limited partner interest astra contributed net assets wholly owned subsidiary astra usa inc partnership exchange general partner interest partnership renamed astrazeneca lp azlp upon astras merger zeneca group plc became exclusive distributor products kbi retained rights maintaining limited partner interest azlp merck consent protective rights intended preserve business economic interests including restrictions power general partner make certain distributions dispositions furthermore limited events default additional rights granted company including powers direct actions remove replace partnerships chief executive officer chief financial officer merck earns ongoing revenue based sales kbi products revenue billion billion billion respectively primarily relating sales nexium well prilosec addition merck earns certain partnership returns recorded equity income affiliates returns include priority return provided partnership agreement preferential return representing mercks share undistributed azlp gaap earnings variable return related companys limited partner interest returns aggregated million million million respectively conjunction restructuring discussed astra purchased option asset option payment million recorded deferred income buy mercks interest kbi products excluding gastrointestinal medicines nexium prilosec nonppi products april astrazeneca exercised asset option merck received million astrazeneca representing net present value march projected future pretax revenue received merck nonppi products recorded reduction companys investment azlp company recognized million deferred income component income expense net addition merck granted astra option shares option buy mercks common stock interest kbi mercks interest nexium prilosec exercisable exercise price shares option primarily based net present value projected future pretax revenue received merck nexium prilosec determined time exercise subject certain trueup mechanisms company believes likely astrazeneca exercise shares option astrazeneca exercises option company longer record equity income azlp supply sales azlp decline substantially table contents sanofi pasteur msd merck pasteur mrieux connaught sanofi pasteur sa established equallyowned joint venture market vaccines europe collaborate development combination vaccines distribution europe sales joint venture products follows millions gardasil influenza vaccines viral vaccines rotateq hepatitis vaccines vaccines johnson johnsonmerck consumer pharmaceuticals company september merck sold interest jjmcp joint venture jj venture merck jj formed develop manufacture market distribute certain overthecounter otc consumer products united states canada merck received onetime payment million recognized pretax gain million reflected income expense net mercks rights pepcid brand outside united states canada affected transaction following transaction jj owns ventures assets include exclusive rights market otc pepcid mylanta mylicon local otc brands currently sold united states canada partnership assets also included manufacturing facility termination jjmcp joint venture provides merck greater flexibility allowing company capitalize pipeline potential prescription tootc switches well actively pursue otc licensing activities united states canada sales products marketed joint venture million period january september divestiture date million million merckscheringplough partnership merck scheringplough collectively partners entered agreement create equally owned partnership develop market united states new prescription medicines cholesterol management ezetimibe first new class cholesterollowering agents launched united states zetia marketed ezetrol outside united states combination product containing active ingredients zetia zocor approved united states vytorin marketed inegy outside united states cholesterol agreements provided sharing operating income generated msp partnership based upon percentages varied product sales level country operating income included expenses partners contractually agreed share expenses incurred support msp partnership shared partners included equity income affiliates however costs reflected overall results partners results mercks interest msp partnership prior merger reflected equity income affiliates billion result merger msp partnership became wholly owned company activity resulting sale msp partnership products merger consolidated mercks results discussion performance products see sales table contents sales joint venture products follows millions premerger postmerger total vytorin zetia amounts exclude sales products partners outside msp partnership merial limited merck sold interest merial limited merial joint venture sanofiaventis merck sanofiaventis rhnepoulenc sa formed merial combining animal health businesses fully integrated animal health company standalone joint venture equally owned party merck received billion cash recorded billion pretax gain reflected income expense net sales products marketed joint venture billion january september divestiture date march merck sanofiaventis mutually terminated agreement form new animal health joint venture termination agreement without penalty either party capital expenditures capital expenditures billion billion billion expenditures united states billion million million depreciation expense billion billion billion billion billion billion respectively applied locations united states total depreciation expense included accelerated depreciation million million million respectively associated restructuring activities see note consolidated financial statements analysis liquidity capital resources mercks strong financial profile enables fully fund research development focus external alliances support inline products maximize upcoming launches providing significant cash returns shareholders selected data millions working capital total debt total liabilities equity cash provided operations total debt cash provided operating activities billion billion billion increase cash provided operating activities compared reflects increased results operations partially offset million payment made jj result arbitration settlement well net payments approximately million internal revenue service irs result conclusion examination certain mercks federal income tax returns discussed increase cash provided operating activities compared primarily reflects inclusion full year legacy scheringplough operations well billion payments vioxx settlement funds million payment made connection previously disclosed settlement canada revenue agency cra cash provided operating activities continues companys primary source funds finance operating needs capital expenditures treasury stock purchases dividends paid shareholders global economic downturn sovereign debt issues among factors adversely impacted foreign receivables certain european countries see note consolidated financial statements company table contents continues receive payment receivables conditions resulted increase average length time takes collect accounts receivable outstanding thereby adversely affecting cash provided operating activities cash used investing activities billion compared billion primarily reflecting higher proceeds sales securities investments proceeds disposition certain businesses partially offset higher purchases securities investments addition proceeds astrazenecas asset option exercise decrease restricted assets contributed cash flows investing activities cash used investing activities billion compared cash provided investing activities billion change reflects lower proceeds sales securities investments higher purchases securities investments well decrease restricted assets proceeds disposition mercks interest merial partially offset use cash fund merger proceeds received related astrazenecas asset option exercise cash used financing activities billion compared billion higher use cash financing activities primarily driven lower proceeds issuance debt higher purchases treasury stock higher payments debt partially offset increase shortterm borrowings cash used financing activities billion compared billion reflecting lower proceeds issuance debt purchases treasury stock increased dividends paid stockholders higher payments debt partially offset increase shortterm borrowings dividends paid stockholders billion billion billion effort implement mercks strategy expand product offerings capabilities emerging markets company anticipates future allocate capital resources across regions december total worldwide cash investments billion including billion cash cash equivalents shortterm investments billion longterm investments substantial majority cash investments held foreign subsidiaries would subject significant tax payments cash investments repatriated however cash provided operating activities united states continues companys primary source funds finance domestic operating needs capital expenditures treasury stock purchases dividends paid shareholders april irs concluded examination mercks federal income tax returns result company required make net payments approximately million companys unrecognized tax benefits years examination exceeded adjustments related examination period therefore company recorded net million tax provision benefit net benefit reflects decrease unrecognized tax benefits years examination partially offset increases unrecognized tax benefits years subsequent examination period result settlement company disagrees irs treatment one issue raised examination appealing matter irs administrative process previously disclosed october cra issued merck notice reassessment containing adjustments related certain intercompany pricing matters february merck cra negotiated settlement agreement regard matters accordance settlement merck paid additional tax approximately million interest approximately million additional amounts penalties due assessment settlement accounted first quarter merck previously established reserves matters portion taxes paid expected creditable us tax purposes addition previously disclosed cra proposed adjustments relating intercompany pricing matters july cra issued assessments miscellaneous audit issues tax years adjustments would increase canadian tax due approximately million plus approximately million interest december company disagrees positions taken cra believes without merit company continues contest assessments cra appeals process cra expected prepare similar adjustments later years management believes resolution matters material effect companys financial position liquidity irs finalized examination scheringploughs tax years audit cycle company reached agreement irs adjustment income related intercompany pricing table contents matters income adjustment mostly reduced nols tax credit carryforwards additionally company seeking resolution one issue raised examination irs administrative appeals process companys reserves uncertain tax positions adequate cover adjustments related examination period irs began examination tax years company companys contractual obligations december follows payments due period millions total thereafter purchase obligations loans payable current portion longterm debt longterm debt interest related debt obligations vioxx liability reserve related interest unrecognized tax benefits operating leases merck entered transaction require company make future bulk supply purchases million maximum fouryear period commencing upon occurrence certain predetermined events amount reflected table predetermined events yet occurred therefore timing resulting payments given year yet determined december companys consolidated balance sheet reflects liabilities unrecognized tax benefits interest penalties billion including million reflected current liability due high degree uncertainty regarding timing future cash outflows liabilities unrecognized tax benefits beyond one year reasonable estimate period cash settlement years beyond made purchase obligations enforceable legally binding obligations purchases goods services including minimum inventory contracts research development advertising amounts reflected research development obligations include contingent milestone payments loans payable current portion longterm debt reflects million longdated notes subject repayment option holders required funding obligations relating companys pension postretirement benefit plans expected material however company currently anticipates contributing approximately million million respectively pension plans postretirement benefit plans may company entered new billion day credit facility new billion fouryear credit facility maturing may company terminated existing billion day credit facility expired may billion revolving credit facility scheduled mature august outstanding facilities provide backup liquidity companys commercial paper borrowing facility used general corporate purposes company drawn funding either facility december merck closed underwritten public offering billion senior unsecured notes consisting million aggregate principal amount notes due billion aggregate principal amount notes due interest notes payable semiannually notes series redeemable whole part time companys option varying redemption prices proceeds notes used general corporate purposes including reduction shortterm debt december company filed securities registration statement securities exchange commission sec automatic shelf registration process available wellknown seasoned issuers effective three years connection merger effective november company executed full unconditional guarantee existing debt subsidiary merck sharp dohme corp msd msd executed full unconditional guarantee existing debt company excluding commercial paper including payments principal interest guarantees extend debt issued subsequent merger table contents companys longterm credit ratings assigned moodys investors service standard poors aa stable outlook aa stable outlook respectively ratings continue allow access capital markets flexibility obtaining funds competitive terms company continues maintain conservative financial profile company places cash investments instruments meet high credit quality standards specified investment policy guidelines guidelines also limit amount credit exposure one issuer despite strong financial profile certain contingent events realized discussed note consolidated financial statements could material adverse impact companys liquidity capital resources company participate offbalance sheet arrangements involving unconsolidated subsidiaries provide financing potentially expose company unrecorded financial obligations november board directors declared quarterly dividend per share companys common stock first quarter april merck announced board directors approved additional purchases billion mercks common stock treasury company purchased billion common stock million shares treasury company approximately billion remaining program previous november treasury stock purchase authorization treasury stock purchases time limit made time open market block transactions privately negotiated transactions company purchased billion common stock purchases treasury stock made financial instruments market risk disclosures company manages impact foreign exchange rate movements interest rate movements earnings cash flows fair values assets liabilities operational means use various financial instruments including derivative instruments significant portion companys revenues earnings foreign affiliates exposed changes foreign exchange rates objectives accounting related companys foreign currency risk management program well interest rate risk management activities discussed foreign currency risk management significant portion companys revenues denominated foreign currencies company established revenue hedging balance sheet risk management net investment hedging programs protect volatility future foreign currency cash flows changes fair value caused volatility foreign exchange rates objective revenue hedging program reduce potential longerterm unfavorable changes foreign exchange rates decrease us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen achieve objective company hedge portion forecasted foreign currency denominated thirdparty intercompany distributor entity sales expected occur planning cycle typically three years future company layer hedges time increasing portion thirdparty intercompany distributor entity sales hedged gets closer expected date forecasted foreign currency denominated sales probable hedged transaction occur portion sales hedged based assessments costbenefit profiles consider natural offsetting exposures revenue exchange rate volatilities correlations cost hedging instruments hedged anticipated sales specified component portfolio similarly denominated foreign currencybased sales transactions responds hedged currency risk manner company manages anticipated transaction exposure principally purchased local currency put options provide company right obligation sell foreign currencies future predetermined price us dollar strengthens relative currency hedged anticipated sales total changes options cash flows offset decline expected future us dollar equivalent cash flows hedged foreign currency sales conversely us dollar weakens options value reduces zero company benefits increase us dollar equivalent value anticipated foreign currency cash flows table contents connection companys revenue hedging program purchased collar option strategy may utilized purchased collar option strategy company writes local currency call option purchases local currency put option compared purchased put option strategy alone purchased collar strategy reduces upfront costs associated purchasing puts collection premium writing call options us dollar weakens relative currency hedged anticipated sales purchased put option value collar strategy reduces zero company benefits increase us dollar equivalent value anticipated foreign currency cash flows however benefit would capped strike level written call us dollar strengthens relative currency hedged anticipated sales written call option value collar strategy reduces zero changes purchased put cash flows collar strategy would offset decline expected future us dollar equivalent cash flows hedged foreign currency sales company may also utilize forward contracts revenue hedging program us dollar strengthens relative currency hedged anticipated sales increase fair value forward contracts offsets decrease expected future us dollar cash flows hedged foreign currency sales conversely us dollar weakens decrease fair value forward contracts offsets increase value anticipated foreign currency cash flows weaker us dollar would result net benefit market value mercks hedges would declined estimated million million respectively uniform weakening us dollar december market value determined using foreign exchange option pricing model holding factors except exchange rates constant merck principally uses purchased local currency put options uniform weakening us dollar would yield largest overall potential loss market value options sensitivity measurement assumes change one foreign currency relative us dollar would affect foreign currencies relative us dollar although predictive nature company believes threshold reflects reasonably possible nearterm changes mercks major foreign currency exposures relative us dollar cash flows contracts reported operating activities consolidated statement cash flows primary objective balance sheet risk management program mitigate exposure foreign currency denominated net monetary assets foreign subsidiaries us dollar functional currency effects volatility foreign exchange instances merck principally utilizes forward exchange contracts enable company buy sell foreign currencies future fixed exchange rates economically offset consequences changes foreign exchange monetary assets merck routinely enters contracts offset effects exchange exposures denominated developed country currencies primarily euro japanese yen exposures developing country currencies company enter forward contracts partially offset effects exchange exposures deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate cost hedging instrument company also minimize effect exchange monetary assets liabilities managing operating activities net asset positions local level company used may future use forward contracts hedge changes fair value certain foreign currency denominated availableforsale securities attributable fluctuations foreign currency exchange rates derivative contracts designated fair value hedges sensitivity analysis changes value us dollar foreign currency denominated derivatives investments monetary assets liabilities indicated us dollar uniformly strengthened currency exposures company december income taxes would declined approximately million company net long position relative major foreign currencies consideration forward contracts uniform strengthening us dollar yield largest overall potential net loss earnings due exchange december company net short position relative major foreign currencies consideration forward contracts therefore uniform weakening us dollar would reduced income taxes million measurement assumes change one foreign currency relative us dollar would affect foreign currencies relative us dollar although predictive nature company believes table contents threshold reflects reasonably possible nearterm changes mercks major foreign currency exposures relative us dollar cash flows contracts reported operating activities consolidated statement cash flows effective january venezuelan government devalued currency bsf per us dollar twotiered official exchange rate essentials rate bsf per us dollar nonessentials rate bsf per us dollar january company required remeasure local currency operations venezuela us dollars venezuelan economy determined hyperinflationary throughout company settled transactions essentials rate therefore remeasured monetary assets liabilities utilizing essentials rate december venezuelan government announced would eliminate essentials rate effective january transactions would settled official rate bsf per us dollar result announcement company remeasured december monetary assets liabilities new official rate company also uses forward exchange contracts hedge net investment foreign operations movements exchange rates forward contracts designated hedges net investment foreign operation company hedges portion net investment certain foreign operations measures ineffectiveness based upon changes spot foreign exchange rates effective portion unrealized gains losses contracts recorded foreign currency translation adjustment within comprehensive income oci remains accumulated comprehensive income aoci either sale complete substantially complete liquidation subsidiary cash flows contracts reported investing activities consolidated statement cash flows foreign exchange risk also managed use foreign currency debt companys senior unsecured eurodenominated notes designated effective economic hedges net investment foreign operation accordingly foreign currency transaction gains losses due spot rate fluctuations eurodenominated debt instruments included foreign currency translation adjustment within oci interest rate risk management company may use interest rate swap contracts certain investing borrowing transactions manage net exposure interest rate changes reduce overall cost borrowing company use leveraged swaps general leverage investment activities would put principal capital risk february company entered nine payfloating receivefixed interest rate swap contracts notional amounts billion aggregate designated fair value hedges fixedrate notes notional amounts matched amount hedged fixedrate notes two interest rate swap contracts designated fair value hedges fixedrate notes matured notional amounts million effectively converted companys million fixedrate notes due floating rate instruments interest rate swap contracts designated hedges fair value changes notes attributable changes benchmark london interbank offered rate libor swap rate fair value changes notes attributable changes benchmark interest rate recorded interest expense offset fair value changes swap contracts also company terminated payfloating receivefixed interest rate swap contracts designated fair value hedges fixedrate notes notional amounts match amount hedged fixedrate notes swaps effectively converted billion fixedrate notes maturity dates varying march june floating rate instruments interest rate swap contracts designated hedges fair value changes notes attributable changes benchmark libor swap rate result swap terminations company received million cash included million accrued interest unamortized adjustment carrying value debt associated interest rate swap contracts million amortized reduction interest expense respective term notes cash flows contracts reported operating activities consolidated statement cash flows companys investment portfolio includes cash equivalents shortterm investments market values significantly affected changes interest rates market value companys table contents medium longterm fixedrate investments modestly affected changes us interest rates changes medium longterm us interest rates significant impact market value companys fixedrate borrowings generally longer maturities sensitivity analysis measure potential changes market value mercks investments debt related swap contracts change interest rates indicated one percentage point increase interest rates december would positively affected net aggregate market value instruments billion billion respectively one percentage point decrease december would negatively affected net aggregate market value billion billion respectively fair value mercks debt determined using pricing models reflecting one percentage point shifts appropriate yield curves fair values mercks investments determined using combination pricing duration models critical accounting policies companys consolidated financial statements prepared conformity gaap accordingly include certain amounts based managements best estimates judgments estimates used accounting amounts recorded connection mergers acquisitions including initial fair value determinations assets liabilities primarily iprd intangible assets well subsequent fair value measurement additionally estimates used determining items provisions sales discounts returns depreciable amortizable lives recoverability inventories including produced preparation product launches amounts recorded contingencies environmental liabilities reserves pension postretirement benefit plan assumptions sharebased compensation assumptions restructuring costs impairments longlived assets including intangible assets goodwill investments taxes income uncertainty inherent estimates actual results may differ estimates application following accounting policies result accounting estimates potential significant impact financial statements mergers acquisitions business combination acquisition method accounting requires assets acquired liabilities assumed recorded date merger acquisition respective fair values limited exceptions assets acquired liabilities assumed business combination arise contingencies recognized fair value fair value reasonably estimated acquisition date fair value asset acquired liability assumed arises contingency determined asset liability recognized probable reasonably estimable criteria met asset liability recognized fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date accordingly company may required value assets fair value measures reflect companys intended use assets excess purchase price consideration transferred estimated fair values net assets acquired recorded goodwill transaction costs costs restructure acquired company expensed incurred operating results acquired business reflected companys consolidated financial statements date merger acquisition company determines assets acquired meet definition business acquisition method accounting transaction accounted acquisition assets rather business combination therefore goodwill recorded fair values intangible assets including acquired iprd determined utilizing information available near merger acquisition date based expectations assumptions deemed reasonable management given considerable judgment involved determining fair values company typically obtains assistance thirdparty valuation specialists significant items amounts allocated acquired iprd capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project merck make separate determination useful life asset begin amortization judgments made determining estimated fair values assigned assets acquired liabilities assumed business combination well asset lives materially affect companys results operations fair values identifiable intangible assets related currently marketed products product rights primarily determined using income approach fair value estimated based assets discounted projected net cash flows companys estimates market participant net cash flows consider table contents historical projected pricing margins expense levels performance competing products applicable relevant industry therapeutic area growth drivers factors current expected trends technology product life cycles time investment required develop products technologies ability obtain marketing regulatory approvals ability manufacture commercialize products extent timing potential new product introductions companys competitors life assets underlying patent net cash flows probabilityadjusted appropriate consider uncertainties associated underlying assumptions well risk profile net cash flows utilized valuation probabilityadjusted future net cash flows product discounted present value utilizing appropriate discount rate fair values identifiable intangible assets related iprd determined using income approach fair value estimated based assets probability adjusted future net cash flows reflect different stages development product associated probability successful completion net cash flows discounted present value using appropriate discount rate revenue recognition revenues sales products recognized time delivery title risk loss passes customer recognition revenue also requires reasonable assurance collection sales proceeds completion performance obligations domestically sales discounts issued customers direct discounts pointofsale indirectly intermediary wholesaler known chargebacks indirectly form rebates additionally sales generally made limited right return certain conditions revenues recorded net provisions sales discounts returns established time sale addition revenues recorded net time value money discounts customers collection accounts receivable expected excess one year provision aggregate indirect customer discounts covers chargebacks rebates chargebacks discounts occur contracted customer purchases directly intermediary wholesaler contracted customer generally purchases product contracted price plus markup wholesaler wholesaler turn charges company back difference price initially paid wholesaler contract price paid wholesaler customer provision chargebacks based expected sellthrough levels companys wholesale customers contracted customers well estimated wholesaler inventory levels rebates amounts owed based upon definitive contractual agreements legal requirements private sector public sector medicaid medicare part benefit providers final dispensing product pharmacy benefit plan participant provision based expected payments driven patient usage contract performance benefit provider customers company uses historical customer segment mix adjusted known events order estimate expected provision amounts accrued aggregate indirect customer discounts evaluated quarterly basis comparison information provided wholesalers health maintenance organizations pharmacy benefit managers customers amounts accrued adjustments recorded trends significant events indicate change estimated provision appropriate company continually monitors provision aggregate indirect customer discounts material adjustments estimates associated aggregate indirect customer discount provision summarized information changes aggregate indirect customer discount accrual follows millions balance january current provision adjustments prior years payments balance december table contents accruals chargebacks reflected direct reduction accounts receivable accruals rebates current liabilities accrued balances relative provisions included accounts receivable accrued current liabilities million billion respectively december million billion respectively december company maintains returns policy allows us pharmaceutical customers return product within specified period prior subsequent expiration date generally three six months twelve months product expiration estimate provision returns based upon historical experience actual returns additionally company considers factors levels inventory distribution channel product dating expiration period whether products discontinued entrance market additional generic competition changes formularies launch overthecounter products among others product returns provision us pharmaceutical sales approximately net sales distribution programs us wholesalers company encourages wholesalers align purchases underlying demand maintain inventories specified levels terms programs allow wholesalers earn fees upon providing visibility inventory levels well achieving certain performance parameters inventory management customer service levels reducing shortage claims reducing product returns information provided wholesaler distribution programs includes items sales trends inventory onhand onorder quantity product returns wholesalers generally provide mentioned data company regulatory requirement report lot level information manufacturers level information needed determine remaining shelf life original sale date inventory given current wholesaler inventory levels generally less month company believes collection order lot information across wholesale customers would limited use estimating sales discounts returns inventories produced preparation product launches company capitalizes inventories produced preparation product launches sufficient support estimated initial market demand typically capitalization inventory begin related product candidates phase iii clinical trials considered high probability regulatory approval company monitors status respective product within regulatory approval process however company generally disclose specific timing regulatory approval company aware specific risks contingencies normal regulatory approval process specific issues identified research process relating safety efficacy manufacturing marketing labeling related inventory would generally capitalized expiry dates inventory affected stage completion company manages levels inventory stage optimize shelf life inventory relation anticipated market demand order avoid product expiry issues inventories capitalized anticipated future sales shelf lives support realization inventory value inventory shelf life sufficient meet initial product launch requirements inventories produced preparation product launches capitalized december million december million contingencies environmental liabilities company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well additional matters antitrust actions see note consolidated financial statements company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjusted periodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable significant factors considered review legal defense reserves follows actual costs incurred company development companys legal defense strategy structure light scope litigation number cases brought company table contents costs outcomes completed trials current information regarding anticipated timing progression related costs pretrial activities trials associated litigation amount legal defense reserves december approximately million million respectively represents companys best estimate minimum amount defense costs incurred connection outstanding litigation however events additional trials events could arise course litigation could affect ultimate amount legal defense costs incurred company company continue monitor legal defense costs review adequacy associated reserves may determine increase reserves time future based upon factors set forth believes would appropriate company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents legitimate claim contribution asserted liability initially accrued based upon estimated transaction costs manage site accruals adjusted site investigations feasibility studies related cost assessments remedial techniques completed extent potentially responsible parties may jointly severally liable expected contribute determined company also remediating environmental contamination resulting past industrial activity certain sites takes active role identifying providing costs past merck performed worldwide survey assess sites potential contamination resulting past industrial activities assessment indicated physical investigation warranted investigation performed providing better evaluation need remedial action need identified remedial action initiated definitive information became available course investigations andor remedial efforts site estimates refined accruals established adjusted accordingly estimates related accruals continue refined annually company believes compliance issues associated applicable environmental laws regulations would material adverse effect company expenditures remediation environmental liabilities million estimated million aggregate years managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively liabilities undiscounted consider potential recoveries parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures result material adverse effect companys financial position results operations liquidity capital resources year sharebased compensation company expenses sharebased payment awards employees including grants stock options requisite service period based grant date fair value awards company determines fair value certain sharebased awards using blackscholes optionpricing model uses historical current market data estimate fair value method incorporates various assumptions riskfree interest rate expected volatility expected dividend yield expected life options pensions postretirement benefit plans net periodic benefit cost pension postretirement benefit plans totaled million million million higher costs compared primarily due incremental costs associated merger pension postretirement benefit plan information financial reporting purposes calculated using actuarial assumptions including discount rate plan benefit obligations expected rate return plan assets company reassesses benefit plan assumptions regular basis pension postretirement benefit plans discount rate evaluated measurement dates modified reflect table contents prevailing market rate portfolio highquality fixedincome debt instruments would provide future cash flows needed pay benefits included benefit obligation come due december discount rates companys us pension postretirement benefit plans ranged compared range december expected rate return pension postretirement benefit plans represents average rate return earned plan assets period benefits included benefit obligation paid developing expected rate return company considers longterm compound annualized returns historical market data well actual returns companys plan assets using reference information company develops forwardlooking return expectations asset category weightedaverage expected longterm rate return target portfolio allocated across investment categories expected portfolio performance reflects contribution active management appropriate result analysis companys expected rate return range compared range us pension postretirement benefit plans company established investment guidelines us pension postretirement plans create asset allocation expected deliver rate return sufficient meet longterm obligation plan given acceptable level risk target investment portfolio companys us pension postretirement benefit plans allocated us equities international equities fixedincome investments cash investments portfolios equity weighting consistent longterm nature plans benefit obligations expected annual standard deviation returns target portfolio approximates reflects equity allocation diversification benefits among asset classes portfolio invests nonus pension plans targeted investment portfolio varies based duration pension liabilities local government rules regulations although significant percentage plan assets invested us equities concentration risk mitigated use strategies diversified within management guidelines actuarial assumptions based upon managements best estimates judgment reasonably possible change plus minus basis points discount rate assumption assumptions held constant would estimated million favorable unfavorable impact net periodic benefit cost reasonably possible change plus minus basis points expected rate return assumption assumptions held constant would estimated million favorable unfavorable impact net periodic benefit cost required funding obligations relating companys pension postretirement benefit plans expected material preceding hypothetical changes discount rate expected rate return assumptions would impact companys funding requirements net loss amounts reflect experience differentials primarily relating differences expected actual returns plan assets well effects changes actuarial assumptions recorded component aoci expected returns pension plans based calculated marketrelated value assets methodology asset gainslosses resulting actual returns differ companys expected returns recognized marketrelated value assets ratably fiveyear period also net loss amounts aoci excess certain thresholds amortized net periodic benefit cost average remaining service life employees amortization net losses companys us plans december expected increase net periodic benefit cost approximately million annually restructuring costs restructuring costs recorded connection restructuring programs designed reduce cost structure increase efficiency enhance competitiveness result company made estimates judgments regarding future plans including future termination benefits exit costs incurred restructuring actions take place accruing costs company recognize amount within range costs best estimate within range amount within range better estimate amount company recognizes minimum amount within range connection actions management also assesses recoverability longlived assets employed business certain instances asset lives shortened based changes expected useful lives affected assets table contents severance related costs reflected within restructuring costs assetrelated charges reflected within materials production costs marketing administrative expenses research development expenses depending upon nature asset impairments longlived assets company assesses changes economic regulatory legal conditions makes assumptions regarding estimated future cash flows evaluating value companys property plant equipment goodwill intangible assets company periodically evaluates whether current facts circumstances indicate carrying values longlived assets held used may recoverable circumstances determined exist estimate undiscounted future cash flows assets appropriate asset groupings compared carrying value determine whether impairment exists asset determined impaired loss measured based difference assets fair value carrying value quoted market prices available company estimate fair value using discounted value estimated future cash flows approach goodwill represents excess consideration transferred fair value net assets businesses purchased assigned reporting units company tests goodwill impairment least annual basis frequently impairment indicators exist first assessing qualitative factors determine whether likely fair value reporting unit less carrying amount factors considered assessment include general macro economic conditions conditions specific industry market cost factors could significant effect earnings cash flows overall financial performance reporting unit whether sustained declines companys share price additionally company evaluates extent fair value exceeded carrying value reporting unit last date valuation performed company concludes likely fair value reporting unit less carrying amount quantitative fair value test performed acquired intangibles excluding iprd recorded fair value assigned estimated useful life amortized primarily straightline basis estimated useful lives events circumstances warrant review company assess recoverability future operations using pretax undiscounted cash flows derived lowest appropriate asset groupings impairments recognized operating results extent carrying value intangible asset exceeds fair value determined based net present value estimated future cash flows iprd represents fair value assigned incomplete research projects company acquires business combinations time acquisition reached technological feasibility amounts capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment project company tests iprd impairment least annually frequently impairment indicators exist onestep test compares fair value iprd intangible asset carrying value impairment testing purposes company may combine separately recorded iprd intangible assets one unit account based relevant facts circumstances generally company combine iprd intangible assets testing purposes operate single asset essentially inseparable fair value less carrying amount impairment loss recognized within companys operating results impairments investments company reviews investments impairments based determination whether decline market value investment carrying value otherthantemporary company considers available evidence evaluating potential impairments investments including duration extent fair value less cost equity securities companys ability intent hold investments debt securities otherthan temporary impairment occurred company expect recover entire amortized cost basis debt security company intend sell impaired debt security likely required sell debt security recovery amortized cost basis amount otherthantemporary impairment recognized earnings limited portion attributed credit loss remaining portion otherthantemporary impairment related factors recognized oci table contents taxes income companys effective tax rate based pretax income statutory tax rates tax planning opportunities available various jurisdictions company operates estimated effective tax rate year applied companys quarterly operating results event significant unusual onetime item recognized expected recognized companys quarterly operating results tax attributable item would separately calculated recorded time unusual onetime item company considers resolution prior year tax matters items significant judgment required determining companys tax provision evaluating tax positions recognition measurement tax position based managements best judgment given facts circumstances information available reporting date company evaluates tax positions determine whether benefits tax positions likely sustained upon audit based technical merits tax position tax positions likely sustained upon audit company recognizes largest amount benefit greater likely realized upon ultimate settlement financial statements tax positions likely sustained upon audit company recognize portion benefit financial statements likely threshold met period tax position taken company may subsequently recognize benefit tax position tax matter effectively settled statute limitations expires likely threshold met subsequent period see note consolidated financial statements tax regulations require items included tax return different times items reflected financial statements timing differences create deferred tax assets liabilities deferred tax assets generally represent items used tax deduction credit tax return future years company already recorded tax benefit financial statements company establishes valuation allowances deferred tax assets amount expected future taxable income likely support use deduction credit deferred tax liabilities generally represent tax expense recognized financial statements payment deferred expense company already taken deduction tax return yet recognized expense financial statements december foreign earnings billion retained indefinitely subsidiary companies reinvestment therefore provision made income taxes would payable upon distribution earnings would practicable determine amount related unrecognized deferred income tax liability recently issued accounting standards june fasb issued amended guidance presentation comprehensive income financial statements amendment provides companies option present components net income comprehensive income either one continuous statement comprehensive income two separate consecutive statements eliminates option present components comprehensive income part statement changes stockholders equity provisions new guidance effective interim annual periods beginning adoption new guidance impact companys financial position results operations cash flows cautionary factors may affect future results report written reports oral statements made time time company may contain socalled forwardlooking statements based managements current expectations subject risks uncertainties may cause results differ materially set forth statements one identify forwardlooking statements use words anticipates expects plans estimates forecasts projects words similar meaning one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product development product approvals product potential development programs one must carefully consider statement understand many factors could cause actual results differ materially companys forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially table contents company assume obligation update forwardlooking statement one carefully evaluate statements light factors including risk factors described companys filings securities exchange commission especially forms q k item risk factors annual report company discusses detail various important risk factors could cause actual results differ expected historic results company notes factors investors permitted private securities litigation reform act one understand possible predict identify factors consequently reader consider list complete statement potential risks uncertainties item quantitative qualitative disclosures market risk information required item incorporated reference discussion financial instruments market risk disclosures item managements discussion analysis financial condition results operations table contents item financial statements supplementary data financial statements consolidated balance sheet merck co inc subsidiaries december related consolidated statements income equity cash flows three years period ended december notes consolidated financial statements report dated february pricewaterhousecoopers llp independent registered public accounting firm follows consolidated statement income merck co inc subsidiaries years ended december millions except per share amounts sales costs expenses materials production marketing administrative research development restructuring costs equity income affiliates income expense net income taxes taxes income net income less net income attributable noncontrolling interests net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders accompanying notes integral part consolidated financial statement table contents consolidated balance sheet merck co inc subsidiaries december millions except per share amounts assets current assets cash cash equivalents shortterm investments accounts receivable net allowance doubtful accounts inventories excludes inventories classified assets see note deferred income taxes current assets total current assets investments property plant equipment cost land buildings machinery equipment office furnishings construction progress less accumulated depreciation goodwill intangibles net assets liabilities equity current liabilities loans payable current portion longterm debt trade accounts payable accrued current liabilities income taxes payable dividends payable total current liabilities longterm debt deferred income taxes noncurrent liabilities merck co inc stockholders equity common stock par value authorized shares issued shares paidin capital retained earnings accumulated comprehensive loss less treasury stock cost shares shares total merck co inc stockholders equity noncontrolling interests total equity accompanying notes integral part consolidated financial statement table contents consolidated statement equity merck co inc subsidiaries years ended december millions except per share amounts accumulated non common paidin retained comprehensive treasury controlling stock capital earnings loss stock interests total balance january net income attributable merck co inc total comprehensive loss net tax comprehensive income net tax scheringplough merger cancellations treasury stock preferred stock conversions cash dividends declared common stock per share net income attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december net income attributable merck co inc total comprehensive loss net tax comprehensive income net tax cash dividends declared common stock per share mandatory conversion convertible preferred stock treasury stock shares purchased net income attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december net income attributable merck co inc total comprehensive income net tax comprehensive income net tax cash dividends declared common stock per share treasury stock shares purchased net income attributable noncontrolling interests distributions attributable noncontrolling interests sharebased compensation plans balance december accompanying notes integral part consolidated financial statement table contents consolidated statement cash flows merck co inc subsidiaries years ended december millions cash flows operating activities net income adjustments reconcile net income net cash provided operating activities depreciation amortization intangible asset impairment charges gain disposition interest equity method investment gain astrazeneca lp asset option exercise gain related merckscheringplough partnership equity income affiliates dividends distributions equity affiliates deferred income taxes sharebased compensation net changes assets liabilities accounts receivable inventories trade accounts payable accrued current liabilities income taxes payable noncurrent liabilities net cash provided operating activities cash flows investing activities capital expenditures purchases securities investments proceeds sales securities investments proceeds sale interest equity method investment acquisitions businesses net cash acquired dispositions businesses net cash divested scheringplough merger net cash acquired proceeds astrazeneca lp asset option exercise decrease restricted assets net cash used provided investing activities cash flows financing activities net change shortterm borrowings payments debt proceeds issuance debt purchases treasury stock dividends paid stockholders dividends paid proceeds exercise stock options net cash used financing activities effect exchange rate changes cash cash equivalents net increase cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year supplemental cash flow information see note accompanying notes integral part consolidated financial statement table contents notes consolidated financial statements merck co inc subsidiaries millions except per share amounts nature operations merck co inc merck company global health care company delivers innovative health solutions prescription medicines vaccines biologic therapies animal health consumer care products markets directly joint ventures companys operations principally managed products basis comprised four operating segments pharmaceutical animal health consumer care alliances segments one reportable segment pharmaceutical segment pharmaceutical segment includes human health pharmaceutical vaccine products marketed either directly company joint ventures human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities company also animal health operations discover develop manufacture market animal health products including vaccines company sells veterinarians distributors animal producers additionally company consumer care operations develop manufacture market overthecounter foot care sun care products sold wholesale retail drug food chain mass merchandiser outlets november legacy merck co inc scheringplough corporation scheringplough merged merger results scheringploughs business included mercks financial statements periods subsequent completion merger therefore mercks financial results reflect full year scheringplough operations summary accounting policies principles consolidation consolidated financial statements include accounts company subsidiaries controlling interest maintained intercompany balances transactions eliminated controlling interest determined majority ownership interest absence substantive thirdparty participating rights case variable interest entities majority exposure expected losses residual returns consolidated subsidiaries merck ownership less outside shareholders interests shown noncontrolling interests equity investments affiliates company significant influence controlling interest interests entities owned equally company third party shared control carried equity basis mergers acquisitions business combination acquisition method accounting requires assets acquired liabilities assumed recorded date merger acquisition respective fair values limited exceptions assets acquired liabilities assumed business combination arise contingencies recognized fair value fair value reasonably estimated acquisition date fair value asset acquired liability assumed arises contingency determined asset liability recognized probable reasonably estimable criteria met asset liability recognized fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date accordingly company may required value assets fair value measures reflect companys intended use assets excess purchase price consideration transferred estimated fair values net assets acquired recorded goodwill transaction costs costs restructure acquired company expensed incurred operating results acquired business reflected companys consolidated financial statements date merger acquisition company determines assets acquired meet definition business acquisition method accounting transaction accounted acquisition assets rather business combination therefore goodwill recorded table contents foreign currency translation net assets international subsidiaries local currencies determined functional currencies translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recorded foreign currency translation account included accumulated comprehensive income loss aoci reflected separate component equity subsidiaries operate highly inflationary economies subsidiaries us dollar determined functional currency nonmonetary foreign currency assets liabilities translated using historical rates monetary assets liabilities translated current rates us dollar effects rate changes included income expense net result merger functional currency operations companys international subsidiaries reevaluated resulted change functional currency certain subsidiaries cash equivalents cash equivalents comprised certain highly liquid investments original maturities less three months inventories inventories valued lower cost market cost substantial majority domestic pharmaceutical vaccine inventories determined using lastin firstout lifo method financial reporting tax purposes cost inventories determined using firstin firstout fifo method inventories consist currently marketed products certain products awaiting regulatory approval evaluating recoverability inventories produced preparation product launches company considers probability revenue obtained future sale related inventory together status product within regulatory approval process investments investments marketable debt equity securities classified availableforsale reported fair value fair values companys investments determined using quoted market prices active markets identical assets liabilities quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities changes fair value considered temporary reported net tax comprehensive income oci declines fair value equity securities considered thantemporary impairment losses charged income expense net company considers available evidence evaluating potential impairments investments including duration extent fair value less cost equity securities companys ability intent hold investments debt securities otherthantemporary impairment occurred company expect recover entire amortized cost basis debt security company intend sell impaired debt security likely required sell debt security recovery amortized cost basis amount otherthantemporary impairment recognized earnings recorded income expense net limited portion attributed credit loss remaining portion otherthantemporary impairment related factors recognized oci realized gains losses debt equity securities included income expense net revenue recognition revenues sales products recognized time delivery title risk loss passes customer recognition revenue also requires reasonable assurance collection sales proceeds completion performance obligations domestically sales discounts issued customers direct discounts pointofsale indirectly intermediary wholesaler known chargebacks indirectly form rebates additionally sales generally made limited right return certain conditions revenues recorded net provisions sales discounts returns established time sale addition revenues recorded net time value money discounts customers collection accounts receivable expected excess one year accruals chargebacks reflected direct reduction accounts receivable accruals rebates recorded current liabilities accrued balances relative provisions chargebacks rebates included accounts receivable accrued current liabilities million billion respectively december million billion respectively december company recognizes revenue sales vaccines federal government placement vaccine stockpiles accordance securities exchange commission sec interpretation commission guidance regarding accounting sales vaccines bioterror countermeasures federal government placement pediatric vaccine stockpile strategic national stockpile table contents depreciation depreciation provided estimated useful lives assets principally using straightline method tax purposes accelerated tax methods used estimated useful lives primarily range years buildings years machinery equipment office furnishings software capitalization company capitalizes certain costs incurred connection obtaining developing internaluse software including external direct costs material services payroll costs employees directly involved software development capitalized software costs included property plant equipment amortized beginning software project substantially complete asset ready intended use capitalized software costs associated companys multiyear implementation enterprisewide resource planning system amortized years december approximately million million respectively remaining unamortized capitalized software costs associated initiative capitalized software costs amortized periods ranging years costs incurred preliminary project stage postimplementation stage well maintenance training costs expensed incurred goodwill goodwill represents excess consideration transferred fair value net assets businesses purchased goodwill assigned reporting units evaluated impairment least annual basis frequently impairment indicators exist first assessing qualitative factors determine whether likely fair value reporting unit less carrying amount company concludes likely fair value reporting unit less carrying amount quantitative fair value test performed based upon companys recent annual impairment test completed october likely fair value reporting unit excess carrying value acquired intangibles acquired intangibles include products product rights tradenames patents recorded fair value assigned estimated useful life amortized primarily straightline basis estimated useful lives ranging years see note events circumstances warrant review company assess recoverability acquired intangibles future operations using pretax undiscounted cash flows derived lowest appropriate asset groupings impairments recognized operating results extent carrying value intangible asset exceeds fair value determined based net present value estimated future cash flows inprocess research development inprocess research development iprd represents fair value assigned incomplete research projects company acquires business combinations time acquisition reached technological feasibility amounts capitalized accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project merck make determination useful life intangible asset generally determined period substantially cash flows expected generated begin amortization company tests iprd impairment least annually frequently impairment indicators exist onestep test compares fair value iprd intangible asset carrying value fair value less carrying amount impairment loss recognized within companys operating results research development research development expensed incurred upfront milestone payments due third parties connection research development collaborations prior regulatory approval expensed incurred payments due third parties upon subsequent regulatory approval capitalized amortized shorter remaining license product patent life nonrefundable advance payments goods services used future research development activities expensed activity performed goods received rather payment made research development expenses include restructuring costs periods iprd impairment charges million billion respectively sharebased compensation company expenses sharebased payments employees requisite service period based grant date fair value awards table contents restructuring costs company records liabilities costs associated exit disposal activities period liability incurred accordance existing benefit arrangements employee termination costs accrued restructuring actions probable estimable accruing costs company recognize amount within range costs best estimate within range amount within range better estimate amount company recognizes minimum amount within range costs onetime termination benefits employee required render service termination order receive benefits recognized ratably future service period contingencies legal defense costs company records accruals contingencies legal defense costs expected incurred connection loss contingency probable liability incurred amount reasonably estimated taxes income deferred taxes recognized future tax effects temporary differences financial income tax reporting based enacted tax laws rates company evaluates tax positions determine whether benefits tax positions likely sustained upon audit based technical merits tax position tax positions likely sustained upon audit company recognizes largest amount benefit greater likely realized upon ultimate settlement financial statements tax positions likely sustained upon audit company recognize portion benefit financial statements company recognizes interest penalties associated uncertain tax positions component taxes income consolidated statement income use estimates consolidated financial statements prepared conformity accounting principles generally accepted united states gaap accordingly include certain amounts based managements best estimates judgments estimates used accounting amounts recorded connection mergers acquisitions including initial fair value determinations assets liabilities primarily iprd intangible assets well subsequent fair value measurement additionally estimates used determining items provisions sales discounts returns depreciable amortizable lives recoverability inventories including produced preparation product launches amounts recorded contingencies environmental liabilities reserves pension postretirement benefit plan assumptions sharebased compensation assumptions restructuring costs impairments longlived assets including intangible assets goodwill investments taxes income uncertainty inherent estimates actual results may differ estimates reclassifications certain reclassifications made prior year amounts conform current year presentation recently adopted accounting standards following new accounting standards issued fasb adopted company january company prospectively adopted new guidance revenue recognition multiple deliverables revenue arrangements entered materially modified adoption date guidance eliminates residual method current guidance replaces relative selling price method allocating revenue multiple deliverable arrangement selling price deliverable shall determined using vendor specific objective evidence selling price exists otherwise thirdparty evidence selling price shall used neither exists deliverable vendor shall use best estimate selling price deliverable effect adoption companys financial position results operations material october conjunction annual goodwill impairment testing company early adopted amended guidance simplifies entity tests goodwill impairment amended guidance allows companies first assess qualitative factors determine likely fair value reporting unit less carrying value whether perform step one twostep goodwill impairment test table contents recently issued accounting standards june fasb issued amended guidance presentation comprehensive income financial statements amendment provides companies option present components net income comprehensive income either one continuous statement comprehensive income two separate consecutive statements eliminates option present components comprehensive income part statement changes stockholders equity provisions new guidance effective interim annual periods beginning adoption new guidance impact companys financial position results operations cash flows merger november merck scheringplough completed merger merger scheringplough acquired shares merck became whollyowned subsidiary scheringplough renamed merck sharp dohme corp msd scheringplough continued surviving public company renamed merck co inc however accounting purposes merger treated acquisition merck considered accounting acquirer terms merger agreement issued outstanding share scheringplough common stock converted right receive combination cash share common stock company issued outstanding share merck common stock automatically converted share common stock newly combined company based closing price merck stock november consideration received scheringplough shareholders valued per share billion aggregate cash portion consideration funded combination existing cash including sale mercks interest merial limited sale redemption investments issuance debt upon completion merger issued outstanding share scheringplough mandatory convertible preferred stock scheringplough preferred stock converted accordance terms preferred stock remained outstanding one share merck mandatory convertible preferred stock preferred stock rights set forth merck certificate incorporation rights substantially similar rights schering plough preferred stock august outstanding preferred stock automatically converted terms right receive cash shares merck common stock see note merger expanded companys pipeline product candidates broadened companys commercial portfolio expanded global presence increased manufacturing capabilities additionally company expects realize substantial cost savings synergies including opportunities consolidation sales marketing research development table contents calculation consideration transferred millions except per shareunit amounts scheringplough common stock shares outstanding november net treasury shares units merger consideration arising conversion preferred stock shares units eligible cash per shareunit cash consideration outstanding sharesunits preferred stock makewhole dividend payments value scheringplough deferred stock units settled cash total cash consideration shares units eligible common stock exchange ratio per shareunit equivalent merck shares shares issued settle certain performancebased awards merck shares issued merck common stock share price november common stock equity consideration fair value preferred stock converted fair value sharebased compensation awards employee benefit related amounts payable result merger total consideration transferred upon completion merger period days thereafter holders preferred stock entitled convert share preferred stock number units merger consideration equal makewhole conversion rate determined accordance terms preferred stock amount represents units merger consideration relating preferred stock converted holders day period following merger represents present value remaining dividend payments conversion date mandatory conversion date august paid holders preferred stock elected convert connection merger using discount rate stipulated terms preferred stock represents cash consideration paid holders scheringplough deferred stock units issued prior converted right receive cash specified merger agreement attributable precombination service represents fair value scheringplough stock option performance share unit deferred stock unit replacement awards attributable precombination service issued holders awards merger fair value outstanding scheringplough stock option performance share unit awards issued prior immediately vested effective time merger attributed precombination service included consideration transferred stock option performance share unit deferred stock unit awards immediately vest upon completion merger awards fair value awards attributed precombination service included part consideration transferred fair value attributed postcombination service recognized compensation cost requisite service period postcombination financial statements merck table contents supplemental pro forma data scheringploughs results operations included mercks financial statements periods subsequent completion merger scheringplough contributed revenues billion estimated losses billion merck period consummation merger december following unaudited supplemental pro forma data presents consolidated information merger completed january year ended december unaudited sales net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders unaudited supplemental pro forma data reflect application following adjustments consolidation merckscheringplough partnership msp partnership became wholly owned company additional depreciation amortization expense would recognized assuming fair value adjustments inventory property plant equipment intangible assets additional interest expense financing costs would incurred borrowing arrangements loss interest income cash shortterm investments used fund merger transaction costs associated merger conversion portion outstanding preferred stock unaudited supplemental pro forma financial information reflect potential realization cost savings relating integration two companies pro forma data considered indicative results would occurred merger related borrowings consummated january indicative future results restructuring merger restructuring program february company commenced actions global restructuring program merger restructuring program conjunction integration legacy merck legacy scheringplough businesses merger restructuring program intended optimize cost structure combined company additional actions program continued july company announced latest phase merger restructuring program company expects reduce workforce measured time merger additional across company worldwide majority workforce reductions phase merger restructuring program relate manufacturing including animal health administrative headquarters organizations previously announced workforce reductions approximately earlier phases program primarily reflect elimination positions sales administrative headquarters organizations well sale closure certain manufacturing research development sites consolidation office facilities company continue hire employees strategic growth areas business necessary company continue pursue productivity efficiencies evaluate manufacturing supply chain capabilities ongoing basis may result future restructuring actions company recorded total pretax restructuring costs billion billion billion related program since inception merger restructuring program december merck recorded total pretax accumulated costs approximately billion eliminated approximately positions comprised employee separations well elimination table contents contractors positions vacant time merger restructuring actions merger restructuring program expected substantially completed end exception certain actions principally manufacturingrelated expected substantially completed total cumulative pretax costs estimated approximately billion billion company estimates approximately two thirds cumulative pretax costs relate cash outlays primarily related employee separation expense approximately onethird cumulative pretax costs noncash relating primarily accelerated depreciation facilities closed divested global restructuring program october merck announced global restructuring program restructuring program reduce cost structure increase efficiency enhance competitiveness part restructuring program company expects eliminate approximately positions active employees vacancies across company worldwide pretax restructuring costs million million million recorded respectively related restructuring program since inception restructuring program december merck recorded total pretax accumulated costs billion eliminated approximately positions comprised employee separations elimination contractors vacant positions restructuring program substantially completed end exception certain manufacturingrelated actions expected completed total cumulative pretax costs estimated billion company estimates twothirds cumulative pretax costs relate cash outlays primarily employee separation expense approximately onethird cumulative pretax costs noncash relating primarily accelerated depreciation facilities closed divested segment reporting restructuring charges unallocated expenses table contents following table summarizes charges related merger restructuring program restructuring program activities type cost separation accelerated year ended december costs depreciation total merger restructuring program materials production marketing administrative research development restructuring costs restructuring program materials production research development restructuring costs year ended december merger restructuring program materials production marketing administrative research development restructuring costs restructuring program materials production marketing administrative research development restructuring costs year ended december merger restructuring program materials production restructuring costs restructuring program materials production research development restructuring costs table contents separation costs associated actual headcount reductions well headcount reductions probable could reasonably estimated approximately positions eliminated merger restructuring program approximately positions eliminated restructuring program approximately positions eliminated merger restructuring program approximately positions eliminated restructuring program approximately positions eliminated restructuring program approximately positions eliminated merger restructuring program position eliminations comprised actual headcount reductions elimination contractors vacant positions certain employees anticipated separated part planned restructuring actions restructuring program instead transferred buyer conjunction sale facility accordingly accrual separation costs associated employees reversed resulting reduction expenses accelerated depreciation costs primarily relate manufacturing research administrative facilities equipment sold closed part programs accelerated depreciation costs represent difference depreciation expense recognized revised useful life site based upon anticipated date site closed divested depreciation expense determined utilizing useful life prior restructuring actions sites continue operate respective closure dates since future cash flows sufficient recover respective book values merck required accelerate depreciation site assets rather write immediately activity includes million million million respectively asset abandonment shutdown related costs approximately million contract termination costs additionally activity includes million million million respectively employeerelated costs curtailment settlement termination charges associated pension postretirement benefit plans see note sharebased compensation costs activity also reflects net pretax gains losses resulting sales facilities related assets million million million respectively adjustments recorded amounts material period table contents following table summarizes charges spending relating merger restructuring program restructuring program activities separation accelerated costs depreciation total merger restructuring program restructuring reserves january expenses payments receipts net noncash activity restructuring reserves december expenses payments receipts net noncash activity restructuring reserves december restructuring program restructuring reserves january expenses payments receipts net noncash activity restructuring reserves december expenses payments receipts net noncash activity restructuring reserves december cash outlays associated merger restructuring program expected substantially completed end exception certain actions principally manufacturingrelated expected substantially completed cash outlays associated remaining restructuring reserves restructuring program primarily manufacturingrelated expected completed end legacy scheringplough program prior merger scheringplough commenced productivity transformation program designed reduce avoid costs increase productivity company recorded million million million respectively accelerated depreciation costs included materials production costs addition restructuring costs reflect million net gain primarily related sale manufacturing facility million separation costs remaining reserve related plan substantially complete million million december respectively acquisitions divestitures research collaborations license agreements may merck completed acquisition inspire pharmaceuticals inc inspire specialty pharmaceutical company focused developing commercializing ophthalmic products terms merger agreement merck acquired outstanding shares common stock inspire price per share cash total approximately million transaction accounted acquisition business accordingly assets acquired liabilities assumed recorded respective fair values acquisition date determination fair value requires management make significant estimates assumptions connection acquisition substantially purchase price allocated inspires product product right intangible assets related deferred tax liabilities deferred tax asset relating inspires net operating loss carryforwards goodwill transaction closed may accordingly table contents results operations acquired business included companys results operations since acquisition date pro forma financial information included inspires historical financial results significant compared companys financial results march company sold merck biomanufacturing network provider contract manufacturing development services biopharmaceutical industry wholly owned merck fujifilm corporation fujifilm terms agreement fujifilm purchased equity interests two merck subsidiaries together owned assets merck biomanufacturing network comprising facilities located research triangle park north carolina billingham united kingdom part agreement fujifilm merck committed certain continued development manufacturing activities two companies transaction resulted gain million reflected income expense net company acquired facility located billingham united kingdom completed acquisition avecia biologics limited february december company acquired outstanding stock smartcells inc smartcells private company developing glucose responsive insulin formulation treatment diabetes mellitus total purchase consideration company determined fair value acquisition date million included upfront cash payment contingent consideration consisting future clinical development regulatory milestones well contingent consideration future sales products resulting acquisition transaction accounted acquisition business accordingly assets acquired liabilities assumed recorded respective fair values acquisition date determination fair value requires management make significant estimates assumptions connection acquisition substantially preliminary purchase price allocated iprd remaining net assets acquired significant fair value contingent consideration determined utilizing probability weighted estimated cash flow stream adjusted expected timing payment subsequent acquisition date quarterly basis contingent consideration liability remeasured current fair value changes recorded earnings de minimis transaction closed december accordingly results operations acquired business included companys results operations since acquisition date pro forma financial information included smartcells historical financial results significant compared companys financial results may merck announced restructured codevelopment cocommercialization agreement ariad pharmaceuticals inc ariad ridaforolimus mk investigational orally available mtor inhibitor currently evaluated treatment multiple cancer types exclusive license agreement restructured agreement merck acquired full control development worldwide commercialization ridaforolimus ariad received million upfront fee company recorded research development expense eligible receive milestone payments associated regulatory filings approvals ridaforolimus multiple cancer indications achievement significant sales thresholds lieu profit split us sales provided previous agreement ariad receive royalties global net sales ridaforolimus sales recorded merck merck assumed responsibility activities acquired decision rights matters relating development manufacturing commercialization ridaforolimus investigational new drug application transferred merck merck leading interactions regulatory agencies ridaforolimus accepted review food drug administration fda european medicines agency agreement ariad terminable merck upon nine months notice immediately upon good faith determination serious safety issue agreement terminable either party result insolvency party uncured material breach party ariad failure merck perform certain product development responsibilities collaborative arrangements company continues strategy establishing external alliances complement substantial internal research capabilities including research collaborations licensing preclinical clinical compounds technology platforms drive near longterm growth company supplements internal research licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds well new technologies across broad range therapeutic areas arrangements table contents often include upfront payments royalty profit share payments contingent upon occurrence certain future events linked success asset development well expense reimbursements payments third party cozaarhyzaar merck ei dupont de nemours company dupont agreed form longterm research marketing collaboration develop class therapeutic agents high blood pressure heart disease discovered dupont called angiotensin ii receptor antagonists include cozaar hyzaar return merck provided dupont marketing rights united states canada prescription medicines sinemet sinemet cr company since regained global marketing rights sinemet sinemet cr pursuant agreement dupont company exclusive licensing agreement market cozaar hyzaar return royalties profit share payments dupont patents provided market exclusivity united states cozaar hyzaar expired april addition cozaar hyzaar lost patent protection number major european markets march remicadesimponi subsidiary scheringplough entered licensing agreement centocor ortho biotech inc centocor johnson johnson jj company market remicade prescribed treatment inflammatory diseases scheringploughs subsidiary exercised option contract centocor license rights develop commercialize simponi golimumab fully human monoclonal antibody company exclusive marketing rights products outside united states japan certain asian markets december scheringplough centocor revised distribution agreement regarding development commercialization distribution remicade simponi extending companys rights exclusively market remicade match duration companys exclusive marketing rights simponi addition scheringplough centocor agreed share certain development costs relating simponis autoinjector delivery system october european commission approved simponi treatment rheumatoid arthritis immune system disorders two presentations novel autoinjector prefilled syringe result companys marketing rights products extend years first commercial sale simponi european union eu following receipt pricing reimbursement approval within eu april merck jj reached agreement amend agreement governing distribution rights remicade simponi terms amended distribution agreement merck relinquished marketing rights remicade simponi jj territories including canada central south america middle east africa asia pacific effective july merck retained exclusive marketing rights throughout europe russia turkey retained territories addition beginning july profits derived mercks exclusive distribution two products retained territories equally divided merck jj prior terms distribution agreement contribution income profit split merck jj would declined merck increased jj year would equally divided jj also received onetime payment merck million april company recorded charge income expense net financial instruments derivative instruments hedging activities company manages impact foreign exchange rate movements interest rate movements earnings cash flows fair values assets liabilities operational means use various financial instruments including derivative instruments significant portion companys revenues earnings foreign affiliates exposed changes foreign exchange rates objectives accounting related companys foreign currency risk management program well interest rate risk management activities discussed table contents foreign currency risk management significant portion companys revenues denominated foreign currencies company established revenue hedging balance sheet risk management net investment hedging programs protect volatility future foreign currency cash flows changes fair value caused volatility foreign exchange rates objective revenue hedging program reduce potential longerterm unfavorable changes foreign exchange rates decrease us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen achieve objective company hedge portion forecasted foreign currency denominated thirdparty intercompany distributor entity sales expected occur planning cycle typically three years future company layer hedges time increasing portion thirdparty intercompany distributor entity sales hedged gets closer expected date forecasted foreign currency denominated sales probable hedged transaction occur portion sales hedged based assessments costbenefit profiles consider natural offsetting exposures revenue exchange rate volatilities correlations cost hedging instruments hedged anticipated sales specified component portfolio similarly denominated foreign currencybased sales transactions responds hedged currency risk manner company manages anticipated transaction exposure principally purchased local currency put options provide company right obligation sell foreign currencies future predetermined price us dollar strengthens relative currency hedged anticipated sales total changes options cash flows offset decline expected future us dollar equivalent cash flows hedged foreign currency sales conversely us dollar weakens options value reduces zero company benefits increase us dollar equivalent value anticipated foreign currency cash flows connection companys revenue hedging program purchased collar option strategy may utilized purchased collar option strategy company writes local currency call option purchases local currency put option compared purchased put option strategy alone purchased collar strategy reduces upfront costs associated purchasing puts collection premium writing call options us dollar weakens relative currency hedged anticipated sales purchased put option value collar strategy reduces zero company benefits increase us dollar equivalent value anticipated foreign currency cash flows however benefit would capped strike level written call us dollar strengthens relative currency hedged anticipated sales written call option value collar strategy reduces zero changes purchased put cash flows collar strategy would offset decline expected future us dollar equivalent cash flows hedged foreign currency sales company may also utilize forward contracts revenue hedging program us dollar strengthens relative currency hedged anticipated sales increase fair value forward contracts offsets decrease expected future us dollar cash flows hedged foreign currency sales conversely us dollar weakens decrease fair value forward contracts offsets increase value anticipated foreign currency cash flows fair values derivative contracts recorded either assets gain positions liabilities loss positions consolidated balance sheet changes fair value derivative contracts recorded period either current earnings oci depending whether derivative designated part hedge transaction type hedge transaction derivatives designated cash flow hedges effective portion unrealized gains losses contracts recorded aoci reclassified sales hedged anticipated revenue recognized hedge relationship highly effective hedge ineffectiveness de minimis derivatives designated cash flow hedges unrealized gains losses recorded sales period cash flows contracts reported operating activities consolidated statement cash flows company enter derivatives trading speculative purposes primary objective balance sheet risk management program mitigate exposure foreign currency denominated net monetary assets foreign subsidiaries us dollar functional table contents currency effects volatility foreign exchange instances merck principally utilizes forward exchange contracts enable company buy sell foreign currencies future fixed exchange rates economically offset consequences changes foreign exchange monetary assets merck routinely enters contracts offset effects exchange exposures denominated developed country currencies primarily euro japanese yen exposures developing country currencies company enter forward contracts partially offset effects exchange exposures deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate cost hedging instrument company also minimize effect exchange monetary assets liabilities managing operating activities net asset positions local level monetary assets liabilities denominated currency functional currency given subsidiary remeasured spot rates effect balance sheet date effects changes spot rates reported income expense net forward contracts designated hedges marked market income expense net accordingly fair value changes forward contracts help mitigate changes value remeasured assets liabilities attributable changes foreign currency exchange rates except extent spotforward differences differences significant due shortterm nature contracts typically average maturities inception less one year company used may future use forward contracts hedge changes fair value certain foreign currency denominated availableforsale securities attributable fluctuations foreign currency exchange rates derivative contracts designated fair value hedges accordingly changes fair value hedged securities due fluctuations spot rates recorded income expense net offset fair value changes forward contracts attributable spot rate fluctuations changes contracts fair value due spotforward differences excluded designated hedge relationship recognized income expense net amounts well hedge ineffectiveness significant cash flows contracts reported operating activities consolidated statement cash flows company also uses forward exchange contracts hedge net investment foreign operations movements exchange rates forward contracts designated hedges net investment foreign operation company hedges portion net investment certain foreign operations measures ineffectiveness based upon changes spot foreign exchange rates effective portion unrealized gains losses contracts recorded foreign currency translation adjustment within oci remains aoci either sale complete substantially complete liquidation subsidiary cash flows contracts reported investing activities consolidated statement cash flows foreign exchange risk also managed use foreign currency debt companys senior unsecured eurodenominated notes designated effective economic hedges net investment foreign operation accordingly foreign currency transaction gains losses due spot rate fluctuations eurodenominated debt instruments included foreign currency translation adjustment within oci included cumulative translation adjustment pretax gains million million million postmerger period eurodenominated notes designated effective economic hedges net investment foreign operation interest rate risk management company may use interest rate swap contracts certain investing borrowing transactions manage net exposure interest rate changes reduce overall cost borrowing company use leveraged swaps general leverage investment activities would put principal capital risk february company entered nine payfloating receivefixed interest rate swap contracts notional amounts billion aggregate designated fair value hedges fixedrate notes notional amounts matched amount hedged fixedrate notes two interest rate swap contracts designated fair value hedges fixedrate notes matured notional amounts million effectively converted companys million fixedrate notes due floating rate instruments interest rate swap contracts designated hedges fair table contents value changes notes attributable changes benchmark london interbank offered rate libor swap rate fair value changes notes attributable changes benchmark interest rate recorded interest expense offset fair value changes swap contracts also company terminated payfloating receivefixed interest rate swap contracts designated fair value hedges fixedrate notes notional amounts match amount hedged fixedrate notes swaps effectively converted billion fixedrate notes maturity dates varying march june floating rate instruments interest rate swap contracts designated hedges fair value changes notes attributable changes benchmark libor swap rate result swap terminations company received million cash included million accrued interest unamortized adjustment carrying value debt associated interest rate swap contracts million amortized reduction interest expense respective term notes cash flows contracts reported operating activities consolidated statement cash flows presented table fair value derivatives segregated derivatives designated hedging instruments designated hedging instruments december fair value fair value derivative us dollar derivative us dollar millions balance sheet caption asset liability notional asset liability notional derivatives designated hedging instruments foreign exchange contracts deferred income taxes current current assets foreign exchange contracts non current assets foreign exchange contracts current accrued current liabilities foreign exchange contracts non deferred income taxes current noncurrent liabilities interest rate swaps noncurrent assets interest rate swaps deferred income taxes noncurrent noncurrent liabilities derivatives designated hedging instruments foreign exchange contracts deferred income taxes current current assets foreign exchange contracts current accrued current liabilities table contents table provides information location pretax gain loss amounts derivatives designated fair value hedging relationship ii designated cash flow hedging relationship iii designated foreign currency net investment hedging relationship iv designated hedging relationship years ended december derivatives designated fair value hedging relationships interest rate swap contracts amount gain recognized income expense net derivatives amount loss recognized income expense net hedged item derivatives designated foreign currency cash flow hedging relationships foreign exchange contracts amount loss reclassified aoci sales amount loss gain recognized oci derivatives derivatives designated foreign currency net investment hedging relationships foreign exchange contracts amount gain recognized income expense net derivatives amount loss recognized oci deriviatives derivatives designated hedging relationship foreign exchange contracts amount gain recognized income expense net derivatives amount gain recognized sales ineffectiveness hedge represents amount excluded hedge effectiveness testing derivative contracts mitigate changes value remeasured foreign currency denominated monetary assets liabilities attributable changes foreign currency exchange rates december company estimates million pretax net unrealized losses derivatives maturing within next months hedge foreign currency denominated sales period reclassified aoci sales amount ultimately reclassified sales may differ foreign exchange rates change realized gains losses ultimately determined actual exchange rates maturity investments debt equity securities information availableforsale investments december follows gross unrealized gross unrealized fair amortized fair amortized value cost gains losses value cost gains losses corporate notes bonds commercial paper us government agency securities municipal securities assetbacked securities mortgagebacked securities foreign government bonds debt securities equity securities availableforsale debt securities included shortterm investments totaled billion december remaining debt securities billion mature within five years december debt securities pledged collateral table contents fair value measurements fair value defined exchange price would received asset paid transfer liability exit price principal advantageous market asset liability orderly transaction market participants measurement date company uses fair value hierarchy maximizes use observable inputs minimizes use unobservable inputs measuring fair value three levels inputs used measure fair value level highest priority level lowest level quoted prices unadjusted active markets identical assets liabilities level observable inputs level prices quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities level unobservable inputs supported little market activity companys level assets whose values determined using pricing models discounted cash flow methodologies similar techniques significant unobservable inputs well instruments determination fair value requires significant judgment estimation inputs used measure financial assets liabilities fall within one level described categorization based lowest level input significant fair value measurement instrument table contents financial assets liabilities measured fair value recurring basis financial assets liabilities measured fair value recurring basis december summarized fair value measurements using fair value measurements using quoted prices significant quoted prices significant active significant active significant markets observable unobservable markets observable unobservable identical assets inputs inputs identical assets inputs inputs level level level total level level level total assets investments corporate notes bonds commercial paper us government agency securities municipal securities assetbacked securities mortgagebacked securities foreign government bonds equity securities debt securities assets securities held employee compensation derivative assets purchased currency options forward exchange contracts interest rate swaps total assets liabilities derivative liabilities forward exchange contracts written currency options interest rate swaps total liabilities primarily assetbacked securities highlyrated standard poors rating aaa moodys investors service rating aaa secured primarily credit card auto loan home equity receivables weightedaverage lives primarily years less mortgagebacked securities represent aaarated securities issued unconditionally guaranteed payment principal interest us government agencies fair value determination derivatives includes impact credit risk counterparties derivatives companys credit risk effects significant significant transfers level level december cash cash equivalents billion included billion cash equivalents considered level fair value hierarchy level valuation techniques companys level investment securities included certain mortgagebacked securities valued primarily using pricing models incorporate transaction details contractual terms maturity timing amount future cash inflows well assumptions liquidity credit valuation adjustments marketplace participants table contents table provides summary changes fair value financial assets measured fair value recurring basis using significant unobservable inputs level years ended december beginning balance january sales total realized unrealized gains losses included earnings comprehensive income ending balance december losses recorded earnings level assets still held december amounts recorded income expense net financial instruments measured fair value companys financial instruments measured fair value recurring basis recorded amounts approximate fair value due liquid shortterm nature cash cash equivalents receivables payables estimated fair value loans payable longterm debt including current portion december billion compared carrying value billion december billion compared carrying value billion fair value estimated using quoted dealer prices concentrations credit risk ongoing basis company monitors concentrations credit risk associated corporate government issuers securities financial institutions conducts business credit exposure limits established limit concentration single issuer institution cash investments placed instruments meet high credit quality standards specified companys investment policy guidelines approximately threequarters companys cash cash equivalents invested three highly rated money market funds majority companys accounts receivable arise product sales united states europe primarily due drug wholesalers retailers hospitals government agencies managed health care providers pharmacy benefit managers company monitors financial performance creditworthiness customers properly assess respond changes credit profile company also continues monitor economic conditions including volatility associated international sovereign economies associated impacts financial markets business taking consideration global economic downturn sovereign debt issues certain european countries company continues monitor credit economic conditions within greece spain italy portugal among members eu deteriorating economic conditions well inherent variability timing cash receipts resulted may continue result increase average length time takes collect accounts receivable outstanding time value money discounts recorded customers collection accounts receivable expected excess one year company expect writeoffs adjustments accounts receivable would material adverse effect financial position liquidity results operations december companys accounts receivable greece italy spain portugal totaled approximately billion amount hospital public sector receivables approximately billion aggregate approximately related greece italy spain portugal respectively december companys total accounts receivable outstanding one year approximately million approximately related accounts receivable greece italy spain portugal mostly comprised hospital public sector receivables table contents previously disclosed company received zero coupon bonds greek government settlement receivables related certain government sponsored institutions company sold portion bonds company recorded impairment charges reduce remaining bonds fair value company sold remaining bonds company continued receive payments greek hospital public sector receivables company factored approximately million hospital public sector accounts receivable nonrecourse basis spain italy december company executed factoring approximately million hospital public sector accounts receivable italy factoring subject certain closing conditions companys five largest customers cardinal health inc mckesson corporation amerisourcebergen corporation alliance healthcare zuellig pharma ltd represented aggregate approximately onefourth accounts receivable december company monitors creditworthiness customers grants credit terms normal course business bad debts minimal company normally require collateral security support credit sales derivative financial instruments executed international swaps derivatives association master agreements master agreements several companys financial institution counterparties also include credit support annexes annexes contain provisions require collateral exchanged depending value derivative assets liabilities companys credit rating credit rating counterparty december company received cash collateral million million respectively various counterparties obligation return collateral recorded accrued current liabilities company advanced cash collateral counterparties december inventories inventories december consisted finished goods raw materials work process supplies total approximates current cost reduction lifo costs recognized inventories assets inventories valued lifo method comprised approximately inventories december respectively amounts recognized assets comprised almost entirely raw materials work process inventories december amounts included billion billion respectively inventories expected sold within one year largely vaccines addition amounts included million million december respectively inventories produced preparation product launches table contents goodwill intangibles following table summarizes goodwill activity segment pharmaceutical total goodwill balance january additions goodwill balance december additions goodwill balance december includes cumulative translation adjustments goodwill balances reclassification goodwill pharmaceutical segment consumer care segment result segment change occurred see note certain adjustments intangibles december consisted gross gross carrying accumulated carrying accumulated amount amortization net amount amortization net products product rights inprocess research development tradenames total identifiable intangible assets company recorded impairment charge million related marketed product amounts capitalized inprocess research development accounted indefinitelived intangible assets subject impairment testing completion abandonment projects upon successful completion project company make separate determination useful life assets begin amortization approximately million million respectively iprd reclassified products product rights upon receipt marketing approval major market connection merger company recorded fair value human animal health research projects underway schering plough msp partnership significant projects include victrelis bridion vorapaxar well ezetimibeatorvastatin combination product victrelis approved fda eu company filed nda fda ezetimibeatorvastatin combination product vorapaxar phase iii clinical development bridion approved many countries outside united states remains phase iii clinical development united states company recorded million iprd impairment charges within research development expenses primarily pipeline programs abandoned determined alternative use well expected delays launch timing changes cash flow assumptions certain compounds addition impairment charges related pipeline programs previously deprioritized either deemed alternative use period outlicensed third party consideration less related assets carrying value company recorded billion iprd impairment charges within research development expenses amount billion related writedown vorapaxar intangible asset company determined developments clinical research program vorapaxar including termination clinical trial constituted triggering event required company evaluate vorapaxar intangible asset table contents impairment company continues monitor remaining million asset value vorapaxar impairment remaining million iprd impairment charges recorded attributable compounds abandoned determined either alternative use returned respective licensor well expected delays launch timing changes cash flow assumptions certain compounds iprd projects remain development subject inherent risks uncertainties drug development possible company able successfully develop complete iprd programs profitably commercialize underlying product candidates aggregate amortization expense primarily recorded within materials production costs billion billion million estimated aggregate amortization expense next five years follows billion billion billion billion billion joint ventures equity method affiliates equity income affiliates reflects performance companys joint ventures equity method affiliates comprised following years ended december astrazeneca lp merckscheringplough upon completion merger msp partnership became wholly owned company see primarily reflects results sanofi pasteur msd johnson johnsonmerck consumer pharmaceuticals company disposed september well merial limited disposed september astrazeneca lp merck entered agreement astra ab astra develop market astra products royaltybearing license mercks total sales astra products reached level triggered first step establishment joint venture business carried astra merck inc ami merck astra owned share joint venture formed developed marketed astras new prescription medicines united states including prilosec first class medications known proton pump inhibitors slows production acid cells stomach lining merck astra completed restructuring ownership operations joint venture whereby merck acquired astras interest ami renamed kbi inc kbi contributed kbis operating assets new us limited partnership astra pharmaceuticals lp partnership exchange limited partner interest astra contributed net assets wholly owned subsidiary astra usa inc partnership exchange general partner interest partnership renamed astrazeneca lp azlp upon astras merger zeneca group plc became exclusive distributor products kbi retained rights maintaining limited partner interest azlp merck consent protective rights intended preserve business economic interests including restrictions power general partner make certain distributions dispositions furthermore limited events default additional rights granted company including powers direct actions remove replace partnerships chief executive officer chief financial officer merck earns ongoing revenue based sales kbi products revenue billion billion billion respectively primarily relating sales nexium well prilosec addition merck earns certain partnership returns recorded equity income affiliates reflected table returns include priority return provided partnership agreement preferential return representing mercks share undistributed azlp gaap earnings variable return related companys limited partner interest table contents conjunction restructuring discussed astra purchased option asset option payment million recorded deferred income buy mercks interest kbi products excluding gastrointestinal medicines nexium prilosec nonppi products april astrazeneca exercised asset option merck received million astrazeneca representing net present value march projected future pretax revenue received merck nonppi products recorded reduction companys investment azlp company recognized million deferred income component income expense net addition merck granted astra option shares option buy mercks common stock interest kbi mercks interest nexium prilosec exercisable exercise price shares option primarily based net present value projected future pretax revenue received merck nexium prilosec determined time exercise subject certain trueup mechanisms company believes likely astrazeneca exercise shares option summarized financial information azlp follows years ended december sales materials production costs expense net income taxes december current assets noncurrent assets current liabilities mercks partnership returns azlp generally contractually determined noted based percentage income azlp respect mercks limited partnership interest sanofi pasteur msd merck pasteur mrieux connaught sanofi pasteur sa established equallyowned joint venture market vaccines europe collaborate development combination vaccines distribution europe joint venture vaccine sales billion billion billion johnson johnsonmerck consumer pharmaceuticals company september merck sold interest johnson johnsonmerck consumer pharmaceuticals company jjmcp joint venture jj venture merck jj formed develop manufacture market distribute certain overthecounter otc consumer products united states canada merck received onetime payment million recognized pretax gain million reflected income expense net mercks rights pepcid brand outside united states canada affected transaction following transaction jj owns ventures assets include exclusive rights market otc pepcid mylanta mylicon local otc brands currently sold united states canada partnership assets also included manufacturing facility sales products marketed joint venture million period january september divestiture date million million merckscheringplough partnership merck scheringplough collectively partners entered agreement create equally owned partnership develop market united states new prescription medicines cholesterol management ezetimibe first new class cholesterollowering agents launched united states zetia marketed ezetrol outside united states combination product containing active ingredients zetia zocor approved united states vytorin marketed inegy outside table contents united states cholesterol agreements provided sharing operating income generated msp partnership based upon percentages varied product sales level country operating income included expenses partners contractually agreed share expenses incurred support msp partnership shared partners included equity income affiliates however costs reflected overall results partners result merger msp partnership became wholly owned company mercks share results msp partnership date merger reflected equity income affiliates activity resulting sale msp partnership products merger consolidated mercks results see note information respect litigation involving msp partnership partners related sale promotion zetia vytorin summarized financial information msp partnership follows period january november sales vytorin zetia materials production costs expense net income taxes mercks share income taxes mercks share msp partnerships income taxes differs equity income recognized msp partnership primarily due timing recognition certain transactions merck msp partnership including milestone payments merial limited merck sold interest merial limited merial joint venture sanofiaventis merck sanofiaventis rhnepoulenc sa formed merial combining animal health businesses fully integrated animal health company standalone joint venture equally owned party merck received billion cash recorded billion pretax gain reflected income expense net sales products marketed joint venture billion january september divestiture date march merck sanofiaventis mutually terminated agreement form new animal health joint venture termination agreement without penalty either party investments affiliates accounted using equity method including joint ventures totaled million december million december amounts reported assets amounts due joint ventures included deferred income taxes current assets million december million december table contents summarized information affiliates excluding msp partnership azlp disclosed separately follows years ended december sales materials production costs expense net income taxes december current assets noncurrent assets current liabilities noncurrent liabilities includes information jjmcp divestiture september includes information merial divestiture september loans payable longterm debt commitments loans payable december included billion commercial paper million shortterm foreign borrowings million long dated notes subject repayment option holders loans payable december included billion notes due million commercial paper million shortterm foreign borrowings million longdated notes subject repayment option holders longterm debt december consisted eurodenominated notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due debentures due notes due debentures due debentures due presented table included million borrowings variable rates averaging also included foreign borrowings million million december respectively varying rates table contents exception notes due debentures due notes listed table redeemable whole part mercks option time varying redemption prices connection merger effective november company executed full unconditional guarantee existing debt subsidiary msd msd executed full unconditional guarantee existing debt company excluding commercial paper including payments principal interest guarantees extend debt issued subsequent merger certain companys borrowings require merck comply financial covenants including requirement total debt capitalization ratio defined applicable agreements exceed december company compliance covenants aggregate maturities longterm debt next five years follows million billion billion billion million may company entered new billion day credit facility new billion fouryear credit facility maturing may company terminated existing billion day credit facility expired may billion revolving credit facility scheduled mature august outstanding facilities provide backup liquidity companys commercial paper borrowing facility used general corporate purposes company drawn funding either facility rental expense operating leases net sublease income million million million minimum aggregate rental commitments noncancellable leases follows million million million million million thereafter million company significant capital leases contingencies environmental liabilities company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well additional matters antitrust actions except vioxx litigation enhance litigation defined separate assessments provided note opinion company unlikely resolution matters material companys financial position results operations cash flows given preliminary nature litigation discussed including vioxx litigation enhance litigation complexities involved matters company unable reasonably estimate possible loss range possible loss matters company knows among factors claims survive dispositive motion practice ii extent claims including size potential class particularly damages specified indeterminate iii discovery process affect litigation iv settlement posture parties litigation v factors may material effect litigation company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjusted periodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable companys decision obtain insurance coverage dependent market conditions including cost availability existing time decisions made result number factors product liability insurance become less available cost increased significantly company evaluated risks determined cost obtaining product liability insurance outweighs likely benefits coverage available insurance certain product liabilities effective august including liability legacy merck products first sold date company continue evaluate insurance needs costs availability benefits product liability insurance future table contents vioxx litigation product liability lawsuits previously disclosed merck defendant approximately federal state lawsuits alleging personal injury economic loss result purchase use vioxx remaining cases coordinated multidistrict litigation us district court eastern district louisiana vioxx mdl judge eldon e fallon actions discussed paragraph lawsuits collectively referred vioxx product liability lawsuits us vioxx product liability lawsuits tried one currently scheduled trial merck previously disclosed outcomes several vioxx product liability lawsuits tried prior posttrial appeals resolved december texas supreme court denied plaintiffs petition review ernst v merck merck previously disclosed details associated ernst case lawsuits pending various us courts putative class actions purportedly brought behalf individual purchasers users vioxx seeking reimbursement alleged economic loss vioxx mdl proceeding approximately class actions remain june merck moved strike class claims judgment pleadings regarding master complaint includes abovereferenced cases briefing motion completed september vioxx mdl court heard oral argument mercks motion october took advisement missouri state court certified class missouri plaintiffs seeking reimbursement outofpocket costs relating vioxx trial scheduled begin may addition indiana plaintiffs filed motion certify class indiana vioxx purchasers case pending circuit court marion county indiana april kentucky state court denied mercks motion summary judgment certified class kentucky plaintiffs seeking reimbursement outofpocket costs relating vioxx trial court subsequently entered amended class certification order january merck appealed order kentucky court appeals february kentucky court appeals reversed trial courts amended class certification order denied certification class kentucky plaintiffs merck also named defendant several lawsuits brought behalf government entities eleven suits brought state attorneys general one brought behalf county actions vioxx mdl proceeding actions allege merck misrepresented safety vioxx one suits seek recovery expenditures vioxx governmentfunded health care programs medicaid along relief penalties attorneys fees action brought attorney general kentucky seeks penalties alleged consumer fraud act violations judge fallon remanded kentucky case state court january merck appealing decision lawsuit brought county putative class action filed santa clara county california behalf similarly situated california counties merck moved judgment pleadings case brought santa clara county september court heard oral argument motion january addition merck moved dismiss case brought attorney general oklahoma december march judge fallon partially granted partially denied mercks motion summary judgment louisiana attorney general case trial remaining claims judge fallon completed april judge fallon found favor merck june dismissing louisiana attorney generals remaining claims prejudice louisiana attorney general filed notice appeal fifth circuit dismissed appeal without prejudice pursuant scheduling rules october louisiana attorney general requested stay appeal shareholder lawsuits previously disclosed addition vioxx product liability lawsuits various putative class actions individual lawsuits federal securities laws state laws filed merck various current former officers directors vioxx securities lawsuits vioxx securities lawsuits coordinated multidistrict litigation us district court district new jersey judge table contents stanley r chesler consolidated purposes august judge chesler granted part denied part mercks motion dismiss fifth amended class action complaint consolidated securities action among things claims based statements made voluntary withdrawal vioxx september dismissed october defendants answered fifth amended class action complaint discovery currently proceeding accordance courts scheduling order scheduling order plaintiffs class certification motion must filed april fact discovery must completed march previously disclosed several individual securities lawsuits filed foreign institutional investors also consolidated vioxx securities lawsuits october plaintiffs filed amended complaints pending individual securities lawsuits also october new individual securities lawsuit filed district new jersey several foreign institutional investors case also consolidated vioxx securities lawsuits january defendants filed motions dismiss one individual lawsuits abp lawsuit stipulation order defendants required respond complaints remaining individual securities lawsuits resolution motions dismiss abp lawsuit addition previously disclosed various putative class actions filed federal court employee retirement income security act erisa merck certain current former officers directors vioxx erisa lawsuits cases consolidated judge chesler august parties reached agreement principle merck would pay million settle vioxx erisa lawsuits november judge chesler granted final approval settlement dismissed vioxx erisa lawsuits prejudice international lawsuits previously disclosed addition lawsuits discussed merck named defendant litigation relating vioxx australia brazil canada europe israel collectively vioxx foreign lawsuits following trial representative action first instance judge federal court australia entered orders dismissed claims merck regard mercks australian subsidiary merck sharp dohme australia pty ltd msd australia court dismissed certain claims awarded applicant court found suffered myocardial infarction mi ingesting vioxx approximately months au based statutory claims vioxx fit purpose merchantable quality even though court rejected applicants claim merck msd australia knew ought known prior voluntary withdrawal vioxx september vioxx materially increased risk mi court also determined findings fact law common claims group members whose individual claims would proceed reference findings msd australia appealed adverse findings full federal court full court heard appeal crossappeal august october full court allowed msd australias appeal set aside judgment favor applicant dismissed action full court held vioxx proven cause applicants mi msd australia liable applicant damages negligence former trade practices act full court also affirmed first instance decision favor msd australia applicants statutory defect claim holding msd australias state art defense proven based development scientific knowledge time effect decision upon claims remaining group members remains determined applicant seeking leave appeal full courts judgment high court australia january merck announced entered agreement canada settlement agreement resolve claims including certain class actions putative class actions related vioxx canada agreement pending approval courts canadas provinces canada settlement agreement approved specified conditions including among others right merck terminate optouts met conditions set forth certain merck termination rights accordingly may waived merck merck would make payments aggregating minimum c approximately million us dollars december maximum c approximately million us dollars december canada settlement amount exact canada settlement amount depend number individuals submit table contents documented claims determined meet certain threshold gates relating alleged injury event alleged usage vioxx addition payments eligible claimants experienced diagnosed mi sudden cardiac death diagnosed ischemic stroke settlement also includes fixed payments c provinces territories c towards class counsel fees c administrative expenses involved implementation canada settlement agreement approved legal fees administrative expenses exceed specified amounts excess would paid amount funded eligible claimants derivative claimants company recorded reserve fourth quarter settlement canada settlement agreement provides merck denies allegations denies damages payable concede admit liability merck make payment pay notice dissemination costs certain administrative costs unless approvals courts canadas provinces secured termination rights expired without merck terminated canada settlement agreement entirety merck also certain rights terminate canada settlement agreement part relation provinces territories ontario quebec insurance company directors officers insurance coverage applicable vioxx securities lawsuits remaining stated upper limits approximately million result previously disclosed insurance arbitration additional insurance coverage claims also available needed upperlevel excess policies provide coverage variety risks disputes insurers availability companys insurance coverage claims likely additional disputes amounts actually recovered policies discussed paragraph may less stated upper limits investigations previously disclosed merck received subpoenas department justice doj requesting information related mercks research marketing selling activities respect vioxx federal health care investigation criminal statutes previously disclosed march merck received letter us attorneys office district massachusetts identifying target grand jury investigation regarding vioxx company established million reserve vioxx liability reserve connection anticipated resolution dojs investigation november company announced reached resolution federal state authorities regarding matter pending court approval civil settlement agreements signed united states individually states district columbia merck pay approximately twothirds vioxx liability reserve resolve civil allegations related vioxx result united states participating states released merck civil liability related governments allegations regarding sale promotion vioxx company also agreed plead guilty one count misdemeanor misbranding vioxx federal food drug cosmetic act promoting drug treatment rheumatoid arthritis prior fdas approval indication april company pay fine approximately onethird vioxx liability reserve federal government part plea agreement december us district court district massachusetts conducted hearing regard resolution hearing parties advised court nature resolution core documents comprising resolution court scheduled subsequent hearing march court may issue ruling concerning whether accepts mercks plea resolution reserves company believes meritorious defenses vioxx product liability lawsuits vioxx securities lawsuits vioxx foreign lawsuits collectively vioxx lawsuits vigorously defend view inherent difficulty predicting outcome litigation particularly many claimants claimants seek indeterminate damages company unable predict outcome matters time reasonably estimate possible loss range loss respect remaining vioxx lawsuits noted company established vioxx liability reserve reserve table contents respect canada settlement agreement company established liability reserves respect vioxx litigation unfavorable outcomes vioxx litigation could material adverse effect companys financial position liquidity results operations product liability litigation fosamax previously disclosed merck defendant product liability lawsuits united states involving fosamax fosamax litigation december approximately cases include approximately plaintiff groups filed pending merck either federal state court including one case seeks class action certification well damages andor medical monitoring approximately actions plaintiffs allege among things suffered osteonecrosis jaw onj generally subsequent invasive dental procedures tooth extraction dental implants andor delayed healing association use fosamax addition plaintiffs approximately actions generally allege sustained femur fractures andor bone injuries association use fosamax cases alleging onj andor jaw related injuries august judicial panel multidistrict litigation jpml ordered certain fosamax product liability cases pending federal courts nationwide transferred consolidated one multidistrict litigation fosamax mdl coordinated pretrial proceedings fosamax mdl transferred judge john keenan us district court southern district new york result jpml order approximately cases judge keenan judge keenan issued case management order various amendments thereto set forth schedule governing proceedings focused primarily upon resolving class action certification motions completing fact discovery initial group cases october first fosamax mdl trial boles v merck fosamax mdl court declared mistrial eight person jury could reach unanimous verdict boles case retried june resulted verdict favor plaintiff amount million merck filed posttrial motions seeking judgment matter law alternative new trial october court denied mercks posttrial motions sua sponte ordered remittitur reducing verdict million plaintiff rejected remittitur ordered court requested new trial damages scheduled take place september merck intends appeal verdict boles new trial damages concluded next fosamax mdl trial maley v merck jury may returned unanimous verdict mercks favor february judge keenan selected new bellwether case judith graves v merck replace flemings v merck bellwether case fosamax mdl court dismissed granted summary judgment favor merck november second circuit affirmed courts granting summary judgment favor merck flemings case graves jury returned unanimous verdict favor merck november jury secrest v merck returned unanimous verdict favor merck october next trial scheduled fosamax mdl raber v merck subsequently dismissed addition february judge keenan ordered two bellwether trials conducted fosamax mdl spano v merck scheduled tried may jellema v merck scheduled tried may dismissed plaintiff replacement case selected first quarter case tried beginning november outside fosamax mdl trial florida anderson v merck scheduled begin june florida state court postponed trial date new date set january trial ready date carballo v merck continued august april ward v merck case scheduled tried june addition july application made atlantic county superior court new jersey requesting fosamax cases pending new jersey considered mass tort designation centralized management one judge new jersey october new jersey supreme court ordered pending future actions filed new jersey arising use fosamax seeking damages table contents existing dental jawrelated injuries including onj solely seeking medical monitoring designated mass tort centralized management purposes judge carol e higbee atlantic county superior court december approximately onj cases pending merck atlantic county new jersey july judge higbee entered case management order various amendments thereto setting forth schedule contemplates completing fact expert discovery initial group cases reviewed trial february jury rosenberg v merck first trial new jersey coordinated proceeding returned verdict mercks favor trial sessner v merck case commenced february flores v merck case scheduled tried jointly sessner v merck february judge higbee severed flores case sessner trial flores trial rescheduled california parties reviewing claims three plaintiffs carrie smith et al v merck case claims pedrojetti v merck cases one plaintiffs expected tried mid discovery ongoing fosamax mdl litigation new jersey coordinated proceeding remaining jurisdictions fosamax cases pending company intends defend lawsuits cases alleging femur fractures andor bone injuries december approximately cases alleging femur fractures andor bone injuries filed new jersey state court pending judge higbee atlantic county superior court parties selected initial group cases reviewed fact discovery plaintiffs subsequently dismissed advised dismiss seven cases selected discovery remaining cases continuing trial dates new jersey state femur fracture cases set march merck submitted motion transfer jpml seeking federal cases alleging femur fractures bone injuries consolidated one multidistrict litigation coordinated pretrial proceedings motion transfer granted may federal cases involving allegations femur fracture bone injuries transferred district new jersey fosamax mdl sited judge garrett brown initially assigned preside second fosamax mdl proceeding judge joel pisano assigned preside litigation november due judge browns retirement case management order entered requires parties review cases later reduced cases fact discovery deadline july expert discovery deadline november projected trial date first case tried sometime march petition filed seeking coordinate femur fracture cases filed california state court single judge orange county california petition granted judge ronald l bauer appointed preside coordinated proceedings expected replaced judge steven perk scheduling order yet entered additionally four femur fracture cases pending state courts one femur fracture case pending federal court outside mdl one case pending state courts massachusetts florida alabama georgia one pending federal court texas also one osteonecrosis hip case pending federal court idaho discovery ongoing federal state courts femur fracture cases pending company intends defend lawsuits nuvaring previously disclosed beginning may number complaints filed various jurisdictions asserting claims companys subsidiaries organon usa inc organon pharmaceuticals usa inc organon international collectively organon scheringplough arising organons marketing sale nuvaring combined hormonal contraceptive vaginal ring plaintiffs contend organon scheringplough among things failed adequately design manufacture nuvaring failed adequately warn alleged increased risk venous thromboembolism vte posed nuvaring andor downplayed risk vte plaintiffs seek damages injuries allegedly sustained product use including alleged deaths heart attacks strokes majority cases currently pending federal multidistrict litigation nuvaring mdl venued missouri coordinated proceeding new jersey state court table contents december approximately nuvaring cases cases approximately pending nuvaring mdl us district court eastern district missouri judge rodney sippel approximately pending coordinated discovery proceedings bergen county superior court new jersey judge brian r martinotti four additional cases pending various state courts pursuant orders judge sippel nuvaring mdl parties originally selected pool twenty cases prepare trial pool since narrowed eight cases first trials nuvaring mdl selected pursuant judge martinottis order new jersey proceeding parties selected ten trial pool cases prepared trial parties completed fact discovery originally selected trial pool cases jurisdiction company anticipates expert discovery completed first trial pool cases summer certain cases original trial pool voluntarily dismissed two cases judgment entered mercks favor result certain replacement trial pool cases remain fact discovery moreover january parties new jersey coordinated proceeding selected additional trial pool cases completion fact discovery company anticipates status conferences held coordinated proceeding following completion expert discovery summer determine methodology selecting first cases tried time parties also discuss time frame filing motions relating admissibility expert testimony causation company intends defend lawsuits propeciaproscar previously disclosed merck defendant product liability lawsuits united states involving propecia andor proscar december approximately lawsuits involving total approximately plaintiffs instances spouses joined suits allege experienced persistent sexual side effects following cessation treatment propecia andor proscar filed merck lawsuits early stages pending federal courts new jersey washington washington dc florida illinois colorado missouri ohio state court new jersey certain federal plaintiffs petitioned jpml federal lawsuits consolidated pretrial purposes certain new jersey state court plaintiffs petitioned consolidation new jersey state court cases resolution motions remains pending company intends defend lawsuits governmental proceedings effective august merck us department health human services office inspector general hhsoig executed unified corporate integrity agreement unified cia replaced individual cias signed merck scheringplough prior merger unified cia incorporated certain requirements individual cias merck scheringplough similar although identical legacy cias merck assumed compliance obligations unified cia february effective november merck hhsoig executed new corporate integrity agreement new cia replaced unified cia term five years previously disclosed merck received civil investigative demand cid issued doj addressed inspire pharmaceuticals inc company acquired merck may cid advises relates false claims act investigation concerning allegations inspire caused submission false claims federal health benefits programs drug azasite marketing treatment indications approved fda company cooperating government investigation previously disclosed company received subpoena doj requesting information relating companys marketing selling activities respect integrilin avelox january june civil federal health care investigation company also previously disclosed received subpoena requesting information related companys marketing selling activities respect temodar pegintron intron january present federal health care investigation criminal statutes company cooperating dojs investigations table contents previously disclosed company received letters doj sec seek information activities number countries reference foreign corrupt practices act company cooperating agencies requests believes inquiry part broader review pharmaceutical industry practices foreign countries regard company received may continue receive additional requests information either doj sec vytorinzetia litigation previously disclosed april merck shareholder filed putative class action lawsuit federal court consolidated district new jersey another federal securities lawsuit caption merck co inc vytorin securities litigation amended consolidated complaint filed october named defendants merck merckscheringplough pharmaceuticals llc certain companys current former officers directors complaint alleges merck delayed releasing unfavorable results enhance clinical trial regarding efficacy vytorin merck made false misleading statements expected earnings knowing results enhance study released sales vytorin would decline mercks earnings would suffer december merck defendants moved dismiss lawsuit grounds plaintiffs failed state claim relief granted september court denied defendants motion dismiss june lead plaintiffs filed motion leave amend consolidated complaint granted february parties currently briefing lead plaintiffs motion class certification similar consolidated putative class action securities lawsuit pending district new jersey filed scheringplough shareholder scheringplough former chairman president chief executive officer fred hassan caption scheringplough corporationenhance securities litigation amended consolidated complaint filed september names defendants scheringplough merckscheringplough pharmaceuticals certain companys current former officers directors underwriters participated august public offering scheringploughs common preferred stock december scheringplough defendants filed motions dismiss lawsuit grounds plaintiffs failed state claim relief granted september court denied defendants motion dismiss parties currently briefing lead plaintiffs motion class certification previously disclosed april member merck erisa plan filed putative class action lawsuit merck certain companys current former officers directors alleging breached fiduciary duties erisa since time similar erisa lawsuits filed merck district new jersey lawsuits consolidated caption merck co inc vytorin erisa litigation consolidated amended complaint filed february names defendants merck various current former members companys board directors plaintiffs allege erisa plans investment merck stock imprudent mercks earnings dependent commercial success cholesterol drug vytorin defendants knew known results scientific study would cause medical community turn less expensive drugs cholesterol management april merck defendants moved dismiss lawsuit grounds plaintiffs failed state claim relief granted september court denied defendants motion dismiss similar consolidated putative class action erisa lawsuit currently pending district new jersey filed member schering plough erisa plan scheringplough certain current former officers directors alleging breached fiduciary duties erisa caption scheringplough corp enhance erisa litigation consolidated amended complaint filed october names defendants scheringplough various thencurrent former members scheringploughs board directors thencurrent former members committees scheringploughs board directors november company defendants filed motion dismiss lawsuit grounds plaintiffs failed state claim relief granted motion denied june november parties reached agreement principle settle matter november parties informed court would submit motion preliminary approval settlement table contents classwide basis november court ordered case dismissed without costs without prejudice right upon good cause shown within days seek reopen action settlement consummated january court extended day period additional days november stockholder company filed shareholder derivative lawsuit local international brotherhood electrical workers pension fund v clark local district new jersey behalf nominal defendant company shareholders company company certain companys officers directors alleged insiders certain predecessor companies former officers directors alleged insiders alleged breaches fiduciary duties waste unjust enrichment gross mismanagement similar shareholder derivative lawsuit cain v hassan filed scheringplough stockholder district new jersey lawsuit company scheringploughs thencurrent board directors certain companys thencurrent former officers directors alleged insiders plaintiffs local cain v hassan alleged defendants withheld enhance study results made false misleading statements thereby deceiving causing harm company scheringplough respectively investing public unjustly enriching insiders wasting corporate assets plaintiff local voluntarily dismissed suit without prejudice july also july intervenorplantiff cain v hassan action filed second amended complaint defendants moved dismiss second amended complaint october december parties cain v hassan executed stipulation settlement would terminate litigation plaintiff moved approval settlement proposed settlement include payment monetary consideration immaterial legal fees plaintiffs counsel hearing held february motion approval settlement november company shareholder filed derivative lawsuit state court new jersey case captioned rose v hassan asserts claims substantially identical claims alleged cain v hassan april defendants rose v hassan moved stay case dismiss without prejudice favor federal derivative action august new jersey state court dismissed rose v hassan without prejudice september plaintiff rose v hassan filed notice appeal january plaintiff moved additional days file appeal brief event cain v hassan settlement approved discovery federal lawsuits referred section collectively enhance litigation coordinated substantially complete company believes meritorious defenses enhance litigation intends vigorously defend lawsuits company unable predict outcome matters time reasonably estimate possible loss range loss respect enhance litigation unfavorable outcomes resulting enhance litigation could material adverse effect companys financial position liquidity results operations insurance company directors officers insurance coverage applicable vytorin shareholder lawsuits brought legacy scheringplough shareholders stated upper limits approximately million company fiduciary insurance vytorin erisa lawsuits stated upper limits approximately million disputes insurers availability companys insurance coverage claims likely additional disputes amounts actually recovered policies discussed paragraph may less stated limits commercial litigation awp litigation previously disclosed company andor certain subsidiaries remain defendants cases brought various states alleging manipulation pharmaceutical manufacturers average wholesale prices awp sometimes used public private payors calculating provider reimbursement levels outcome lawsuits could include substantial damages imposition substantial fines penalties injunctive administrative remedies table contents company settled certain awp cases brought states utah south carolina alaska idaho kentucky pennsylvania mississippi wisconsin iowa massachusetts certain new york counties company andor certain subsidiaries continue defendants cases brought states kdur antitrust litigation previously disclosed june january scheringplough settled patent litigation upshersmith inc upshersmith esi lederle inc lederle respectively relating generic versions kdur scheringploughs longacting potassium chloride product supplement used cardiac patients lederle upshersmith filed abbreviated new drug applications andas following commencement administrative proceeding united states federal trade commission ftc alleging anticompetitive effects settlements resolved scheringploughs favor putative class nonclass action suits filed behalf direct indirect purchasers kdur scheringplough upsher smith lederle consolidated multidistrict litigation us district court district new jersey suits claimed violations federal state antitrust laws well state statutory common law causes action sought unspecified damages april indirect purchasers voluntarily dismissed case february special master recommended district court dismiss remaining lawsuits summary judgment march district court adopted recommendation granted summary judgment defendants dismissed matter entirety plaintiffs appealed decision third circuit court appeals defendants simultaneously appealing december decision district court certify certain direct purchaser plaintiffs claims class action patent litigation time time generic manufacturers pharmaceutical products file andas fda seeking market generic forms companys products prior expiration relevant patents owned company protect patent rights company may file patent infringement lawsuits generic companies certain products company marketed via agreements companies currently involved patent infringement litigation united states include azasite cancidas nasonex nexium noxafil vytorin zetia similar lawsuits defending companys patent rights may exist countries company intends vigorously defend patents believes valid infringement generic companies attempting market products prior expiration patents litigation assurance outcomes adverse could result significantly shortened periods exclusivity products respect legacy scheringplough products potentially significant intangible asset impairment charges azasite may patent infringement suit filed united states sandoz inc sandoz respect sandozs application fda seeking prepatent expiry approval market generic version azasite lawsuit automatically stays fda approval sandozs anda october adverse court decision whichever may occur earlier cancidas november patent infringement lawsuit filed united states teva parenteral medicines inc tpm respect tpms application fda seeking prepatent expiry approval sell generic version cancidas lawsuit dismissed rights granted tpm also march patent infringement lawsuit filed united states sandoz respect sandozs application fda seeking prepatent expiry approval sell generic version cancidas june sandoz amended challenge mercks cancidas patents stating seek fda approval earlier expiry patent occurs july sandoz maintain challenge cancidas patent expires september therefore lawsuit continue however fda approve sandozs application earlier july integrilin february patent infringement lawsuit filed jointly millennium pharmaceuticals inc united states tpm respect tpms application fda seeking approval sell generic version integrilin prior expiry last expire listed patent october parties entered settlement agreement allowing tpm sell generic version integrilin beginning june table contents nasonex december patent infringement suit filed united states apotex corp apotex respect apotexs application fda seeking prepatent expiry approval market generic version nasonex lawsuit automatically stays fda approval apotexs anda may adverse court decision whichever may occur earlier trial expected take place nexium november patent infringement lawsuit filed jointly astrazeneca united states ranbaxy laboratories ltd ranbaxy respect ranbaxys application fda seeking prepatent expiry approval sell generic version nexium previously disclosed astrazeneca merck ranbaxy entered settlement agreement provided ranbaxy entitled bring generic esomeprazole product market united states may company astrazeneca received cid ftc july regarding settlement agreement ranbaxy company cooperating ftc responding cid march patent infringement lawsuit filed jointly astrazeneca ivax pharmaceuticals inc ivax later acquired teva pharmaceuticals inc teva respect ivaxs application fda seeking prepatent expiry approval sell generic version nexium january astrazeneca merck tevaivax entered settlement agreement provides tevaivax entitled bring generic esomeprazole product market united states may patent infringement lawsuits also filed united states dr reddys laboratories dr reddys sandoz lupin ltd lupin respect respective applications fda seeking prepatent expiry approval sell generic versions nexium january astrazeneca merck dr reddys entered settlement agreement provides dr reddys entitled bring generic esomeprazole product market united states may june astrazeneca merck sandoz entered settlement agreement provides sandoz entitled bring generic esomeprazole product market united states may january astrazeneca merck lupin entered settlement agreement provides lupin entitled bring generic esomeprazole product market united states may february patent infringement lawsuit filed jointly astrazeneca united states hamni usa inc hamni respect hamnis application fda seeking prepatent expiry approval sell generic version nexium august patent infringement lawsuit filed jointly astrazeneca united states hetero drugs ltd unit iii hetero respect heteros application fda seeking prepatent expiry approval sell generic version nexium january patent infringement lawsuit filed jointly astrazeneca united states torrent pharmaceuticals ltd torrent respect torrents application fda seeking pre patent expiry approval sell generic version nexium patent infringement lawsuit also filed jointly astrazeneca february united states sun pharma global fze sun pharma respect application fda seeking prepatent expiry approval sell generic version nexium iv october astrazeneca merck sun pharma entered settlement agreement provides sun pharma entitled bring generic esomeprazole iv product market united states january noxafil may patent infringement suit filed united states sandoz respect sandozs application fda seeking prepatent expiry approval market generic version noxafil lawsuit automatically stays fda approval sandozs anda september adverse court decision whichever may occur earlier nuvaring february patent infringement suit brought merck international trade commission itc femina pharma incorporated femina respect product nuvaring complaint alleged nuvaring infringes patent owned femina feminas itc complaint sought exclusion order importation nuvaring united states hearing began itc proceeding january january femina withdrew complaint terminated action addition november femina brought patent infringement lawsuit merck eastern district virginia asserting nuvaring infringes patent case stayed pending outcome itc proceeding company believes femina intends pursue litigation eastern district virginia propecia december patent infringement lawsuit filed united states hetero drugs limited hetero respect heteros application fda seeking prepatent expiry approval sell generic version propecia march company settled lawsuit hetero agreeing allow hetero sell generic mg finasteride product beginning july table contents temodar july patent infringement action filed jointly cancer research technologies limited crt united states barr laboratories barr later acquired teva respect barrs application fda seeking prepatent expiry approval sell generic version temodar january court issued decision finding crt patent unenforceable grounds prosecution laches inequitable conduct november appeals court issued decision reversing trial courts finding december barr filed petition seeking rehearing en banc appeal petition denied june barr filed petition review us supreme court denied virtue agreement barr launch product appeal process company agreed barr launch product august september patent infringement lawsuit filed jointly crt united states sun pharmaceutical industries inc sun respect suns application fda seeking prepatent expiry approval sell generic version temodar lawsuit automatically stayed fda approval suns anda february adverse court decision whichever may occur earlier november patent infringement lawsuit filed jointly crt united states accord healthcare inc accord respect application fda seeking prepatent expiry approval sell generic version temodar lawsuit automatically stayed fda approval accords application april adverse court decision whichever may occur earlier company crt entered agreements sun accord stay respective lawsuits pending outcome us supreme court appeal process barr lawsuit light us supreme courts denial barrs petition sun accord agreed withdraw challenges temodar patent respective lawsuits withdrawn vytorin december patent infringement lawsuit filed united states mylan pharmaceuticals inc mylan respect mylans application fda seeking prepatent expiry approval sell generic version vytorin lawsuit automatically stays fda approval mylans application may adverse court decision whichever may occur earlier trial mylan jointly respect zetia vytorin conducted december decision expected february patent infringement lawsuit filed united states teva respect tevas application fda seeking prepatent expiry approval sell generic version vytorin july patent infringement lawsuit dismissed teva agreed sell generic versions zetia vytorin companys exclusivity rights expire april except certain circumstances august patent infringement lawsuit filed united states impax laboratories inc impax respect impaxs application fda seeking pre patent expiry approval sell generic version vytorin agreement reached impax stay lawsuit pending outcome lawsuit mylan october patent infringement lawsuit filed united states actavis inc actavis respect actavis application fda seeking prepatent expiry approval sell generic version vytorin lawsuit automatically stays fda approval actavis application may adverse court decision whichever may occur earlier zetia march patent infringement lawsuit filed united states glenmark pharmaceuticals inc usa parent corporation collectively glenmark respect glenmarks application fda seeking prepatent expiry approval sell generic version zetia may glenmark agreed settlement virtue glenmark permitted launch generic product united states december subject receiving final fda approval june patent infringement lawsuit filed united states mylan respect mylans application fda seeking prepatent expiry approval sell generic version zetia lawsuit automatically stays fda approval mylans application december adverse court decision whichever may occur earlier trial mylan jointly respect zetia vytorin conducted december decision expected september patent infringement lawsuit filed united states teva respect tevas application fda seeking prepatent expiry approval sell generic version zetia july patent infringement lawsuit dismissed without rights granted teva litigation various pending legal proceedings involving company principally product liability intellectual property lawsuits feasible predict outcome proceedings opinion table contents company either likelihood loss remote reasonably possible loss associated resolution proceedings expected material companys financial position results operations cash flows either individually aggregate legal defense reserves legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable significant factors considered review legal defense reserves follows actual costs incurred company development companys legal defense strategy structure light scope litigation number cases brought company costs outcomes completed trials current information regarding anticipated timing progression related costs pretrial activities trials associated litigation amount legal defense reserves december approximately million million respectively represents companys best estimate minimum amount defense costs incurred connection outstanding litigation however events additional trials events could arise course litigation could affect ultimate amount legal defense costs incurred company company continue monitor legal defense costs review adequacy associated reserves may determine increase reserves time future based upon factors set forth believes would appropriate environmental matters company subsidiaries parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents proceedings seek require operators hazardous waste disposal facilities transporters waste sites generators hazardous waste disposed sites clean sites reimburse government cleanup costs company made party proceedings alleged generator waste disposed sites case government alleges defendants jointly severally liable cleanup costs although joint several liability alleged proceedings frequently resolved allocation cleanup costs among parties nearly reflects relative contributions parties site situation companys potential liability varies greatly site site sites potential liability de minimis others final costs cleanup yet determined feasible predict outcome many proceedings brought federal state agencies private litigants opinion company proceedings ultimately result liability would material adverse effect financial position results operations liquidity capital resources company company taken active role identifying providing costs amounts include reduction anticipated recoveries cleanup costs former site owners operators recalcitrant potentially responsible parties previously disclosed approximately plaintiffs filed amended complaint merck defendants us district court eastern district california asserting claims clean water act resource conservation recovery act well negligence nuisance suit seeks damages personal injury diminution property value medical monitoring alleged real personal property damage associated groundwater surface water soil contamination found site former merck subsidiary merced california certain defendants suit settled plaintiffs regarding aspects plaintiffs claims lawsuit proceeding phased manner jury trial commenced february jury asked make certain factual findings regarding whether contamination moved offsite areas plaintiffs could exposed contamination amounts defendants phase trial included merck three original defendants march phase jury returned mixed verdict finding favor merck defendants plaintiffs claims specifically jury found contamination site enter affect plaintiffs municipal water supply wells private domestic wells jury found however plaintiffs could exposed contamination via air emissions prior well via surface water form storm drainage channeled adjacent irrigation canal including flood april response posttrial motions merck defendants september court table contents entered order setting aside part phase jurys findings favor plaintiffs specifically court held plaintiffs could exposed contamination surface flood water april flood fact time later mercks motion reconsideration remainder jurys phase verdict adverse merck denied following retirement judge handling case september case assigned judge david carter us district court central district california judge carter selected plaintiffs whose claims reviewed depending outcome mercks anticipated summary judgment motions possibly tried early previously disclosed doj us environmental protection agency epa notified company pursuing civil penalties merck excess million alleged violations air water waste regulations resulting epas multimedia inspections mercks west point riverside pennsylvania facilities mercks subsequent information submissions epa stipulation settling matter filed us district court middle district pennsylvania september pursuant company denied alleged violations agreed civil penalty amount million following courts approval stipulation november merck paid civil penalty united states claims merck dismissed prejudice managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively liabilities undiscounted consider potential recoveries parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures result material adverse effect companys financial position results operations liquidity capital resources year equity merck certificate incorporation authorizes shares common stock shares preferred stock authorized shares preferred stock series shares designated mandatory convertible preferred stock mandatory convertible preferred stock connection merger holders scheringplough preferred stock received preferred stock rights substantially similar rights scheringplough preferred stock accordance merck restated certificate incorporation result merger preferred stock became subject makewhole acquisition provisions preferred stock effective november makewhole acquisition conversion period ended november preferred stock convertible makewhole conversion rate share preferred stock converted period holder received cash merck common shares holders also received dividend makewhole payment per share depending date conversion total shares preferred stock converted shares merck common stock cash payments approximately million made holders converted addition makewhole dividend payments million made holders converted representing present value remaining future dividend payments conversion date mandatory conversion date august using discount rate stipulated terms preferred stock august remaining outstanding mandatory convertible preferred stock automatically converted terms right receive cash shares merck common stock share mandatory convertible preferred stock holders received cash shares merck common stock result conversion approximately million paid holders approximately million merck common shares issued table contents capital stock summary common stock treasury stock transactions shares millions follows common treasury common treasury common treasury stock stock stock stock stock stock balance january mandatory conversion convertible preferred stock issuances shares connection merger issuances purchases treasury stock cancellations treasury stock balance december issuances primarily reflect activity sharebased compensation plans pursuant merger agreement certain mercks treasury shares cancelled noncontrolling interests connection restructuring ami merck assumed billion par value preferred stock obligation dividend rate per annum carried kbi included noncontrolling interests astrazeneca exercises shares option see note preferred stock obligation retired sharebased compensation plans company sharebased compensation plans employees nonemployee directors employees certain companys equity method investees may granted options purchase shares company common stock fair market value time grant addition stock options company grants performance share units psus restricted stock units rsus certain management level employees plans approved companys shareholders result merger scheringplough stock incentive plan scheringplough sip amended restated sharebased compensation instruments remain available future grant scheringplough sip merck employees employees scheringplough prior merger outstanding sharebased compensation instruments well sharebased compensation instruments available future grant legacy merck legacy scheringplough incentive plans also result merger certain sharebased compensation instruments previously granted scheringplough sip legacy scheringplough incentive plans exchanged merck replacement awards awards related precombination services became payable cash fair value replacement awards attributable precombination service million included calculation consideration transferred see note significant portion legacy scheringplough awards vested opening balance sheet time merger scheringplough share based compensation instruments immediately vest upon completion merger exchanged merck replacement awards generally vest basis original grants made scheringplough legacy incentive plans immediately vested employee terminated company within two years merger certain circumstances fair value merck replacement awards attributed postcombination services recognized compensation cost subsequent merger requisite service period awards december million shares collectively authorized future grants companys sharebased compensation plans prior merger employee sharebased compensation awards settled primarily treasury shares subsequent merger awards either settled newly issued shares treasury shares table contents employee stock options granted purchase shares company stock fair market value time grant awards generally vest onethird year threeyear period contractual term years rsus stock awards granted employees entitle holder shares common stock awards vest fair value stock option rsu awards determined fixed grant date based companys stock price psus stock awards ultimate number shares issued contingent companys performance preset objective set objectives fair value psu determined date grant based companys stock price rsus certain psus granted december employees participate dividends basis common shares dividends nonforfeitable holder rsus psus issued january dividends declared vesting period payable employees upon vesting fair value stock option rsu psu replacement awards determined fixed time merger psu performance period number shares stock expected issued adjusted based probability achievement performance target final compensation expense recognized based ultimate number shares issued rsu psu distributions shares company stock end vesting performance period generally three years subject terms applicable awards total pretax sharebased compensation cost recorded million million million respectively related income tax benefits million million million respectively company uses blackscholes option pricing model determining fair value option grants applying model company uses historical data current market data estimate fair value options blackscholes model requires several assumptions including expected dividend yield riskfree interest rate volatility term options expected dividend yield based historical patterns dividend payments risk free rate based rate grant date zerocoupon us treasury notes term equal expected term option expected volatility estimated using blend historical implied volatility historical component based historical monthly price changes implied volatility obtained market data companys traded options expected life represents amount time options granted expected outstanding based historical forecasted exercise behavior weighted average exercise price options granted per option respectively weighted average fair value options granted per option respectively determined using following assumptions years ended december expected dividend yield riskfree interest rate expected volatility expected life years summarized information relative stock option plan activity options thousands follows weighted weighted average average remaining aggregate number exercise contractual intrinsic options price term value outstanding january granted exercised forfeited outstanding december exercisable december table contents additional information pertaining stock option plans provided table years ended december total intrinsic value stock options exercised fair value stock options vested cash received exercise stock options fair value stock options vested excludes fair value options vested result merger attributable precombination service summary nonvested rsu psu activity shares thousands follows rsus psus weighted weighted average average number grant date number grant date shares fair value shares fair value nonvested january granted vested forfeited nonvested december december million total pretax unrecognized compensation expense related nonvested stock options rsu psu awards recognized weighted average period years segment reporting sharebased compensation costs unallocated expenses pension postretirement benefit plans company defined benefit pension plans covering eligible employees united states certain international subsidiaries pension benefits united states based formula considers final average pay years credited service addition company provides medical dental life insurance benefits principally eligible us retirees similar benefits dependents postretirement benefit plans december changes companys benefit plans approved discussed company uses december yearend measurement date pension plans postretirement benefit plans net periodic benefit cost net periodic benefit cost pension postretirement benefit plans consisted following components pension benefits postretirement benefits years ended december service cost interest cost expected return plan assets net amortization termination benefits curtailments settlements net periodic benefit cost table contents higher costs compared primarily due incremental costs associated merger net periodic benefit cost attributable us pension plans included table million million million connection restructuring actions see note termination charges recorded pension postretirement benefit plans related expanded eligibility certain employees exiting merck also connection restructuring activities curtailments recorded pension postretirement benefit plans addition settlements recorded certain domestic international pension plans obligations funded status summarized information changes plan assets benefit obligation funded status amounts recorded december follows postretirement pension benefits benefits fair value plan assets january actual return plan assets company contributions mergers acquisitions divestitures effects exchange rate changes benefits paid settlements fair value plan assets december benefit obligation january service cost interest cost mergers acquisitions divestitures actuarial losses gains benefits paid effects exchange rate changes plan amendments curtailments termination benefits settlements benefit obligation december funded status december recognized assets accrued current liabilities deferred income taxes noncurrent liabilities table contents fair value us pension plan assets included preceding table billion billion december respectively projected benefit obligation us pension plans billion billion respectively approximately companys pension projected benefit obligation december relates international defined benefit plans individual plan significant relative total projected benefit obligation december accumulated benefit obligation billion billion respectively pension plans billion billion respectively related us pension plans pension plans projected benefit obligations excess plan assets december fair value plan assets billion billion respectively benefit obligations billion billion respectively plans accumulated benefit obligations excess plan assets december fair value plan assets billion billion respectively accumulated benefit obligations billion billion respectively plan assets entities required use fair value hierarchy maximizes use observable inputs minimizes use unobservable inputs measuring fair value three levels inputs used measure fair value level highest priority level lowest level quoted prices unadjusted active markets identical assets liabilities level observable inputs level prices quoted prices similar assets liabilities inputs observable corroborated observable market data substantially full term assets liabilities level unobservable inputs supported little market activity level assets whose values determined using pricing models discounted cash flow methodologies similar techniques significant unobservable inputs well instruments determination fair value requires significant judgment estimation december million million respectively approximately companys pension investments year end categorized level assets inputs used measure financial assets fall within one level described categorization based lowest level input significant fair value measurement instrument table contents fair values companys pension plan assets december asset category follows fair value measurements using fair value measurements using quoted prices significant quoted prices significant active significant active significant markets observable unobservable markets observable unobservable identical assets inputs inputs identical assets inputs inputs level level level total level level level total assets cash cash equivalents investment funds us large cap equities us smallmid cap equities nonus developed markets equities nonus emerging markets equities government agency obligations corporate obligations fixed income obligations real estate equity securities us large cap us smallmid cap nonus developed markets fixed income securities government agency obligations corporate obligations mortgage assetbacked securities investments insurance contracts derivatives liabilities derivatives plans level investments real estate generally valued market appraisals plans level investments insurance contracts generally valued using crediting rate approximates market returns invest underlying securities whose market values unobservable determined using pricing models discounted cash flow methodologies similar techniques table contents table provides summary changes fair value including transfers andor financial assets measured fair value using significant unobservable inputs level companys pension plan assets insurance real insurance real contracts estate total contracts estate total beginning balance january actual return plan assets relating assets still held december relating assets sold year purchases sales transfers level ending balance december fair values companys postretirement benefit plan assets december asset category follows fair value measurements using fair value measurements using quoted prices significant quoted prices significant active significant active significant markets observable unobservable markets observable unobservable identical assets inputs inputs identical assets inputs inputs level level level total level level level total assets cash cash equivalents investment funds us large cap equities us smallmid cap equities nonus developed markets equities nonus emerging markets equities fixed income obligations equity securities us large cap us smallmid cap nonus developed markets fixed income securities government agency obligations corporate obligations mortgage assetbacked securities fixed income obligations total pension postretirement benefit plan assets excluded fair value hierarchy include interest receivable well payables receivables related purchases sales investments respectively company established investment guidelines us pension postretirement plans create asset allocation expected deliver rate return sufficient meet longterm obligation plan given acceptable level risk target investment portfolio companys us pension postretirement benefit plans allocated us equities international equities fixedincome investments cash investments portfolios equity weighting consistent longterm nature plans benefit obligations expected annual standard table contents deviation returns target portfolio approximates reflects equity allocation diversification benefits among asset classes portfolio invests nonus pension plans targeted investment portfolio varies based duration pension liabilities local government rules regulations although significant percentage plan assets invested us equities concentration risk mitigated use strategies diversified within management guidelines expected contributions contributions pension plans postretirement benefit plans expected approximately million million respectively expected benefit payments expected benefit payments follows pension postretirement benefits benefits expected benefit payments based assumptions used measure benefit obligations include estimated future employee service amounts recognized comprehensive income net loss amounts reflect experience differentials primarily relating differences expected actual returns plan assets well effects changes actuarial assumptions net loss amounts excess certain thresholds amortized net pension postretirement benefit cost average remaining service life employees following amounts reflected components oci postretirement pension plans benefit plans years ended december net loss gain arising period prior service credit cost arising period net loss amortization included benefit cost prior service cost credit amortization included benefit cost estimated net loss gain prior service cost credit amounts amortized aoci net pension postretirement benefit cost million million respectively pension plans million million respectively postretirement benefit plans table contents actuarial assumptions company reassesses benefit plan assumptions regular basis weighted average assumptions used determining pension plan us pension postretirement benefit plan information follows us pension pension plans postretirement benefit plans december net periodic benefit cost discount rate expected rate return plan assets salary growth rate benefit obligation discount rate salary growth rate net cost rates preceding table include costs associated scheringplough benefit plans date merger december expected rate return pension postretirement benefit plans represents average rate return earned plan assets period benefits included benefit obligation paid determined country basis developing expected rate return within country longterm historical returns data considered well actual returns plan assets capital markets experience using reference information longterm return expectations asset category weighted average expected return countrys target portfolio developed according allocation among investment categories expected portfolio performance reflects contribution active management appropriate companys expected rate return range compared range us pension postretirement benefit plans health care cost trend rate assumptions postretirement benefit plans follows december health care cost trend rate assumed next year rate cost trend rate assumed decline year trend rate reaches ultimate trend rate one percentage point change health care cost trend rate would following effects one percentage point increase decrease effect total service interest cost components effect benefit obligation benefit plan changes december compensation benefits committee companys board directors approved managements proposal change mercks primary us defined benefit pension plans benefit formulas cash balance formulas beginning service january active participants plans december accrue pension benefits prospectively using new cash balance formulas based age service pay interest however transition period january december participants earn greater benefit calculated employees legacy final average pay formula new cash balance formula years service december participants earn future benefits cash balance formula changes plans reduced pension benefit obligations table contents december approximately million corresponding offset aoci largely attributable change using final average pay career average pay amortized reduction net periodic benefit cost employees future service period approximately years also december company approved changes us retiree healthcare plans including changes certain employees contribution subsidy level eligibility criteria subsidized retiree medical coverage elimination certain retiree dental coverage reduce mercks future costs related plans changes reduced companys benefit obligations related us retiree healthcare plans december approximately million corresponding offset aoci amortized reduction net periodic benefit cost employees future service period approximately years savings plans company also maintains defined contribution savings plans united states including plans assumed connection merger company matches percentage employees contributions consistent provisions plan employee eligible total employer contributions plans million million million respectively income expense net years ended december interest income interest expense exchange losses gains net increase interest income compared primarily reflects higher average investment balances decline interest income increase interest expense compared largely attributable merger exchange losses reflect million losses due two venezuelan currency devaluations discussed net presented table reflects million charge related resolution arbitration proceeding involving companys rights market remicade simponi see note million gain disposition companys interest jjmcp joint venture see note million gain sale certain manufacturing facilities related assets see note net reflects million charge vioxx liability reserve see note charges related settlement certain pending awp litigation partially offset million income recognized upon astrazenecas asset option exercise see note million income recognized settlement certain disputed royalties net primarily reflects billion gain resulting recognizing mercks previously held equity interest msp partnership fair value result obtaining control msp partnership merger billion gain sale mercks interest merial see note noted exchange losses reflect losses relating venezuelan currency devaluations effective january venezuelan government devalued currency bsf per us dollar twotiered official exchange rate essentials rate bsf per us dollar nonessentials rate bsf per us dollar january company required remeasure local currency operations venezuela us dollars venezuelan economy determined hyperinflationary throughout company settled transactions essentials rate therefore remeasured monetary assets liabilities utilizing essentials rate december venezuelan government announced would eliminate essentials rate effective january transactions would settled official rate bsf per us dollar result announcement company remeasured december monetary assets liabilities new official rate table contents interest paid million million million excludes commitment fees interest paid net million received company termination certain interest rate swap contracts year see note taxes income reconciliation effective tax rate us statutory rate follows amount tax rate amount tax rate amount tax rate us statutory rate applied income taxes differential arising foreign earnings federal state tax settlements tax rate changes unremitted foreign earnings iprd impairment charges amortization purchase accounting adjustments arbitration settlement charge restructuring state taxes gain equity investments vioxx liability reserve us health care reform legislation includes tax effect contingency reserves research credits export incentives miscellaneous items tax rate reconciliation percentages reflect impact significant decline companys income taxes resulting primarily full year acquisitionrelated costs including iprd impairment charges restructuring charges well arbitration settlement charge charge vioxx liability reserve income taxes consisted years ended december domestic foreign table contents taxes income consisted years ended december current provision federal foreign state deferred provision federal foreign state deferred income taxes december consisted assets liabilities assets liabilities intangibles inventory related accelerated depreciation unremitted foreign earnings equity investments pensions postretirement benefits compensation related unrecognized tax benefits net operating losses tax credit carryforwards subtotal valuation allowance total deferred taxes net deferred income taxes recognized deferred income taxes current assets assets income taxes payable deferred income taxes noncurrent liabilities company net operating loss nol carryforwards several jurisdictions december approximately million deferred taxes nol carryforwards relate foreign jurisdictions none individually significant approximately million valuation allowances established foreign nol carryforwards addition company approximately million deferred tax assets relating various us tax credit carryforwards nol carryforwards amounts million expected fully utilized prior expiry table contents income taxes paid billion billion million respectively stock option exercises significant impact taxes paid reconciliation beginning ending amount unrecognized tax benefits follows balance january additions related current year positions additions related prior year positions additons related merger reductions tax positions prior years settlements lapse statute limitations balance december amount reflects conclusion irs examination mercks federal income tax returns resolution interest rate swap dispute irs discussed company recognize unrecognized tax benefits billion december income tax provision would reflect favorable net impact billion company examination numerous tax authorities various jurisdictions globally company believes reasonably possible total amount unrecognized tax benefits december could decrease million next months result various audit closures settlements expiration statute limitations ultimate finalization companys examinations relevant taxing authorities include formal administrative legal proceedings could significant impact timing reversal unrecognized tax benefits company believes reserves uncertain tax positions adequate cover existing risks exposures interest penalties associated uncertain tax positions amounted benefit expense million million million liabilities accrued interest penalties billion billion december respectively april irs concluded examination mercks federal income tax returns result company required make net payments approximately million companys unrecognized tax benefits years examination exceeded adjustments related examination period therefore company recorded net million tax provision benefit net benefit reflects decrease unrecognized tax benefits years examination partially offset increases unrecognized tax benefits years subsequent examination period result settlement company disagrees irs treatment one issue raised examination appealing matter irs administrative process previously disclosed october canada revenue agency cra issued merck notice reassessment containing adjustments related certain intercompany pricing matters february merck cra negotiated settlement agreement regard matters accordance settlement merck paid additional tax approximately million interest approximately million additional amounts penalties due assessment settlement accounted first quarter merck previously established reserves matters portion taxes paid expected creditable us tax purposes addition previously disclosed cra proposed adjustments relating intercompany pricing matters july cra issued assessments miscellaneous audit issues tax years adjustments would increase canadian tax due approximately million plus approximately million interest december company disagrees positions taken cra believes without merit company continues contest assessments cra appeals process cra expected prepare similar adjustments later years management believes resolution matters material effect companys financial position liquidity table contents october internal revenue service irs auditors asserted two interest rate swaps scheringplough entered unrelated party recharacterized loans affiliated companies resulting additional tax liability tax years september schering plough made payments irs amount million income taxes million interest companys tax reserves adequate cover payments scheringplough filed refund claims taxes interest irs december following irss denial scheringploughs claims refund scheringplough filed suit may us district court district new jersey refund full amount taxes interest decision favor government announced august affirmed us court appeals third circuit june irs finalized examination scheringploughs tax years audit cycle company reached agreement irs adjustment income related intercompany pricing matters income adjustment mostly reduced nols tax credit carryforwards additionally company seeking resolution one issue raised examination irs administrative appeals process companys reserves uncertain tax positions adequate cover adjustments related examination period irs began examination tax years addition various state foreign tax examinations progress significant tax jurisdictions us state foreign companys income tax returns open examination period december foreign earnings billion retained indefinitely subsidiary companies reinvestment therefore provision made income taxes would payable upon distribution earnings would practicable determine amount related unrecognized deferred income tax liability addition company subsidiaries operating puerto rico singapore tax incentive grants begin expire earnings per share company calculates earnings per share pursuant twoclass method earnings allocation formula determines earnings per share common stock participating securities according dividends declared participation rights undistributed earnings method earnings distributed undistributed allocated common shares participating securities based respective rights receive dividends rsus certain psus granted december certain management level employees see note participate dividends basis common shares dividends nonforfeitable holder result rsus psus meet definition participating security rsus psus issued january dividends declared vesting period payable employees upon vesting therefore rsus psus meet definition participating security table contents calculations earnings per share twoclass method follows years ended december basic earnings per common share net income attributable merck co inc less income allocated participating securities net income allocated common shareholders average common shares outstanding earnings per common share assuming dilution net income attributable merck co inc less income allocated participating securities net income allocated common shareholders average common shares outstanding common shares issuable average common shares outstanding assuming dilution issuable primarily sharebased compensation plans million million million respectively common shares issuable sharebased compensation plans excluded computation earnings per common share assuming dilution effect would antidilutive table contents comprehensive income loss components comprehensive income loss follows pretax tax tax year ended december net unrealized loss derivatives net loss realization derivatives net unrealized loss investments net gain realization investments benefit plan net loss gain prior service cost credit net amortization cumulative translation adjustment year ended december net unrealized gain derivatives net loss realization derivatives net unrealized gain investments net gain realization investments benefit plan net loss gain prior service cost credit net amortization cumulative translation adjustment year ended december net unrealized loss derivatives net loss realization derivatives net unrealized gain investments net gain realization investments benefit plan net loss gain prior service cost credit net amortization cumulative translation adjustment also included cumulative translation adjustment pretax gains losses approximately million billion respectively relating translation impacts intangible assets recorded conjunction merger table contents components accumulated comprehensive loss follows december net unrealized gain derivatives net unrealized gain investments pension plan net loss postretirement benefit plan net loss pension plan prior service cost postretirement benefit plan prior service credit cumulative translation adjustment segment reporting companys operations principally managed products basis comprised four operating segments pharmaceutical animal health consumer care alliances includes revenue equity income companys relationship azlp animal health consumer care alliances segments material separate reporting included table pharmaceutical segment includes human health pharmaceutical vaccine products marketed either directly company joint ventures human health pharmaceutical products consist therapeutic preventive agents generally sold prescription treatment human disorders company sells human health pharmaceutical products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations pharmacy benefit managers institutions vaccine products consist preventive pediatric adolescent adult vaccines primarily administered physician offices company sells human health vaccines primarily physicians wholesalers physician distributors government entities large component pediatric adolescent vaccines sold us centers disease control prevention vaccines children program funded us government additionally company sells vaccines federal government placement vaccine stockpiles company also animal health operations discover develop manufacture market animal health products including vaccines company sells veterinarians distributors animal producers additionally company consumer care operations develop manufacture market overthecounter foot care sun care products sold wholesale retail drug food chain mass merchandiser outlets segment composition reflects certain managerial changes implemented consumer care product sales outside united states canada previously included pharmaceutical segment included consumer care segment segment disclosures prior years recast comparable basis table contents accounting policies segments described described note revenues profits segments follows pharmaceutical total year ended december segment sales segment profits included segment profits equity income affiliates depreciation amortization year ended december segment sales segment profits included segment profits equity income affiliates depreciation amortization year ended december segment sales segment profits included segment profits equity income affiliates depreciation amortization segment profits comprised segment sales less certain elements materials production costs operating expenses including components equity income loss affiliates depreciation amortization expenses internal management reporting presented chief operating decision maker merck allocate production costs standard costs research development expenses general administrative expenses cost financing activities separate divisions maintain responsibility monitoring managing costs including depreciation related fixed assets utilized divisions therefore included segment profits table contents sales companys products follows years ended december pharmaceutical cardiovascular zetia vytorin integrilin diabetes obesity januvia janumet diversified brands cozaarhyzaar zocor propecia claritin rx remeron vasotecvaseretic proscar infectious disease isentress pegintron cancidas primaxin invanz avelox noxafil crixivanstocrin rebetol victrelis neurosciences ophthalmology maxalt cosopttrusopt oncology temodar emend intron respiratory immunology singulair remicade nasonex clarinex arcoxia simponi asmanex proventil dulera vaccines gardasil proquadmmr iivarivax rotateq pneumovax zostavax womens health endocrine fosamax nuvaring follistim aq implanon cerazette pharmaceutical total pharmaceutical segment sales segment sales total segment sales sales legacy scheringplough products included postmerger period addition prior merger substantially sales zetia vytorin recognized msp partnership results mercks interest msp partnership recorded equity income affiliates result merger msp partnership became wholly owned company accordingly sales msp partnership products merger reflected table sales zetia vytorin reflect mercks sales products latin america part msp partnership well sales products postmerger period amounts reflect sales vaccines sold major european markets companys joint venture sanofi pasteur msd results reflected equity income affiliates amounts however reflect supply sales sanofi pasteur msd pharmaceutical primarily reflects sales human health pharmaceutical products including products within franchises listed separately reflects nonreportable segments including animal health consumer care revenue companys relationship azlp primarily relating sales nexium well prilosec revenue azlp billion billion billion respectively revenues primarily comprised miscellaneous corporate revenues thirdparty manufacturing sales sales related divested products businesses supply sales included segment results table contents consolidated revenues geographic area derived follows years ended december united states europe middle east africa japan reconciliation total segment profits consolidated income taxes follows years ended december segment profits profits losses adjustments unallocated interest income interest expense equity income affiliates depreciation amortization research development amortization purchase accounting adjustments restructuring costs arbitration settlement charge vioxx liability reserve gain astrazeneca asset option exercise gain related msp partnership gain merial divestiture expenses net profits losses primarily comprised miscellaneous corporate profits losses well operating profits losses related thirdparty manufacturing sales divested products businesses supply sales adjustments represent elimination effect double counting certain items income expense equity income affiliates includes taxes paid joint venture level portion equity income reported segment profits expenses net include expenses corporate manufacturing cost centers miscellaneous income expense net property plant equipment net geographic area located follows years ended december united states europe middle east africa japan company disaggregate assets products services basis internal management reporting therefore information presented table contents report independent registered public accounting firm board directors shareholders merck co inc opinion accompanying consolidated balance sheets related consolidated statements income equity cash flows present fairly material respects financial position merck co inc subsidiaries december december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also opinion merck maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso mercks management responsible financial statements maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included managements report item responsibility express opinions financial statements mercks internal control financial reporting based integrated audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audits obtain reasonable assurance whether financial statements free material misstatement whether effective internal control financial reporting maintained material respects audits financial statements included examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management evaluating overall financial statement presentation audit internal control financial reporting included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk audits also included performing procedures considered necessary circumstances believe audits provide reasonable basis opinions companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company ii provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company iii provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate pricewaterhousecoopers llp florham park new jersey february table contents b supplementary data selected quarterly financial data contained condensed interim financial data table condensed interim financial data unaudited millions except per share amounts th q rd q nd q st q sales materials production marketing administrative research development restructuring costs equity income affiliates income expense net income taxes net income attributable merck co inc basic earnings per common share attributable merck co inc common shareholders earnings per common share assuming dilution attributable merck co inc common shareholders sales materials production marketing administrative research development restructuring costs equity income affiliates income expense net loss income taxes net loss income attributable merck co inc basic loss earnings per common share attributable merck co inc common shareholders loss earnings per common share assuming dilution attributable merck co inc common shareholders amounts include impact vioxx liability reserve see note amounts include net benefit relating settlement federal income tax audit see note amounts reflect income recognized astrazenecas asset option exercise see note amounts include charge relating resolution arbitration proceeding jj see note amounts reflect impacts merger including amortization purchase accounting adjustments inprocess research development impairment charges see note amounts also include impact restructuring actions see note table contents item changes disagreements accountants accounting financial disclosure applicable item controls procedures management company participation chief executive officer chief financial officer evaluated effectiveness companys disclosure controls procedures based evaluation end period covered companys chief executive officer chief financial officer concluded companys disclosure controls procedures defined rules ae de securities exchange act amended act effective management responsible establishing maintaining adequate internal control financial reporting term defined rule af act management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated framework issued committee sponsoring organizations treadway commission coso based evaluation management concluded internal control financial reporting effective december pricewaterhousecoopers llp independent registered public accounting firm performed assessment effectiveness companys internal control financial reporting attestation report included filing previously disclosed company process multiyear implementation enterprisewide resource planning erp system company completed legacy merck us erp deployment second quarter various deployments erp canada major european markets expected erp deployed additional markets also certain us operations addition response business integration activities company continue align streamline design operation financial control environment responsive changing business model managements report managements responsibility financial statements responsibility integrity objectivity companys financial statements rests management financial statements report managements stewardship company assets statements prepared conformity generally accepted accounting principles accordingly include amounts based managements best estimates judgments nonfinancial information included annual report also prepared management consistent financial statements assure financial information reliable assets safeguarded management maintains effective system internal controls procedures important elements include careful selection training development operating financial managers organization provides appropriate division responsibility communications aimed assuring company policies procedures understood throughout organization staff internal auditors regularly monitors adequacy application internal controls worldwide basis ensure personnel continue understand system internal controls procedures policies concerning good prudent business practices company periodically conducts managements stewardship program key management financial personnel program reinforces importance understanding internal controls reviewing key corporate policies procedures systems addition company compliance programs including ethical business practices program reinforce companys longstanding commitment high ethical standards conduct business financial statements financial information included annual report fairly present material respects companys financial condition results operations cash flows formal certification securities exchange commission included filing table contents managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined rule af securities exchange act companys internal control financial reporting designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles united states america management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated framework issued committee sponsoring organizations treadway commission based evaluation management concluded internal control financial reporting effective december inherent limitations internal control financial reporting may prevent detect misstatements projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate effectiveness companys internal control financial reporting december audited pricewaterhousecoopers llp independent registered public accounting firm stated report appears herein kenneth c frazier peter n kellogg chairman president executive vice president chief executive officer chief financial officer item b information none table contents part iii item directors executive officers corporate governance required information directors nominees incorporated reference discussion item election directors companys proxy statement annual meeting shareholders held may information executive officers set forth part document pages required information compliance section securities exchange act incorporated reference discussion heading section beneficial ownership reporting compliance companys proxy statement annual meeting shareholders held may company adopted code conduct values standards applicable employees including principal executive officer principal financial officer principal accounting officer code conduct available companys website wwwmerckcomaboutcodeofconductpdf company intends post website amendments waivers code conduct printed copy sent without charge shareholder requests writing chief ethics officer merck co inc one merck drive whitehouse station nj required information identification audit committee audit committee financial expert incorporated reference discussion heading board committees companys proxy statement annual meeting shareholders held may item executive compensation information required executive compensation incorporated reference discussion headings compensation discussion analysis summary compensation table compensation table grants planbased awards table outstanding equity awards table option exercises stock vested table retirement plan benefits related pension benefits table nonqualified deferred compensation related tables potential payments upon termination change control including discussion subheadings separation individual agreements change control well footnote information various tables companys proxy statement annual meeting shareholders held may required information director compensation incorporated reference discussion heading director compensation related director compensation table schedule director fees table companys proxy statement annual meeting shareholders held may required information headings compensation committee interlocks insider participation compensation benefits committee report incorporated reference companys proxy statement annual meeting shareholders held may item security ownership certain beneficial owners management related stockholder matters information respect securities authorized issuance equity compensation plans set forth part ii document information respect security ownership certain beneficial owners management incorporated reference discussion heading security ownership certain beneficial owners management companys proxy statement annual meeting shareholders held may item certain relationships related transactions director independence required information transactions related persons incorporated reference discussion heading related person transactions companys proxy statement annual meeting shareholders held may table contents required information director independence incorporated reference discussion heading independence directors companys proxy statement annual meeting shareholders held may item principal accountant fees services information required item incorporated reference discussion audit committee beginning caption pre approval policy services independent registered public accounting firm fees companys proxy statement annual meeting shareholders held may part iv item